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Abstract                                                            
                                                    
Objectives:  
Ciclosporin (CsA) is a potent and effective immuno-suppressive drug, but its use is 
associated with the development of gingival hyperplasia in up to 70% of patients. 
 
The mechanism underlying this side effect is unknown and the aim of this in vitro 
study was to investigate the direct effect of CsA on oral epithelium and connective 
tissue and to explore whether oral bacterial products modified the response.  
 
Methods: 
3 human oral and gingival keratinocyte cell lines (OKF6, TR146 and FIBS) and a 
human gingival fibroblast cell line (HGF) along with reconstructed human gingival 
and oral epithelial models (RHGE and RHOE respectively, SkinEthic) were used in 
the study.  
 
Cells/tissues were pre-stimulated for 24h with bacterial supernatants (P. gingivalis 
(Pg), A. actinomycetemcomitans (Aa), F. nucleatum (Fn), and P. intermedia (Pi) at 
1/100 or 1/10 respectively and then exposed to a combination of CsA (2000 or 250 
ng/ml) and bacterial supernatant for further 24h or 48h. 
 
Cell viability, cytokine/ chemokine (IL-1α; IL-6; IL-8) release; cell cycle and 
proliferation markers (DNA synthesis, cyclin B1, cyclin D1, CCNB1, and CCND1) 
and apoptosis (Bax, Bcl-2 protein and gene, and Fas-L gene) were assessed using 
MTT assay, ELISA, FACs analysis, quantitative PCR. Cell cycle analysis, DNA 
synthesis and expression of cyclins D1 and B1 in cell lines were evaluated 
simultaneously. 
 
Results: 
CCNB1 and CCND1 were significantly up-regulated in all RHGE cultures exposed to 
any of the combinations applied compared to controls (CCNB1: CsA+A.a; 1.543± 
0.039; CsA; 0.703± 0.032; A.a; 0.669± 0.002; untreated control; 1± 0.047)(CCND1; 
CsA+A.a; 3.41± 22 versus CsA; 1.046± 0.079; A.a; 2.127± 0.22; and untreated 
3 
 
control; 1± 0.106).  FACS analysis of monolayer cultures showed an apparent 
increase in proliferation rate, illustrated by DNA synthesis, of FIBS, OKF6, and HGF 
consistently with the combination (P.i plus 2000ng/ml CsA) compared to controls. 
CsA at 2000ng/ml caused a significant increase in cytokine release from both 
keratinocyte and fibroblast cell lines. Furthermore, bacterial products in combination 
with CsA had a synergistic effect on IL-6 and IL-8 release from HGF but had a little 
effect on cytokine release from keratinocytes. Conversely, the combined treatments 
significantly decreased IL-8 in RHOE. 
 
Conclusion:   
The results suggest that a clinically relevant dose of CsA (2000ng/ml) along with 
bacterial products stimulate the proliferation of gingival keratinocyte and HGF by 
activating the cell cycle and DNA replication. Thus, the presence of specific 
periodontal microorganisms may be important in the development of the condition.  
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General Introduction:  
 
Ciclosporin (CsA), a hydrophobic fungal metabolite, is a potent immunosuppressant 
used as the first choice for counteracting the rejection phenomena in organ 
transplantation patients and for the treatment of various autoimmune diseases (Condé 
et al., 2008; Faulds et al., 1993).The use of CsA however is associated with various 
side effects including neurotoxicity (Chang et al., 2001), hepatotoxicity (Galan et al., 
1995), nephrotoxicity (Woolfson & Neild, 1997), hypertension (Textor et al., 1994), 
and gingival hyperplasia (Seymour et al., 2000). 
 
CsA-induced gingival hyperplasia was first reported by Rateitschak-Plus et al in 1983 
occurring in 25-81% of patients taking CsA (Seymour & Jacobs, 1992). This lesion 
usually develops in the first 6 months of CsA administration and initially appears as a 
papillary enlargement and it is mostly restricted to the keratinized gingiva but it may 
grow in size with time and cover the crowns of teeth causing difficulties in 
mastication, speech and profound aesthetic and psychological problems (Marshall & 
Bartold, 1999; Ilgenli et al., 1999). 
 
Histopathologically, CsA-induced gingival hyperplasia is characterized by an increase 
in epithelial thickness with elongated rete pegs, increased vascularisation, focal 
infiltration of plasma cells and to a lesser extent lymphocytes (Buduneli et al., 2001; 
Mariani et al., 2004), and increased numbers of fibroblasts with accumulation of 
extracellular matrix components (Mariani et al., 1993; Deliliers et al., 1986).  
 
Despite the intensive studies investigating the cellular and molecular basics of the 
development of CsA-induced gingival hyperplasia, the exact mechanism underlying 
this condition is still unclear (Guo et al., 2008). Various risk factors have been 
described including age, sex, genetic pre-disposition, duration of therapy, concomitant 
medication such as calcium channel blockers, and gingival inflammation (Bartoli et 
al., 2004).    
 
However, a recent study suggested that the imbalance between cell proliferation and 
apoptosis may contribute to the pathogenesis of the hypercellularity observed in CsA-
induced gingival hyperplasia (Kantarci et al., 2007).  
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The effect of CsA on proliferation of HGF is still controversial ranging from absent to 
an increase or a decrease (James et al., 1995; Bartold, 1989; Pistorius et al., 2003). 
However, these discrepancies in studies have been attributed to heterogeneity of the 
HGF strain used (Hassell & Stanek, 1983), or to differences in the experimental 
conditions applied (Leonardi et al., 2001). Moreover, recent studies suggested that 
accumulation of gingival fibroblasts observed in drug-associated gingival hyperplasia 
resulted from the inhibition of apoptosis (Jung et al., 2008; Kantarci et al., 2007). 
 
Furthermore, recent attention has been drawn to the gingival keratinocytes as a 
potential part of the pathogenesis of CsA-associated gingival hyperplasia. The effect 
of CsA on gingival keratinocytes is still inconclusive (Cetinkaya et al., 2006) ranging 
from being pro-proliferative (Lauer et al., 2006), anti-proliferative (Tu et al., 2008), 
pro-apoptotic (Tu et al., 2009), anti-apoptotic (Buduneli et al., 2007), or no effect 
(Birraux et al., 2006). However, all of these in vitro studies were conducted in 
monolayer cultures that lack the multilayer structure of the in vivo epithelium. 
 
It has been shown that the pathogenesis of CsA-induced gingival hyperplasia is 
associated with up-regulated level of salivary contents of proinflammatory cytokines 
including IL-1α, IL-8, and IL-6 compared to healthy controls (Ruhl et al., 2004). 
Furthermore, it has been suggested that the presence of these cytokines may modulate 
the cellular response to the drugs (Sato et al., 2005; Sakagami et al., 2006). The effect 
of CsA on release of IL-6 and IL-8 by HGF in vitro was investigated but the results 
were inconclusive and have been related to the different cell strains used in each study 
(Maita et al., 2002; Morton & Dongari-Bagtzoglou, 1999). However, there have been 
no studies on release of these inflammatory cytokines in gingival keratinocytes 
following treatment with CsA.  
 
The clinical observations of the pathogenesis of CsA-induced gingival hyperplasia 
indicate a potential role for periodontal bacteria in the pathogenesis. However, most 
of these studies have been undertaken in vivo and the findings are still inconclusive: It 
is not clear whether accumulation of dental plaque is a consequence of gingival 
changes caused by the drug itself or it is an essential factor for initiating the 
pathogenesis (Seymour et al., 2000). This difficulty in determining the exact role of 
gingival inflammation might be related to the complexity of the in vivo situation.  
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Furthermore, it has been shown that a short course of treatment with Azithromycin, a 
macrolide antibiotic that acts against both gram-negative and –positive 
microorganisms, effectively improved the condition of the gingiva in patients with 
CsA-induced gingival hyperplasia (Condé et al., 2008). 
 
Seymour & Smith (1991) reported that maintaining adequate oral hygiene in humans 
markedly reduced the severity of CsA-induced gingival hyperplasia but it did not 
prevent the development of the condition. Animal studies have also shown that dental 
plaque exacerbated the development of gingival hyperplasia but a marked regression 
in the condition was noticed when chlorhexidine was applied (Fu et al., 1997; Pilatti 
et al., 1997). McGaw et al (1987) suggested that dental plaque may play a potential 
role as a local reservoir of CsA that affords a constant deposition of this agent on the 
juxtaposed surface of gingival epithelium.  
 
Thus, in light of the previous findings it would be valuable to investigate the potential 
role of pre-existing periodontal status in initiating the pathogenesis of CsA-induced 
gingival hyperplasia through an in vitro study and to investigate whether the exposure 
to a combination of CsA and bacterial products might modify the cellular response.  
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1.1   Oral Mucosa: 
The mouth is a key point of entry for exogenous material into the body and can be 
thought of as the gateway to the digestive and the respiratory systems.  
The oral mucosa shows structural variation in various regions of the oral cavity and 
hence it can be categorized into three functional types (Avery et al., 2002):  
 Lining mucosa: covers the underside of the tongue, inside of the lips, cheeks, 
floor of the mouth, and the alveolar processes. This mucosa must be as 
flexible as possible to perform its function of protection.  
  Masticatory mucosa: covers the hard palate and gingiva that are exposed to 
compressive and shear forces and to abrasion during the mastication of food. 
  Specialized mucosa: covers the dorsal surface of the tongue 
 
1.1.1 Functions of the oral mucosa 
The oral mucosa has specific functional roles within the oral cavity. The main 
function is the protection of underlying tissues by resisting mechanical stress 
(compression, stretching, and shearing), protecting against surface abrasions and also 
by restricting the invasion by exogenous and endogenous pathogens and materials 
(Nanci &Ten Cate, 2008).  
 
Another important function of the oral mucosa is its sensory abilities. Receptors 
within the oral mucosa are able to detect and respond to various stimuli in the mouth 
(temperature, touch, and pain) as well as initiate reflexes (swallowing, gagging, and 
salivating) (Nanci &Ten Cate, 2008).  
 
In addition, the oral mucosa maintains the moist surface of the mucous membrane 
within the oral activity as it contains the ducts of major salivary glands and also is 
directly associated with all of the minor salivary glands (Nanci &Ten Cate, 2008).   
 
1.1.2. Gingiva: 
The gingiva can be defined, in addition to being a part of the periodontium, as an 
extension of the oral mucosa that covers the alveolar processes and the cervical 
portions of the teeth (Bartold & Narayanan, 2006; Genco et al., 1990). Anatomically, 
the gingiva has been divided into three areas: the free marginal gingiva, the 
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interdental gingiva and the attached gingiva (Bartold et al., 2000). Histologically, the 
gingival tissue may be divided into two parts: 
(a) The gingival epithelium and (b) the gingival connective tissue. 
 
The gingival epithelium: 
The gingival epithelium is considered as a first line of defence against both bacterial 
invasion and mechanical trauma (Dale, 2002). As illustrated in (Fig 1.1), human 
gingival epithelium is subdivided into three distinct anatomical areas (Nield-Gehrig & 
Willmann, 2007): (a) oral gingival epithelium (b) sulcular epithelium and (c) 
junctional epithelium. 
(a) Oral gingival epithelium; that lines the outer surface of the gingival tissues. This 
portion of gingival epithelium is keratinized / parakeratinized stratified squamous 
epithelium composed of several cell layers (Bartold et al., 2000; Genco et al., 1990; 
Lindhe et al., 2003): the basal layer (stratum basal or stratum germinativum), stratum 
spinosum (Prickle cell layer), granular layer, and the cornified layer (stratum 
corneum). 
 
The cells of the basal layer (often called the stratum germinativum) are either 
cylindrical or cuboid residing on an uneven basement membrane that separates the 
epithelium from the connective tissue and protrudes epithelial digital extensions, 
termed “rete ridges”, into the underlying tissue (Bartold et al., 2000; Genco et al., 
1990; Lindhe et al., 2003). 
 
Superficial to the basal layer, the cells undergo differentiation resulting in large, 
polyhedral cells that show short cytoplasmic processes resembling spines and forming 
the so-called stratum spinosum, the thickest layer of all the epithelial layers (Bartold 
et al., 2000; Genco et al., 1990; Lindhe et al., 2003). Upward of the stratum 
spinosum, the cells tend to be more flattened, contain cytoplasmic keratohyaline 
granules and form the granular layer (Genco et al., 1990; Bartold et al., 2000). In the 
most superficial layer, the cells become markedly flattened, closely packed and lack 
their nuclei and organelles transforming into keratinized cells of the stratum corneum 
(Genco et al.,1990; Lindhe et al., 2003; Bartold et al., 2000). 
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In addition to those keratinocytes, other cell types can also been identified in the 
gingival epithelium (Bartold et al., 2000; Lindhe et al., 2003) including: 
Immunocompetent lymphocytes, Langerhans cells, (Bartold et al., 2000; Lindhe et al., 
2003) melanin-producing cells, Melanocytes, (Bartold et al., 2000; Mayer, 1973) and 
Merkel cells that are believed to possess a sensory role (Lindhe et al., 2003). 
(b) Sulcular epithelium: the epithelial tissue that lines the gingival sulcus. 
(c) Junctional epithelium: the epithelium tissue that forms the bottom of the gingival 
sulcus and attaches the gingiva to the tooth surface. 
 
Both the oral sulcular and the junctional epithelium are non-keratinized, stratified 
squamous epithelium with a very fast cellular turnover rate (Gorrel et al., 2004). 
However, lacking the cornified cell layer in both the sulcular and the junctional 
epithelium makes them a less effective protective barrier. Consequently, the sulcular 
and junctional areas of the oral epithelium are regarded as weak points for entry into 
and invasion of the gingival connective tissue by bacteria and bacterial products 
(Nield-Gehrig & Willmann, 2007). 
 
 
 
Figure 1.1. Microscopic histological anatomy of the gingival epithelium junctional 
epithelium, oral sulcular epithelium, and oral gingival epithelium. (Taken from 
Williams, Hughes, Odell & Farthing. Pathology of Periodontal Disease. Oxford 
Medical Publications  ISBN 0192619551 1992). 
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The gingival connective tissue: 
The gingival connective tissue consists primarily of cells, extracellular matrix, nerves 
and blood vessels (Genco et al., 1990). The predominant cell in the gingival 
connective tissue is the fibroblast which has been considered as the engineer and 
architect of the extracellular matrix by maintaining an organized synthesis and 
turnover of collagen and glycosaminoglycans (Morton & Bagtzoglou, 1999; Chae et 
al., 2006). Furthermore, gingival fibroblasts possess the ability to express a variety of 
cytokines including IL-1, IL-6, and IL-8 (Modéer et al., 2000).  Additionally, other 
less common cells may normally be identified in the gingival connective tissue 
including undifferentiated mesenchymal cells, mast cells and macrophages (Genco et 
al., 1990; Lindhe et al., 2003).  
 
Extracellular matrix (ECM): 
Extracellular matrix represents the material that surrounds all connective tissue cells 
and underlies all epithelia and endothelia (Embery et al., 2000) deriving its 
importance not only from being a supporting system of tissue’s physical structure, but 
also from its crucial role in regulating proliferation, development, migration and 
function of cells (Embery et al., 2000; Martinez & Araújo, 2004).  
 
The extracellular matrix of the gingival connective tissue consists of collagens and 
non-collagenous proteins (Vardar et al., 2005; Embery et al., 2000). Collagens 
comprise approximately three fifth (60%) of the total proteins present (Mariotti, 1993; 
Palaiologou et al., 2001) and five types of collagen have been identified throughout 
the gingival connective tissue including types 1, 3, 4, 5 and 6 (Mariotti, 1993; 
Narayanan et al., 1980). 
 
With respect to the non-collagenous proteins, they are primarily composed of core 
protein of proteoglycans (PGs) covalently attached to one or more highly anionic 
glycosaminoglycan (GAG) chains (Embery et al., 2000; Vardar et al., 2005). Of the 
glycosaminoglycans currently recognized dermatan sulphate, chondroitin-4-sulfate, 
heparin sulphate and hyaluronic acid are the most abundant (Embery et al., 2000). 
 
 Immunohistochemical studies have also shown a number of proteoglycans in the 
underlying connective tissue including decorin, biglycan, versican and syndecan 
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(Embery et al., 2000), in addition to a variety of adhesive glycoproteins including 
fibronectin, tenascin, laminin, and other glycoproteins such as osteonectin (Embery et 
al., 2000; Mariotti, 1993).  
 
1.2. Gingival Hyperplasia  
1.2.1. Hereditary gingival fibromatosis, also termed idiopathic gingival overgrowth, 
hereditary gingival hyperplasia, and elephantiasis gingivae (Coletta & Graner, 2006; 
Häkkinen & Csiszar, 2007), is a rare genetic disorder characterized by spontaneously 
and slowly progressive gingival enlargement. It can be generalized affecting both the 
maxilla and mandible or localized in specific areas involving, in particular, the 
maxillary tuberosities and the labial gingiva around the lower molars (Coletta & 
Graner, 2006; Häkkinen & Csiszar, 2007). The appearance of gingival enlargement 
usually initiates at the time of permanent tooth eruption and, in fewer cases, at the 
time of eruption of the primary teeth, but it is rarely present at birth (Häkkinen & 
Csiszar, 2007). Furthermore, the development of this condition appears to be 
correlated to the presence of teeth since disappearance of this lesion in edentulous 
patients has been reported in many studies (Coletta & Graner, 2006; Häkkinen & 
Csiszar, 2007).  
 
 Hereditary gingival hyperplasia can be identified as an isolated disease involving 
only the gingivae or as a manifestation of a variety of syndromes (such as: 
Zimmerman-Laband syndrome, Cross syndrome, Rutherford syndrome, Ramon 
syndrome, Juvenile hyaline fibromatosis, and Jones syndrome) in association with 
other characteristics including hypertrichosis, mental retardation, epilepsy, hearing 
loss, supernumerary teeth, and abnormalities of the fingers and toes (Häkkinen & 
Csiszar,  2007; Clocheret et al., 2003). 
 
1.2.2. Drug-induced gingival hyperplasia: 
Drug-induced gingival hyperplasia is a common side effect associated with the 
systemic administration of several drugs (Güncü et al., 2006). These drugs can be 
categorized into three main classes: 
Anticonvulsants: such as phenytoin, the first choice for controlling the convulsive 
seizure disorders in patients experiencing epilepsy (Kato et al., 2005; Hallmon & 
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Rossmann, 1999). The development of phenytoin-induced gingival hyperplasia was 
first reported in 1939 by Kimball and is estimated to occur in up to 57% of patients 
(Brunet et al., 2001). 
 
Calcium channel blockers:, also known as calcium antagonist (Hallmon & Rossmann, 
1999) including nifedipine, diltiazem and verapamil, are antihypertensive agents 
widely used in elderly individuals experiencing angina and various cardiovascular 
diseases (Nishimura et al., 2002). The use of these therapeutic agents has also been 
associated with the development of gingival hyperplasia in approximately 10% of 
patients (Seymour, 2006). 
 
CsA: an immunosuppressive agent broadly used to counteract organ transplant 
rejection phenomenon and to treat various autoimmune disorders such as bullous 
pemphigoid, psoriasis and rheumatoid arthritis (Bostrom et al., 2005). CsA-induced 
gingival hyperplasia was first described in 1983 by Rateitschak-Plüss (Reviewed by 
Das et al., 2002) and is now estimated to occur in up to 30% of CsA-treated patients 
(Seymour, 2006).  
 
1.2.3. Clinical Features of Drug-induced gingival Hyperplasia: 
Gingival hyperplasia usually begins within 1-3 months of drug administration as a 
papillary enlargement that increases in size with continuing treatment, reaching its 
typical marked lobulated nodular appearance after 12- 18 months (Kuru et al., 2004; 
Tyldesley et al., 1984). The condition is usually more prominent in the facial aspects 
of the anterior segments (Seymour & Jacobs, 1992; Strachan et al., 2003; Wilson et 
al., 1998) but it may also be present throughout the mouth (Thomas et al., 1991). The 
clinical presentations of gingival hyperplasia induced by CsA, nifedipine or phenytoin 
are largely similar (Thomas et al., 1991; James et al., 2000; Brunet et al., 2001; 
Akimoto et al., 1991) ranging from being firm and fibrous in consistency to spongy 
and oedematous. It may also be hemorrhagic with secondary inflammation. (Daley & 
Wysocki, 1984; James & Linden, 1992; Eslami et al., 2004). 
 
 Gingival hyperplasia is often localised to the attached gingiva (Marshall & Bartold, 
1999), but in severe cases it may extend lingually, facially, and coronally partially or 
completely involving the crowns. These changes may cause difficulty with 
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mastication and speech, halitosis, tooth displacement, delayed eruption and 
psychological stress due to the aesthetic appearance (Strachan et al., 2003; Kato et al., 
2005) (Fig 1.2). 
 
 As a result of these different clinical presentations, gingival hyperplasia has been 
graded into four categories (Gómez et al., 1997; Miranda et al., 2005) according to 
criteria of Angelopoulos & Goaz (1972)  modified later by Miller & Damm (1992) as 
following: 
Score 0: no gingival hyperplasia (normal gingiva) 
Score 1: mild gingival hyperplasia, in which the hyperplastic gingiva (as much as 
2mm or less) covers only the cervical third or less of the tooth crown. 
Score 2: moderate gingival hyperplasia, where the hyperplastic gingiva (ranging 
Between 2 to 4 mm) extends to the middle third of the tooth crown. 
Score 3: severe gingival hyperplasia, in which the overgrown gingiva (more than 
4mm) covers more than two thirds of the tooth crown. 
 
 
Figure 1.2 A typical clinical status of CsA-induced gingival hyperplasia in 45 year 
old kidney transplant male patient after 10 months of treatment with CsA. (Taken 
from (Popova & Mlachkova, 2007). 
 
 
1.2.4. Histopathological Features of drug-induced gingival Hyperplasia: 
The microscopic examination of sections of drug-induced hyperplastic gingival tissue 
shows increased thickening of the epithelium associated with different degree of 
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acanthosis and parakeratosis and elongated rete pegs (Collan et al., 1982; O’Valle et 
al., 1994; Spolidorio et al., 2004; Mariani et al., 2004; Hyland et al., 2004; Pisanty et 
al., 1988; Pisanty et al., 1990). Enlargement of the underlying gingival connective 
tissue may also be present. This may be the result of increased vascularity, 
accumulation of the extracellular matrix materials involving amorphous ground 
substance and irregular collagen bundles (mostly Collagen type 1 and 3) and a 
significant increase in elongated fibroblasts (Mariani et al., 1993; Ayanoglou & Lesty, 
1999). Focal infiltration of inflammatory cells, mainly plasma cells and to a less 
degree lymphocytes were also reported (Buduneli et al., 2001).  
 
1.2.5. Prevalence of drug-induced gingival hyperplasia: 
Three main categories of drug –induced gingival hyperplasia (CsA, calcium channel 
blockers, and phenytoin) have been recognized but so far there is no agreement with 
respect to an accurate determination of the prevalence rate in each drug category 
(Costa  et al., 2007; Seymour,  2006). Some studies report a wide range of prevalence 
rate estimated between 10% to 50% for phenytoin, 8% to 70% for CsA, and 0.5% to 
83% for nifedipine (Kataoka et al., 2005; Nishikawa et al., 1996; Seymour et al., 
1988; Barak et al., 1987). Other reports however, have shown a prevalence rate of 
50% for phenytoin, with much lower prevalence for CsA and calcium channel 
blockers which are 30% and 10% respectively (Seymour, 2006; Seymour et al., 
2000). This great variability in the prevalence rate may stem from differences in 
clinical criteria and methods used in diagnosis and measurement of gingival changes, 
the characteristics and number of subjects involved in the study sample, in addition to 
other factors including the concomitant use of other drugs which might influence the 
condition, age, gender, and drug variables (Romito et al., 2004; Afonso et al., 2003; 
Brunet et al., 2001; Costa et al., 2006). 
 
1.2.6. Risk Factor for drug-induced gingival hyperplasia: 
1.2.6.1. Demographic variables: 
Age: 
Age has been identified as a significant predisposing factor for the development of 
gingival hyperplasia in patients treated by CsA or phenytoin (Seymour, 2006; Daley 
et al., 1986; Esterberg, 1945; Hefti et al., 1994) or those taking a combination of CsA 
and nifedipine (Thomason et al., 1997). Age has not been reported as a relevant risk 
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factor for calcium channel blockers-induced gingival hyperplasia since these drugs 
have narrow spectrum of efficiency restricted mainly to management of certain 
situations such as hypertension which are more common in the post middle-aged 
(Kataoka et al., 2005; Seymour et al., 2000). The increased susceptibility to phenytoin 
or CsA -induced gingival hyperplasia observed in adolescents could be ascribed to the 
high sensitivity of young gingival fibroblasts to the challenging medication (Wright et 
al., 2005; Daly et al., 1992). 
 
Gender: 
Most available data point out that CsA-induced gingival hyperplasia has a higher 
incidence and severity in men (Thomason et al., 1995; Thomason et al., 1996; 
Tyldesley & Rotter, 1984). Furthermore, some studies have shown that males 
receiving calcium channel blockers were three times more likely than females to be 
affected by gingival enlargement (Ellis et al., 1999). In contrast, other reports have 
revealed no such a positive correlation between gender and development of gingival 
hyperplasia in patients treated by phenytoin (Güncü et al., 2006; Brunet et al., 2001) 
or with CsA alone or a combination of CsA and nifedipine (Somacarrera et al., 1994; 
Pernu  et al., 1992; Cebeci  et al., 1996; King  et al., 1993).  
 
1.2.6.2. Pharmacokinetic Variables: 
 Drug Formulation: 
Wondimu et al (1996) reported that patients treated with CsA solutions had earlier 
onset and more severe gingival hyperplasia than those receiving CsA capsules. These 
findings may be ascribed either to differences in the drug’s pharmacokinetics in terms 
of bioavailability and time to peak blood concentrations, or to a potential local impact 
of CsA achieved by the higher salivary CsA levels available in individuals taking CsA 
solutions than those ingesting CsA capsules (Seymour et al., 2000; Modeer et al., 
1992).  
 
 Duration of therapy: 
Although most studies have shown no positive correlation between the duration of 
drug administration and progress of gingival hyperplasia (Pernu et al., 1992; King et 
al., 1993; Pernu et al., 1993; Wondimu et al., 1993; Vescovi et al., 1997; Thomas et 
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al., 2001), other reports have demonstrated that sharp onset in development of 
gingival hyperplasia occurs within the first 3-6 months and then steadily progress 
(Daley et al., 1986; Somacarrera et al., 1994). These findings were supported by 
animal studies that have shown a positive relationship between gingival hyperplasia 
induced by CsA, nifedipine, and phenytoin and the duration of therapy (Khoori et al., 
2003; Nishikawa et al., 1996). 
 
 Drug dosage and drug serum concentration: 
The role of drug dosage and drug serum concentration in the development of gingival 
hyperplasia has remained a controversial issue ranging from findings presenting a 
strong association between the progression of gingival hyperplasia and both dose and 
drug serum levels (Thomas et al., 2000; Costa et al., 2007; Addy et al., 1983; 
Thomason et al., 1997), to contrasting reports showing no statistically significant link 
(Büchler et al., 2004; Brunet et al., 2001; Nery et al., 1995). There is, however, a 
general consensus that a threshold concentration of the drug may be necessary to elicit 
the gingival alterations, taking into account the potential variation of the threshold 
concentration either inter-individually or from one drug to another (Seymour, 2006; 
Chabria et al., 2003; Somacarrera et al., 1994).  
 
 Salivary drug concentration: 
Conflicting data similar to those observed with the drug serum concentration 
parameter have also been reported for the salivary drug concentration index (Seymour 
et al., 2000).  
 
1.2.6.3. Genetic Factors: 
Gingival fibroblast Heterogeneity: 
Some authors have attributed the inter-individual variation in the susceptibility to 
gingival hyperplasia- inducing drugs to phenotypic and functional heterogeneity 
among subpopulations of gingival fibroblasts in relation to proliferation, synthesis of 
extracellular matrix, expression of collagenase enzymes, tissue inhibitor of 
metalloproteinase activity and response to challenging drugs (Chabria et al., 2003; 
Myrillas et al., 1999; Doufexi et al., 2005). In light of this fact, patients who develop 
drug-induced gingival hyperplasia may have drug-sensitive gingival fibroblast strains 
versus drug-resistant gingival fibroblast subpopulations that could be the most 
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predominant type in those non-responders to drugs (Flynn et al., 2006; Varga et al., 
1998).  
 
Human leukocyte antigen (HLA) Expression: 
 Many studies have concentrated on the potential role of human leukocyte antigens 
(HLA) phenotype as a risk factor for drug-induced gingival hyperplasia (Wright et al., 
2005, Vescovi et al., 2005). However, most findings concur that individuals 
expressing HLA-DR2, A24, and B37 may be more susceptible to developing this side 
effect than those who express HLA-DR1 (Seymour, 2006; Thomason et al., 1996; 
Seymour et al., 2000).  
 
Cytochrome P450 enzyme polymorphism: 
Hepatic cytochrome P450 enzymes are primarily responsible for the metabolism of 
phenytoin, CsA, and nifedipine, and some studies have suggested that P450 
polymorphism may explain the variation in incidence and severity of drug-induced 
gingival hyperplasia among patients (Seymour et al., 2000; Doufexi et al., 2005).  
 
 α2 integrin polymorphism: 
α2 integrin is a transmembrane glycoprotein receptor mediating the initial step of 
collagen phagocytosis by promoting fibroblast adhesion to type I collagen (Kataoka et 
al., 2003; Ogino et al., 2005). Recent investigations have revealed that the decreased 
levels of α2 integrin reported in patients with drug-induced gingival hyperplasia were 
more frequently associated with specific gene (α2 integrin 807 C allele) than that in 
healthy control (Ogino et al., 2005). 
 
Cytokine gene polymorphism: 
Despite the putative pivotal role of cytokines in the pathogenesis of drug-induced 
gingival hyperplasia (section 1), little is known about the influence of cytokine gene 
polymorphisms on development of the condition. However, while some studies have 
failed to report any positive correlation between IL-6 gene polymorphism and 
incidence or severity of CsA-induced gingival overgrowth (Drozdzik et al., 2005), a 
recent report has shown that IL-1α -889 alleles were considerably more frequent in 
healthy control than those experiencing CsA- induced gingival enlargement. 
Therefore, these findings have suggested that IL-1α gene polymorphism might be 
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responsible for the variable susceptibility to CsA in terms of gingival hyperplasia 
development (Bostanci et al., 2006). 
 
Transforming growth factor (TGF-β1) gene polymorphism: 
In agreement with findings that have revealed that TGF-β1 levels either in plasma (at 
low concentrations) or in GCF (at higher levels) might be indicators for progress of 
gingival hyperplasia in patients concomitantly treated by CsA and nifedipine (Wright 
et al., 2004; Ellis et al., 2004), genetic investigations have also shown a positive 
correlation between TGF-β1 gene polymorphism and expression of gingival 
hyperplasia induced by concomitant use of CsA and nifedipine (Linden et al., 2001). 
 
Multidrug resistance (MDR1) gene polymorphism: 
MDR1 genes encode the drug transporter P-glycoprotein (P-gp) which is important 
for the absorption, distribution and elimination of gingival hyperplasia- inducing 
drugs. Hence, any variation in P-gp expression will lead to pharmacokinetic variables 
of the drug, consequently, discrepancy in the effect of the drug (Wei et al., 2005; 
Meisel et al., 2006). While some studies have found no evidence of a relationship 
between the MDR1 gene polymorphism and development of CsA-induced gingival 
hyperplasia (Drozdzik et al., 2004), other reports have shown a marked association 
between this specific gene polymorphism and calcium channel blockers-induced 
gingival enlargement (Meisel et al., 2006).  
 
1.2.6.4. Concomitant medication: 
The effect of concomitant medication on variability of incidence and severity of drug- 
induced gingival hyperplasia has been extensively studied (Seymour, 2006; Wilson et 
al., 1998). A decreased severity of gingival hyperplasia has been reported in patients 
concurrently receiving CsA and other immunosuppressant such as azathioprine and 
prednisolone (Seymour et al., 2000; Hassell & Hefti, 1991; Somacarrera et al., 1994) 
that might be ascribed either to the well-known anti-inflammatory efficacy of 
azathioprine and prednisolone against dental plaque (Thomason et al., 2005) or to the 
lower CsA dosages used on this multiple immunosuppressive regimen (Costa et al., 
2006; Costa et al., 2007; Thomason et al., 2005).  
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Other studies have reported that patients treated with CsA in conjunction with calcium 
channel blockers have shown a higher incidence of gingival enlargement than those 
maintained on CsA alone (Seymour et al., 2000; Bokenkamp et al.,1994; O’valle et 
al., 1995). These findings have been attributed to the synergistic impact of the drug 
combination on the gingival tissue (Spolidorio et al., 2003; Chabria et al., 2003).  
 
The use of phenobarbital and/or carbamazepine along with phenytoin has also been 
markedly associated with higher prevalence of gingival overgrowth than that with 
phenytoin alone (Seymour, 2006; Brunet et al., 2001). 
 
1.2.6.5. Periodontal Variables: 
There is a wealth of conflicting data concerning the exact role of dental plaque and 
gingival inflammation in the aetiology of CsA-induced gingival hyperplasia ranging 
from whether it is a contributory factor or merely a consequence of the gingival 
enlargement (Afonso et al., 2003; Seymour et al., 2000). Some studies have shown 
that dental plaque has no essential role in the development of gingival hyperplasia 
induced by CsA alone or by combined administration of CsA and nifedipine, and also 
claimed that plaque control has only limited efficacy in controlling this disease 
(Khoori et al., 2003; Bostanci et al., 2006; Friskopp & Klintmalm, 1986). Other 
reports, however, have recognized the plaque index and gingivitis as considerable risk 
factors for the expression of gingival overgrowth (Aimetti et al., 2005; Somacarrera et 
al., 1994). These postulations are based on the potential role of dental plaque as a 
reservoir for CsA which affords affective and continuous local concentrations of CsA 
(Niimi et al., 1990)  and were supported by  other findings that  have shown that the 
local bioavailability of CsA is much higher in inflamed sites than in non-inflamed 
ones (Thomas et al., 2000). 
 
There has been strong evidence supporting the importance of the plaque index in 
phenytoin-induced gingival hyperplasia in which the enhanced accumulation of 
collagen in response to phenytoin appears to be promoted by dental plaque-induced 
chronic gingivitis (Akiyama et al., 2006). Furthermore, the importance of bacterial 
gingivitis in emerging gingival hyperplasia induced by nifedipine has also been 
reported by other studies (Seymour et al., 2000; Eslami et al., 2004) These findings 
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were based on the clinical observations that did not show any sign of enlargement in 
edentulous regions (Eslami et al., 2004). 
 
However, despite the conflicting information on the importance of dental plaque in 
this pathogenesis, there is a consensus that bacterial gingivitis at least exacerbates the 
emerging of CsA-induced gingival hyperplasia and that good oral hygiene improves 
the condition (Seymour et al., 2000; Seymour, 2006). 
 
1.3 Oral Bacteria:  
The oral cavity is a habitat for over than 300 species of microorganisms that colonize 
the oral and gingival mucosa (Han & Shi, 2000). These bacteria can be classified as 
commensal (non-pathogenic) and pathogenic bacteria (Kimball et al., 2006). Among 
the most predominant periodontopathic bacteria are the anaerobic Gram-negative 
bacteria including Porphyromonas gingivalis (P.g), Aggregatibacter 
actinomycetemcomitans (A.a), Prevotella  intermedia (P.i), Fusobacterium nucleatum 
(F.n), and Tannerella forsythia (T.f) in addition to oral spirochetes such as Treponema 
denticola (T.d) (Han & Shi, 2000; Bascones & Figuero, 2005; Sela, 2001). The 
periodontopathic bacteria secrete a variety of extracellular virulence factors that 
initiate and progress the periodontal diseases by affecting various pathways including 
cytokine expression, cell cycle and apoptosis (Huang et al., 2001; Sugai & 
Kawamoto, 1998; Stathopoulou & Galicia, 2009) 
 
The relationship between periodontal bacteria and CsA-induced gingival hyperplasia:  
Increasing attention has been focused on the role of periodontal bacteria in the 
initiation and progression of gingival hyperplasia in patients taking CsA but this 
relationship has yet to be clearly defined. Clinical observations, however, revealed 
that development of gingival hyperplasia in patients taking CsA is highly related to 
the oral hygiene status (Vescovi et al., 2005). In addition, McGaw et al (1987) indicated 
the potential role of dental plaque as a local reservoir of CsA that may afford a 
constant deposition of this drug on the adjacent gingival epithelium.  
 
Gong et al (2008) found that P. gingivalis, T. forsythia and T. denticola were more 
frequently present in patients taking CsA and developing gingival hyperplasia 
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compared to those patients who were taking CsA but did not develop the condition. 
These observations were in agreement with Leung et al’s report (2003) that found that 
gram-negative rods and spirochetes were the main bacterial species being detected in 
the subgingival microflora from patients taking CsA and developing chronic 
periodontitis compared to CsA-treated patients without periodontitis.  
 
Moreover, Romito et al (2004) reported that microorganisms including A. 
actinomycetemcomitans (23%), P. gingivalis (36%), P. intermedia (93%), 
Fusobacterium sp. (66%), Campylobacter rectus (30%), Micromonas micros (66%), 
enteric rods (0%), and yeasts (30%) were isolated from patients taking CsA with or 
without gingival hyperplasia. Micromonas micros, however, was more frequently 
present in patients with gingival hyperplasia indicating that colonization of oral cavity 
by this microorganism might play a role in the pathogenesis. Furthermore, these 
clinical findings were supported by an animal study that found that the severity of 
inflammation and the subsequent development of gingival hyperplasia were enhanced 
by the existence of large amounts of gram negative rods and anaerobic bacteria in 
CsA- treated ferret and subject to experimental ligature periodontitis (Fischer et al., 
1996).  
 
These findings were in parallel with other microbiological studies that were carried 
out in patients developing gingival hyperplasia induced by phenytoin and nifedipine. 
Akiyama et al (2005) reported that P. gingivalis and T. denticola had a positive 
correlation with the development of gingival hyperplasia in patients taking phenytoin. 
Takada et al (2003) also found that black pigmented obligate anaerobic Gram-
negative rods, particularly, P. intermedia and to a less degree P. gingivalis were 
predominately existed in the subgingival microflora of patients developing phenytoin- 
induced gingival hyperplasia. Nakou et al (1998) found that F. nucleatum was one of 
the most prevalent subgingival bacterial species being isolated from the nifedipine-
associated gingival enlargement lesions in human. 
 
In contrast with these findings, Romito et al (2003) did not find a positive correlation 
between Gram-negative enteric rods and development of gingival hyperplasia in 
patients taking CsA. However, Saraiva et al (2006) found that transplant surgery 
patients who were under a CsA regimen showed a quantitative and qualitative 
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modulation in their subgingival microflora after 90 days of CsA administration but 
there was no positive correlation between development of gingival hyperplasia and a 
specific species of bacteria. 
Overall there seems to be a general consensus that anaerobic Gram-negative bacteria 
and oral spirochetes predominate in the subgingival microflora in patients 
experiencing CsA-induced gingival hyperplasia. However, it is not clear if the change 
in periodontal microflora is due to the immunosuppressive action being exerted by 
CsA, a subsequent result of gingival hyperplasia or whether the patient’s periodontal 
status may play a role in pathogenesis of CsA-induced gingival hyperplasia. 
 
1.4. Ciclosporin: 
1.4.1. History, uses and effects: 
CsA is a fermented fungal metabolite of Tolypocladium inflatum W. Gams that has a 
lipophilic cyclic polypeptide structure composed of 11 amino acids (Moussaïf et al., 
1997; Lauer et al., 2006). It was discovered accidentally in the early 1970s by Jean 
Borel (reviewed-Thomas et al., 1991; Dreyfuss et al., 1976). It is a potent 
immunosuppressive agent (Moussaïf et al., 1997), and since its introduction, has 
become the first choice for counteracting the rejection phenomenon following human 
organ transplantation (Guaguere et al., 2004; Calne et al., 1978; Thomason et al., 
2005; Kahan, 1989). It had improved the 5-year survival rate following organ 
transplantation from 50% to 90% (Thomas et al., 1991) and also improved the 
management of some autoimmune diseases (Hassell & Hefti, 1991; Faulds et al., 
1993) such as psoriasis (Ellis et al., 1986), atopic dermatitis (Hoare et al., 2000), 
uveitis (Duarte et al., 2003), rheumatoid arthritis (Cutolo et al., 1997), pemphigus 
(Thivolet et al., 1985), type1 diabetes mellitus (Khoori et al., 2003), Behcet’s disease 
(Koh et al., 2004), lupus erythematosis (Isenberg et al., 1980), myasthenia gravis 
(Morton et al., 1999), Crohn’s Disease (Faulds et al., 1993), multiple sclerosis and 
primary biliary cirrhosis (Wright  et al., 2005), immune-mediated ocular diseases such 
as Sjögren syndrome, vernal keratoconjunctivitis and corneal ulcers (Leonardi et al., 
2001).  
 
There are, however, several adverse side effects associated with the use of CsA 
including nephrotoxicity (Woolfson et al., 1997), hepatotoxicity (Galan et al., 1995; 
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Klintmalm  et al., 1981), neurotoxicity (Beaman et al., 1985; Chang et al., 2001), 
hypertension (Arzate et al., 2005), hirsutism (Laupacis et al., 1982; Vescovi et al., 
2005), diabetes (Thomason et al., 2005), osteoporosis (Cueto-Manzano et al., 1999; 
Guo et al., 1998), cutaneous disorders (Afonso et al., 2003; Menni et al., 1991) and 
opportunistic fungal and viral infections (Seymour et al., 1997). 
 
In addition, CsA use may also be accompanied by oral complications including: 
gingival hyperplasia (O’Valle et al., 1994; Seymour et al., 1997; Linden et al., 2001; 
Dongari  et al., 1993), Kaposi’s sarcoma (Stabellini et al., 2004), lingual fungiform 
papillae hypertrophy (Marshall et al., 1999), hairy leukoplakia and increased 
disposition to malignant transformations such as lip cancer (Wright et al., 2005). CsA 
also appears to affect dento-alveolar bone mineralization with the deposition of 
irregular cementum, decreased bone volume and increased marrow volume 
(Ayanoglou et al., 1997; Chin Shen et al., 2001). 
 
1.4.2. Ciclosporin Pharmacokinetics: 
CsA is absorbed primarily in the upper small intestine (Wright et al., 2005) and peak 
CsA concentrations in plasma are attained at about 3-4 hours (Hallmon & Rossmann, 
1999). This absorption, however, depends largely on bile secretion [which is required 
for emulsification of the formulation (Guagu re et al., 2004; Steffan et al., 2004; 
Venkataramanan et al., 1986; Takaya et al., 1989)], oil droplet size, gastrointestinal 
motility, gastric emptying, and any concurrent medication (Wright et al., 2005; Katz 
1997; Steffan et al., 2004). Thus, the variation in these factors could explain the great 
inter-individual variability in terms of pharmacokinetic aspects of CsA (Guagu re et 
al., 2004).  
 
CsA is highly bound to blood cells and plasma components. Hence, it readily 
distributes in various tissues (Mendonza et al., 2004) and it is effectively metabolized 
in the liver and to a less degree in the intestines by the cytochrome P450 enzymes 
CYP3 A4 where the CsA molecule undergoes hydroxylation and demethylation 
yielding multiple metabolites (Steffan et al., 2004, Maurer et al., 1984, Vickers et al., 
1992, Whalen et al., 1999). Finally, CsA which has a serum half-life ranging from 17 
to 40 hours (Hallmon & Rossmann, 1999) is excreted primarily via the bile through 
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faeces with less than 10% eliminated through the kidneys as unchanged CsA 
(Venkataramanan et al., 1988; Guagu re et al., 2004). 
 
1.4.3. Mechanism of the immunosuppressive action of Ciclosporin: 
CsA exerts its specific immunosuppressant activity by directly targeting the T-
lymphocytes (Stabellini et al., 2004) by binding to its respective cytoplasmic 
receptors called cyclophillins, a group of the immunophillin family receptors 
available abundantly in T-cells (Handschumacher et al., 1984; Schreiber, 1991). The 
CsA- cyclophillin complex then interacts with and inhibits calcineurin, a 
calcium/calmodulin-dependent serine/threonine phosphatase (Mendonza et al., 2004, 
Büchler et al., 2004). Calcineurin plays a pivotal role in the transcriptional activation 
of mRNA encoding IL-2 and other cytokines signalling by calcineurin pathways such 
as IL-4 and interferon (IFN)-γ (Guaguere et al., 2004, Rao et al., 1997). Blocking of 
dephosphorylation results in suppression of IL-2 expression (Almawi et al., 2000) 
thereby impeding T-cell activation (Fierro et al., 2003). 
 
 CsA also targets and inhibits other cells involved in the immune response including 
both macrophages and B- lymphocytes (Yagiela et al., 2004; Cutolo et al., 1997).  
 
1.5. Mechanism of CsA-induced gingival hyperplasia: 
 The mechanism underlying the development of CsA-induced gingival hyperplasia is 
still unclear. But it has been suggested that this pathogenesis might reflect complex 
interactions between the drug, gingival tissue and local released mediators (Aimetti et 
al., 2008; Morton & Bagtzoglou, 1999) (Fig 1.3). 
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Figure 1.3. Possible pathways of CsA-induced gingival hyperplasia 
 
 
1.5.1. Effect of CsA on extracellular matrix (ECM) metabolism: 
The physiological balance of ECM metabolism is maintained by equilibrium between 
collagen synthesis and degradation (Lucattelli et al., 2003; Laurent, 1987; Bartold, 
1995). In the gingival tissue, disrupted homeostasis between breakdown and 
expression of ECM may lead either to excessive ECM accumulation (fibrosis) or to 
ECM destruction (periodontitis) (Tüter et al., 2002; Woessner, 1994; Chong et al., 
2007). 
 
1.5.1.1. Effect of CsA on ECM synthesis: 
The mechanism whereby CsA induces excessive accumulation of the gingival 
connective ECM is still a controversial issue ranging from up-regulation of ECM 
synthesis either at gene transcription or protein level (Gagliano et al., 2004; 
Schincaglia et al., 1992) to blocking the proteolytic cascade of matrix proteins 
(Gagliano et al., 2004), or both (Tüter et al., 2002). However, recent findings have 
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revealed that the increased deposition of collagen 1 observed in CsA-induced gingival 
hyperplasia is caused by up regulation of both collagen 1 protein and gene expression 
along with increased deposition of decorin- a proteoglycan known for its inhibitory 
effects of collagen 1 internalization, thus impeding collagen phagocytosis (Dannewitz  
et al., 2006). 
 
Other studies have shown that CsA-induced gingival hyperplasia has been associated 
with increased expression of chondroitin-4-sulphate (C4S) rather than proteoglycans 
(PGs) (Vardar et al., 2005). This result may provide additional support for an 
interesting explanation which describes the dimensional changes in CsA-induced 
gingival hyperplasia as tissue oedema resulting from increased trapping of fluids in 
the ECM, thus an increase in the tissue colloid osmotic pressure due to the excessive 
accumulation of GAGs in the ground substance (Vardar et al., 2005; Zebrowski et al., 
1994; Flynn et al., 2006; Stabellini et al., 2004). These findings have been sustained 
by an in vitro study concluding that fibroblast cultures isolated from CsA-hyperplastic 
gingiva show increased synthesis of GAGs in comparison with control normal 
fibroblasts (Stabellini et al., 2004). In contrast, (Rocha et al., 2000) found no 
significant difference in the synthetic activity of GAGs between CsA-stimulated 
gingival fibroblasts and control healthy fibroblasts. 
 
1.5.1.2. Effect of CsA on ECM degradation: 
Two primary pathways of ECM breakdown have been identified (Lee et al., 2006; 
Sodek & Overall, 1988; Everts et al., 1996): 
1-Extracellular pathway: involving metalloproteinases (MMPs, plasmin and 
stromelysin and tissue inhibitors of metalloproteinases (TIMPs)  
2- Intracellular pathway: This route involves phagocytosis and digestion of collagen 
fibrils by fibroblasts’s lysosomal cysteine proteinases (cathepsins). 
 
Effect of CsA on Extracellular Pathway of ECM degradation: 
 Many investigations have traced the variations in activity and expression of both 
proteolytic enzymes (MMPs) and their specific tissue regulators (TIMPs) that may 
occur during CsA therapy (Gagliano et al., 2004; Yamada et al., 2000; Bolzani et al., 
2000; Hyland et al., 2003). 
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Hyland et al (2003) revealed that CsA down-regulated both MMP-1 gene and protein 
production in gingival fibroblasts at a concentration of 500-2000ng/ml. Bolzani et al 
(2000) also demonstrated that CsA inhibited MMP-2’s gelatinolytic activity in both 
CsA-treated human gingival fibroblasts and CsA- overgrown rat gingival tissue. 
Furthermore, the reduced activity of MMP-1 reported in CsA-treated human gingival 
fibroblasts was correlated with abrogation of MMP-3 expression, an essential 
activator of pro- MMP-1, rather than an increase in TIMP-1 levels (Hyland et al., 
2003; Bolzani et al., 2000).  
 
On the other hand, Gagliano et al (2004) showed that CsA decreased MMP-1 protein 
expression in human gingival fibroblasts without any significant effect on MMP-1 
gene expression. This report also demonstrated that expression of both MMP-2 gene 
and protein was not affected by CsA. Likewise, Yamaguchi et al (2004), Gagliano et 
al (2004) and Dannewitz et al (2006) found that levels of TIMP-1 gene expression in 
human gingival fibroblasts were not significantly modified by CsA treatment.  
 
Additionally, it was revealed that MMP-8 and MMP-9 levels in GCF were not 
modified by CsA therapy. Instead, their elevation might be related to the gingival 
inflammation (Atilla et al., 2001).  
 
Effect of CsA on Intracellular Pathway of ECM degradation: 
Much attention has been paid to the putative role of CsA in the inhibition of the 
intracellular collagen degradation. Decreased levels of α2β1 integrin expression have 
been reported in gingival fibroblasts derived from CsA-hyperplastic gingiva (Kataoka 
et al., 2003) whilst another study has attributed CsA’s inhibitory effects of collagen  
phagocytosis to perturbation of intracellular calcium signalling, thereby down- 
regulating the affinity of α2β1 integrin “transmembrane glycoprotein receptors” to 
type I collagen (Arora  et al., 2001 ).  
 
Additionally, others have shown that the suppressed intracellular degradation of 
collagen reported in human gingival fibroblasts treated with 200ng/ml CsA has been 
correlated with decreasing of both cathepsin L expression and activity (Yamada et al., 
2000; Yamaguchi et al., 2004). These findings, however, were in line with the clinical 
observations involving severe gingival hyperplasia reported in both cathepsin L-
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deficiency mice (Nishimura et al., 2002) and in the congenital disease- Mucolipidosis 
II ( I-cell disease)- characterized by defect in lysosomal cysteine proteinases function 
involving cathepsins (Patel & Ambani, 1980; Taylor & Shuff, 1994). 
 
1.5.2. Effect of CsA on gingival cell proliferation: 
1.5.2.1 Effect of CsA on gingival fibroblast proliferation: 
There is a wealth of conflicting data on the effect of CsA on gingival fibroblast 
proliferation (Hallmon & Rossmann, 1999; Pisanty et al., 1988; Kataoka et al., 2005).
Some in vitro studies concur that long-term exposure to CsA may have a stimulatory 
effect on gingival fibroblast proliferation as reported by Willershausen-Zönnchen et al 
(1992), Marriotti et al (1998) and Bartold (1989).  
 
Bartold et al (1989) found that 10
-9
g/ml CsA up-regulated DNA synthesis and the 
proliferation rate of HGF with  most noticeable stimulation being reported in the 
presence of 10% FBS, and that this capacity was retained even in absence of FBS or 
in the presence of lipopolysaccharide that usually inhibit proliferation of these cells. 
In agreement with Bartold’s findings, Barber et al (1992) demonstrated that addition 
of CsA to HGFs pre-exposed to a lipopolysaccharide derived from F. nucleatum 
reversed the inhibitory effect of these bacterial products on DNA synthesis. Chae et al 
(2006) also showed that treatment of serum starved- HGFs with CsA (100 and 
500ng/ml) for 6 days significantly activated the cell cycle along with an increase in 
the cell viability and DNA incorporation of BrdU. 
 
These findings were also in agreement with a flow-cytometric study that showed an 
increase in the in vitro proliferative activity of CsA-treated HGF illustrated by a 
promoted progression of cell cycle and an increase in the expression level of cyclin 
B1 (Parkar et al., 2004). Similarly, Kim et al (2008) revealed recently that CsA up-
regulated in vitro both cell viability and BrdU incorporation in HGF cell lines with a 
maximal increase being found in HGF cells obtained from CsA-induced overgrown 
gingival tissues. Kantarci et al (2007) also demonstrated immunohistochemically that 
all drug- induced gingival hyperplasia showed an increase in the proliferative activity 
of gingival fibroblasts. Interestingly, Cotrim et al (2003) showed a bimodal effect of 
CsA on proliferation of human gingival fibroblasts cultured for 24h; low doses of 
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(CsA ≤ 200ng/ml) stimulated human gingival fibroblast proliferation, whilst higher 
doses of CsA (400-800ng/ml) inhibited proliferation of these cells.  
 
In contrast to the previous findings, Yamaguchi et al (2004) found that long-term 
exposure to a low dose of CsA (200ng/ml) had no effect on viability of human 
gingival fibroblasts. James et al (1995) also revealed that low doses of CsA had no 
significant effect on proliferation of human gingival fibroblasts. Whilst, extremely 
high doses of CsA 10
-5 
g/ml induced a significant decrease in human gingival 
fibroblast proliferation. Furthermore, Jung et al (2008) revealed in vitro that 24h 
stimulation with CsA failed to induced an increase in HGF proliferation. However, 
these discrepancies between studies could be attributed to heterogeneity of cell line 
strains or to differences in the experimental conditions (incubation period, 
concentrations of CsA used in each study, FCS concentration). 
 
1.5.2.2. Effect of CsA on gingival keratinocyte proliferation: 
Much attention has recently been concentrated on the potential role of gingival 
keratinocytes in the pathogenesis of CsA-induced gingival hyperplasia but findings 
are still inconclusive.  
 
Yoshida et al (2005) assessed proliferation of cultured rat gingival cells after 
incubation for 3days and showed that CsA at concentration of 200-800ng/ml induced 
hyper-proliferation of gingival cells by 23-25% compared to control. These findings 
were supported by an animal study that showed that treatment with CsA caused 
buccal epithelial hyperplasia associated with an increase in proliferating cell nuclear 
antigen  (PCNA) expression (Cetinkaya et al., 2006). The same study also reported an 
increase in epithelial thickness and PCNA expression in both buccal and sulcular 
epithelium of rats subjected to CsA treatment along with ligature-induced gingival 
inflammation suggesting that CsA-induced gingival hyperplasia might be mediated by 
an increase in the proliferative activity of epithelium cells and that dental plaque 
might aggravate the condition (Cetinkaya et al., 2006).  
 
Similarly, Nurmenniemi et al (2001) also demonstrated immunohistochemically that 
the epithelial hyperplasia reported in CsA-induced gingival hyperplasia was 
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associated with hyperproliferation in both sulcular and oral gingival epithelium with a 
maximal proliferative activity being observed in the oral gingival epithelium.  
 
However, Tu et al (2006 & 2008) reported two conflicting data; while they found 
through an animal study that the increase in the epithelial thickness observed in CsA-
induced gingival hyperplasia was associated with an increase in cyclin D1 and PCNA 
expression, their flow cytometric study on human oral epidermoid carcinoma cell 
lines showed that CsA caused a cell cycle stasis. Furthermore, Birraux et al (2006) 
demonstrated that low concentration of CsA had no effect on the proliferation of an 
immortalized normal human oral keratinocyte cell line (HOK-16B), primary oral 
keratinocytes, and epitheloid cervical carcinoma cell line (Hela) cultured for up to 
96h. They did report, however, that higher concentration 10
3
ng/ml of CsA exhibited 
an inhibitory effect on proliferation of all cell types. Moreover, inhibition of both 
primary oral keratinocytes and HOK-16B cell proliferation caused by culture with 
10
4
ng/ml CsA was maintained for at least two days after withdrawal of CsA. 
Interestingly, Lauer et al (2006) showed both the inhibitory and stimulatory effect of 
CsA on human gingival keratinocyte proliferation; CsA significantly reduced their 
proliferation rate from day 3 to day 6 and then stimulated their proliferation from day 
6 to day 9 with maximal increase being observed on day 9 at a concentration of 
1000ng/ml. 
 
1.5.3. Effect of CsA on gingival cell apoptosis: 
Apoptosis, programmed cell death, is stimulated mainly by two characteristic 
pathways: an extrinsic pathway that is mediated by death receptor (TNF-a & Fas), and 
an intrinsic or mitochondrial pathway that is regulated by pro-apoptotic proteins such 
as Bax and Bid and anti-apoptotic proteins such as Bcl-2. Both pathways are executed 
by a key component referred to as caspase-3 that is activated after being cleaved, 
leading in the end to cell apoptosis (Fulda & Debatin, 2006). 
 
Apoptosis in conjunction with cell proliferation maintains tissue homeostasis and 
regulates tissue growth (Shimizu et al., 2002; Alaaddinoglu et al., 2005). However, 
according to findings reported by Shimizu et al (2002) who demonstrated that the 
increase in epithelial thickness observed in nifedipine-induced gingival hyperplasia 
mainly results from prolonged survival of cells rather than an increase in 
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keratinocytes’s mitotic activity, Niimi et al (1990) also revealed that the epithelial 
hyperplasia reported in CsA-induced gingival hyperplasia was not correlated with the 
mitotic activity of keratinocytes but to prolongation of keratinocyte life time through 
suppression of apoptosis. Moreover, an immunohistochemical study of gingival 
epithelial specimens obtained from patients with CsA-induced gingival hyperplasia 
showed a reduction of apoptosis and up regulation of bcl-2 (Bulut et al., 2005). These 
findings were supported by a recent immunohistochemical study that revealed a 
decrease level of caspase-3 expression in biopsies of CsA-induced overgrown gingiva 
indicating that development of CsA-induced gingival hyperplasia might be correlated 
with inhibition of apoptosis (Bulut et al., 2007). 
 
 These observations were consistent with results from studies with HGF. Nishikawa et 
al (1996) suggested that the excessive number of fibroblasts in drug-induced gingival 
hyperplasia may be caused by inhibition of apoptosis. Similarly, Kantarci et al (2007) 
found through an immunohistochemical study of connective tissue biopsies obtained 
from CsA/phenytoin/ and nifedipine-induced overgrown human gingiva that gingival 
fibroblasts showed a decrease level of caspase-3 expression compared to control 
indicating that the decrease in apoptosis rate might play an important role in 
accumulation of gingival fibroblast being observed in all forms of drug-induced 
gingival hyperplasia. 
 
Furthermore, these findings were supported by a recent in vitro report that revealed 
that stimulation of HGF with CsA for 24h caused a significant decrease in apoptosis 
rate through both the intrinsic and extrinsic pathways suggesting that the decreased 
level of apoptosis might play a more significant effect than the increase in cell 
proliferation in increasing the HGF number being reported in this study (Jung et al., 
2008). 
 
In contrast, a recent in vitro study revealed that CsA increased the apoptosis of human 
gingival squamous carcinoma cell line through the mitochondrial pathway by 
increasing the expression level of Bax and caspase 3 protein (Tu et al., 2009) 
However, Alaaddinoglu et al (2005) reported no differences in the levels of 
keratinocyte apoptosis in patients with CsA-induced gingival hyperplasia and 
systemically healthy individuals but experiencing gingivitis. Birraux et al (2006) also 
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found that survival of both CsA-treated oral keratinocyte cell lines and primary oral 
keratinocytes was not associated with changes in apoptosis levels either at 
intracellular bcl-2 levels or TNF-α- induced apoptosis.  
 
1.5.4. Effect of CsA on cytokine release: 
Cytokines and chemokines such as IL-1α, IL-1β, IL-6 and IL-8 play a significant role 
in periodontal diseases (Okada & Murakami, 1998) and growing attention has been 
paid to their potential role in the pathogenesis of CsA-induced gingival hyperplasia 
with conflicting results. 
 
Myrillas et al (1999) reported that incubation of normal and overgrown gingival 
fibroblasts for 24h with different concentrations of CsA released no detectable 
amount of IL-1β compared to control, whereas production of IL-6 in all fibroblast 
strains was suppressed in a dose-dependent manner with the maximal inhibition being 
reported at 2000ng/ml CsA. In contrast, Chae et al (2006) demonstrated that 500ng/ml 
CsA up-regulated production of IL-6 and transforming growth factor (TGF-β1) in 
human gingival fibroblasts in a time-dependent manner with the maximal release 
being reported at 24h. But, interestingly, it has been shown that neutralisation of TGF-
β1 resulted in a significant reduction in expression of CsA-induced IL-6 while release 
of CsA-induced TGF-β1 was not affected by blocking IL-6. These findings suggest 
that TGF-β1 is an essential regulator of CsA-induced IL-6 release in human gingival 
fibroblasts. Additionally, it has been reported that human gingival fibroblasts treated 
with IL-6 or TGF-β1 exhibited an increased rate of proliferation compared to control. 
Furthermore, neutralizing IL-6 and TGF-β1 caused downregulation of CsA-induced 
HGF proliferation rate (Chae et al., 2006; Cotrim et al., 2003). 
 
Leonardi et al (2001) found that the exposure to CsA for 24h caused a significant 
increase in IL-6 and IL-8 release with a parallel decrease in IL-1β release along with a 
reduction in cultured human conjunctival fibroblasts viability; they related their 
findings to the toxic activity of the high doses used of CsA. 
 
Hyland et al (2004) reported that release of both keratinocyte growth factor KGF and 
scatter factor SF was increased in both normal and overgrowth gingival fibroblast 
strains treated with 2000ng/ml CsA. Likewise, Das et al (2002) revealed that normal 
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gingival epithelial cells incubated with 500ng/ml CsA for 3days expressed higher 
levels of KGFR –keratinocyte growth factor receptor- compared to control. The 
authors concluded that the increased level in KGFR is consistent with the increase in 
proliferation rate of epithelial cells observed in CsA-induced gingival hyperplasia. 
 
Chin  et al (2006) demonstrated that CsA caused up-regulation of both EGF 
“epidermal growth factor” and EGFR “epidermal growth factor receptor “ in human 
oral epidermal carcinoma cell lines with the greatest stimulation being reported at 
concentration 100ng/ml . 
 
The effect of CsA on IL-1α and IL-8 has received little direct attention, although it 
has been suggested that pathogenesis of CsA-induced gingival hyperplasia may 
involve alteration in the expression levels of various inflammatory cytokines in the 
gingiva (Ruhl et al., 2004) who found an increase in the salivary levels of IL-1α, IL-6, 
and IL-8 in patients with CsA-induced gingival hyperplasia.  IL-1α, however, may be 
a co-factor for nifedipine-induced gingival hyperplasia (Sato et al., 2005) and 
increased IL-8 levels were reported in cultured HGFs treated with phenytoin (Modéer 
et al., 2000). 
 
1.6 Summary and aims of study: 
The mechanism of CsA-induced gingival hyperplasia is still unclear despite numerous 
studies being conducted in an attempt to understand the pathogenesis of the condition. 
Most studies have focused on the role of connective tissue- CsA interaction with 
conflicting results either in terms of the effect of CsA on gingival fibroblast 
proliferation or on ECM metabolism. More recently, however, attention has focused 
on the potential role of gingival keratinocytes along with other locally released 
mediators as well as the imbalance between cell proliferation and apoptosis in CsA-
associated gingival hyperplasia. The potential role of dental plaque in the 
development of the condition has also been examined, again with inconclusive results. 
This may reflect the complexity of the in vivo conditions, and it is still unclear 
whether the accumulation of dental plaque is a consequence of gingival changes 
caused by the drug itself or an essential factor for initiating the condition.  
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Despite the lack of clear evidence it is generally agreed that the pathogenesis of CsA-
induced gingival hyperplasia is multifactorial including complex interactions between 
the gingival tissue, drug, genetic factors, dental plaque in addition to other locally 
released mediators such as growth factors and cytokines. 
 
There have been very limited studies in vitro investigating whether the pre-exposure 
to bacterial products might modulate the response of human gingival fibroblasts and 
keratinocytes to CsA. Therefore, the aims of the present study were to investigate in 
vitro: 
1- Whether CsA at clinically-relevant concentrations might have direct effects on cell 
viability and release of proinflammatory cytokines including IL-1α, IL-6, and IL-8 in 
monolayer cultures of human gingival fibroblasts and keratinocytes;  
2- Whether the pre-exposure to bacterial products might modulate the response of 
monolayer cultures of the studied cells to CsA in terms of cell viability and the 
cytokine release;  
3- The effect of CsA alone or in combination with bacterial products on proliferation 
and apoptosis of monolayer cultures by a novel multi-parameter flow-cytometric 
analysis; 
4- The response of multilayer cultures of gingival and buccal epithelium to CsA and 
bacterial products in terms of tissue viability, release of the inflammatory cytokines, 
proliferative activity and apoptosis.  
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Chapter Two 
Materials and Methods 
(Monolayer cultures) 
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This chapter describes the main experimental methods used to study the effect of CsA 
with the monolayer cultures.  Any variations in the techniques used will be discussed 
in the appropriate chapters. 
2.1 Cells used in study: 
Four cell lines were used in the study: 
human gingival keratinocytes (FIBS),  
human buccal carcinoma keratinocytes (TR146),  
immortalized human oral keratinocytes (OKF6)  
human gingival fibroblasts (HGF),  
FIBS, TR146 and OKF6 lines were obtained from Centre for Clinical and 
Diagnostic Oral Sciences (CDOS), Barts and The London School of Medicine and 
Dentistry, London.  Upon receipt, the cells were thawed, plated in T-75 Flasks 
(Nunc.dk) and cultured in medium supplemented with 10% FBS and 1% penicillin-
streptomycin (see Table 2.1).  
           HGF cells were purchased from American Type Culture Collection (ATCC) 
(HGF-1, reference code: CRL-2014). All cell lines used in this study were between 
passage 10 and 20.  
 
Cells were then incubated at 37
o
C in a humidified atmosphere containing 5% CO2 and 
95% air. Cells were routinely washed with sterile phosphate buffered saline (PBS) 
and fed with fresh medium twice a week. When the cells reached 80% confluence, 
they were harvested with 0.2% trypsin and EDTA (Gibco Invitrogen. UK) for 
freezing or secondary cultures. 
 
2.2 Cyclosporin (CsA) preparation: 
CsA (25mg) (Sigma-Aldrich, Poole, UK) was dissolved in 25ml absolute ethanol 
(Sigma UK) to make a 1mg/ml stock solution and stored in 1ml aliquots in -80
o
C until 
use. The experimental CsA concentrations were then prepared by individually diluting 
20µl, 10µl, 5µl and 1µl of this stock in 10ml of DMEM yielding a final CsA 
concentration of 2000ng/ml, 1000ng/ml, 500ng/ml, and 100ng/ml respectively
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Cell Line Origin Source Culture Medium 
Keratinocyte    
TR146 human buccal 
carcinoma 
keratinocytes 
Centre for Clinical and 
Diagnostic Oral 
Sciences, Queen Mary 
University, London 
DMEM with 
4.5g/L glucose 
+ L-glutamine 
FIBS Human gingival 
keratinocytes 
Centre for Clinical and 
Diagnostic Oral 
Sciences, Queen Mary 
University, London 
As above 
OKF6 Immortalized human 
oral keratinocytes 
Centre for Clinical and 
Diagnostic Oral 
Sciences, Queen Mary 
University, London 
As above 
Fibroblast    
HGF Human gingival 
fibroblasts 
American Type Culture 
Collection (ATCC) 
DMEM  
+4.5g/L glucose 
+L-glutamine 
+Pyruvate 
 Table 2.1 Cell lines used in the study 
 
 
2.3. Treatment: 
2.3.1  Short-term:  
Cells were seeded into 24- well plates (Falcon) at a density of 4 x 10
4
cell/well and 
allowed to settle down for 24hour. Then, cells were washed once with phosphate 
buffered saline (PBS) and starved for 24h by replacement of the medium by serum- 
Free DMEM.  
 
Following serum starvation, cells were again rinsed with PBS and stimulated with 
increasing concentrations of CsA: 100ng/ml, 500ng/ml, 1000ng/ml, 2000ng/ml and 
control (medium only) in FBS-free DMEM for various time intervals; 4h, 6h, 8h, 12h, 
and 24h. Supernatants were then collected and stored at -80
o
C until use for measuring 
cytokine contents by Enzyme-linked immunosorbent assay (ELISA). After washing 
with PBS, cell viability was evaluated at the end of each time point by MTT assay. 
All experiments were carried out three times in triplicate wells. 
 
2.3.2 Long-term: 
Cells were seeded into 24-well plates at a density of 4 x 10
4
cell/well in DMEM 
containing 10% FBS and allowed to attach to the well for 24 hours. Cells were then 
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starved by incubation in FBS-free DMEM for further 24 hours. They were then 
stimulated for 6 days with FBS-free DMEM containing various concentrations of 
CsA; 100ng/ml, 500ng/ml, 1000ng/ml, 2000ng/ml and 0 (only medium).The culture 
media was collected every other day with re-adding CsA at the same concentrations. 
In other words, supernatants were collected on day 2, 4, and 6 and frozen at – 20oC 
until use for measuring cytokine contents. Cells were washed with phosphate-buffered 
saline (PBS) with every medium changing. Cell viability at the end of the experiment 
was assessed using MTT (see section 2.4.1) assay. All experiments were carried out 
three times in triplicate wells. 
 
2.4. Cell viability assays: 
The MTT assay (Mosman, 1982) has been applied to determine the effect of CsA on 
viability of cultured human gingival keratinocyte, human oral keratinocyte, and 
human gingival fibroblast cell lines. This assay depends on measuring the metabolic 
activity of viable cell’s mitochondrial dehydrogenases presented in their ability to 
reduce the (tetrazolium salt 3[4,5-3 dimethylthiazol-2-YL]-2,5-diphenyltetrazolium 
Bromide) (MTT) to an insoluble blue formazan dye. This analysis was carried out as 
follows: 
1. 500µl of MTT reagent (final concentration: 0.5mg/ml in PBS) was added to 
each well and plates were then incubated for 1h in a humidified atmosphere at 
37
o
C in the dark 
2. Plates were aspirated and rinsed with PBS.  
3. 500l of acidified isopropanol (25l of 0.04N HCL in 20ml isopropanol) was 
then added to each well. The plates were incubated for 1h to elute any 
formazan crystals that had formed. 
4. The optical density (OD), which is known to be directly proportional to the 
number of living cells (Yoshida et al., 2005), was measured at 570nm using a 
micro plate reader (Optima). Cell viability was expressed as the absorbance at 
570nm:  Cell viability = OD (570nm) test / OD (570nm) control x 100 
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2.5 Enzyme-linked immunosorbent assay (ELISA): 
IL-1α, IL-6, IL-8 release was determined by sandwich Elisa (Duo Set®; R & D 
systems, Abingdon, UK). Supernatants were defrosted for testing and the level of 
cytokines were measured according to the manufacturer protocol as outlined below: 
1. 96-well Elisa plates were coated with 100l per well of the respective capture 
antibody (mouse anti-human cytokine) diluted in PBS without carrier protein. 
The plates were then sealed and incubated overnight at room temperature. 
2. Plates were then aspirated and washed by filling each well with 400μl washing 
buffer (0.05% Tween®20 in PBS, PH 7.2-7.4) to remove unbound antigen. 
Complete removal of the content was attained by inverting and tapping the 
plates on to a clean, absorbent paper. This process was repeated twice for a 
total of three times. 
3. Thereafter, plates were blocked with 300l per well of either reagent diluent 
(1% BSA in PBS, PH 7.2 - 7.4) for IL-1α and IL-6 or with block buffer (1% 
BSA in PBS with 0.05% NaN3) for IL-8 and then incubated at room 
temperature for 1h. 
4. The plates were again aspirated and washed three times with washing buffer.  
5. 100µl of standards in reagent diluent (prepared according to manufacturer 
instructions) or samples were then added to the appropriate plate wells which
were sealed with an adhesive strip and incubated for further 2h at room 
temperature. Standards were run in duplicate while the samples were run in 
triplicate. 
6. Aspiration and washing then were performed as described above. 
7. 100µl / well of detection antibody, a specific biotin- conjugated goat anti 
human cytokine (IL-1α or IL-6 or IL-8) diluted in reagent diluent was added to 
each well. Plates were sealed with a new adhesive strip and incubated for 
additional 2h at room temperature. 
8. In order to remove unbound cytokines and other components of the samples, 
Plates were thoroughly aspirated and washed three times with washing buffer 
as described above. 
9. Subsequently, the quantitative determination of the amount of tested cytokines 
in the samples were performed by adding 100l of the streptavidin conjugated 
to horseradish- peroxidase (HRP) diluted in reagent diluent to each well, plates 
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were then sealed and incubated for 20 minutes at room temperature in the 
dark. 
10. Aspiration and washing were performed as described above to remove all 
unbound Avidin-HRP conjugate. 
11. A colour reaction was stimulated by adding 100l of TMB 
(tetramethylbenzidine) substrate solution (Sigma.UK) to each well. This 
reaction which exhibits as a change in colour and develops only in those wells 
that contain the specific cytokine was allowed to develop over a short 
incubation period (20 minutes) at room temperature in the dark. 
12. The colour reaction was terminated by adding 50l 2N H2SO4 to each well. 
The plates were gently tapped to ensure through mixing.  
13. Finally, the optical densities OD were measured immediately at wave length 
of 450nm by using a micro plate reader. 
 
2.5.2  Calculation of cytokine release: 
A standard curve for each set of measured samples was created using Microsoft Excel 
by plotting the log of cytokine concentrations on the X-axis against the log of 
corresponding OD (absorbance) for each standard plotted on the Y-axis (Fig 2.1). 
However, by completing a regression analysis of the points, a straight line of best fit 
can then be determined. This line shows a direct relationship between cytokine 
concentrations and the corresponding absorbance and can be represented by the 
equation:  
 Y= Mx + C       
Where:  M; the gradient of the line and C: a constant 
Practically, M and C can be determined from the standard curve. The ODs of the 
evaluated samples were already measured. Hence, the concentration (X) of cytokine 
produced in pg/ml in the tested samples can be calculated by adjusting the previous 
equation as follows: X= (Y-C)/M. 
 
55 
 
y = 0.6599x - 1.6634
R2 = 0.9933
-1.2
-1
-0.8
-0.6
-0.4
-0.2
0
0.2
0 0.5 1 1.5 2 2.5 3
log conce
lo
g
 O
D
 
Figure 2.1.  IL-1α Standard curve for short-term treated OKT6 cell line. 
 
2.6. Bacterial strains and culture conditions: 
The bacterial strains used in this study are shown in Table 2.2. P. gingivalis W50 
strain and F. nucleatum ATCC12104 strain were maintained on blood agar (BA) 
plates made from sterile blood agar base No.2 (Oxoid, Basingstoke, UK) 
supplemented with 5% (v/v) defibrinated horse blood in an anaerobic cabinet (Don 
Whitely scientific, West Yorkshire, UK) containing 80% N2, 10% H2 and 10% CO2 at 
37
o
C for one week. Colonies (3-4days old) were subcultured in 10 ml of brain heart 
infusion broth (Oxoid Ltd, Basingstoke, UK) supplemented with haemin (5µg ml
-1
) 
and incubated for 24hrs. 
 
P. intermedia T558 strain was cultured on fastidious anaerobic agar (FAA) (Lab M, 
Bury UK) supplemented with 6% defibrinated horse blood (TCS Bioscience Ltd, 
Buckingham, UK) and 0.05µg/ml sterile haemin (from a 5 µg/ml stock solution) in an 
anaerobic atmosphere of 80% N2, 10% H2 and 10% CO2 at 37
o
C. Colonies (3-4days 
old) were subcultured in 20 ml of brain heart infusion broth (Oxoid) supplemented 
with haemin (0.05µg/ml) and incubated for 48hrs.  
 
A. actinomycetemcomitans 280 strain was also cultured on fastidious anaerobic agar 
(FAA) (Lab M, Bury UK) supplemented with 6% defibrinated horse blood (TCS 
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Bioscience Ltd, Buckingham, UK) and 0.05µg/ml sterile haemin (from a 5 µg/ml 
stock solution) in an aerobic atmosphere of 6% CO2 at 37
o
C. Colonies (3-4days old) 
were sub cultured in 20 ml of brain heart infusion broth (Oxoid Ltd, Basingstoke, UK) 
supplemented with 1.0 mg/ml NaHCO3 and incubated for 48hrs. 
 
The purity of plate cultures was confirmed by performing Gram stains. 
 
Cells were pelleted by centrifugation at 10,000 rpm for 15 minutes at 4
o
C and cell-
free supernatants were collected, filter sterilized using 0.22µm disposable Millex-GV 
PVDV low protein binding filters (Millipore Corporation, Bedford MA, USA) and 
stored at -80
o
C until use. 
 
Species Supplied by 
Fusobacterium nucleatum  ATCC12104 Dr. A.Hashim 
Centre for Infectious Diseases 
Porphyromonas gingivalis W50 Dr. A.Hashim 
Prevotella intermedia T588 Dr. R.Whiley 
CDOS  
Aggregatibacter actinomycetemcomitans 280 Dr. R.Whiley 
Table 2.2. Bacterial strains used in this study 
 
2.7 Treatment with bacterial supernatants: 
Cell lines (TR146, OKF6, FIBS and HGF) were seeded into 96 well plates at density 
of (5 x 10
3
 cell/well) in 100µl DMEM containing 10% FBS. Cells were then allowed 
to settle down and attach to the well by incubation at 37
o
C and 5% CO2 for 24h. Cells 
were washed twice with PBS and then starved for 24h by incubation in serum-free 
DMEM at 37
o
C and 5% CO2.  
 
After one wash with PBS, cells were stimulated by different concentrations (0, 1/10, 
1/50 and 1/100) of bacterial supernatants (P.g, A.a, F.n, and P.i) in 100 µl serum-free 
DMEM for 24hours.    
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The potential toxicity of the bacterial supernatants on the cell lines was assessed using 
an Alamar Blue assay and a LDH assay. 
 
2.8 Alamar Blue assay: 
Cell lines (TR146, OKF6, FIBS and HGF) were seeded into 96 well plates at density 
of (5*1000 cell/well) in 100µl DMEM containing 10% FBS. Cells were then allowed 
to settle down and attach to the well by incubation at 37
o
C and 5% CO2 for 24h. Cells 
were washed twice with PBS and then starved for 24h by incubation in serum-free 
DMEM at 37
o
C and 5% CO2.  
 
The cells were stimulated by different concentrations (0, 1/10, 1/50 and 1/100) of 
bacterial supernatants (P.g, A.a, F.n, and P.i) in 100 µl serum-free DMEM containing 
10% Alamar Blue solution (Invitrogen.uk). Cultures were then incubated for further 
24h at 37
o
C and 5% CO2 where fluorescence intensity was then measured by Elisa 
reader using excitation 480nm. Cell viability was calculated as follows: 
Cell viability = fluorescence test/ fluorescence control x 100 
 
2.9 LDH assay: 
The effect of the bacterial supernatants on LDH release by the cells was measured 
using an in vitro Cytotoxicity Detection Kit
plus
 (LDH) (Roche, Mannheim, Germany).  
 
TR146, OKF6, FIBS and HGF were seeded into 96 well plates at density of (5*1000 
cell/well) in 100µl of Pyruvate-free DMEM containing 10% FBS. Cells were then 
allowed to settle down and attach to the well by incubation at 37
o
C and for 24h. Cells 
were washed twice with PBS and then starved for 24h by incubation in serum-free 
DMEM at 37
o
C and 5% CO2.  
 
Cells were then washed with PBS and simulated for 24hour by different 
concentrations (0, 1/10, 1/50 and 1/100) of bacterial supernatants (P.g, A.a, F.n, and 
P.i) in Pyruvate and serum-free DMEM in addition to controls (background control: 
cell-free medium, low control: medium containing un-treated cells, high control: 
totally lysed cells). Afterwards, cells in high control were totally lysed by adding 5 µl 
lysis buffer for 5 minutes and then 100 µl reaction mixture (250µl of catalyst mixed 
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with 11.25ml of dye solution) was added to all cell cultures including controls and 
incubated in the dark at room temperature for 30 minutes. The detection reaction was 
terminated by adding 50µl stop solution and absorbance was immediately measured 
by Elisa reader filter 490nm.  Cytotoxicity was expressed as changes in the optical 
density compared to that of high control as follows: 
% Cytotoxicity = OD (test) - OD (background)/OD (high control)-OD (background) x 100 
 
2.10. Multicolour flow cytometry: 
2.10.1 Reagents and antibodies:  
Reagents and antibodies used in this study are shown in Table 2.3. 
 
Reagents and antibodies Source 
Edu click-it pacific blue flow cytometry kit Invitrogen Ltd, Paisley, UK 
fix & perm Cell permeabilization kit Invitrogen Ltd, Paisley, UK 
Alexa fluor 647-conjugated mouse anti-IgG1 
isotype control 
Invitrogen Ltd, Paisley, UK 
Alexa fluor 488-conjugated mouse anti-IgG2b 
isotype control 
Invitrogen Ltd, Paisley, UK 
Alexa fluor 488-conjugated mouse anti-IgG1 
isotype control 
Invitrogen Ltd, Paisley, UK 
Alexa fluor 488-conjugated mouse anti-human 
Bax (clone 2D2) 
Santa Cruz  Biotechnology, CA, USA 
Alexa Fluor 647-conjugated mouse anti-human 
Bcl-2 (clone C-2) 
Santa Cruz  Biotechnology, CA, USA 
Alexa Fluor 488-conjugated mouse anti-human 
Cyclin D1 (clone A-12) 
Santa Cruz  Biotechnology, CA, USA 
Alexa Fluor 647-conjugated mouse anti-human 
Cyclin B1 (clone D-11) 
Santa Cruz  Biotechnology, CA, USA 
Table 2.3. Reagents and antibodies used for the FACS study 
 
2.10.2. Cell treatment: 
OKF6, FIBS, TR146 and HGF grown in 75cm flask up to 90% confluence were 
trypsinized and seeded at density of 5 x 10
5
 into T75 flasks. HGF cells were seeded at 
density of 2.5 x 10
5
 into T25 flasks. Cell lines were cultured in DMEM containing 
10% FBS for a further 24h.  
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After washing twice with PBS, cells were serum starved for 24h by incubating in 
serum-free DMEM to synchronise cells in the G0 phase of cell cycle (Takeuchi. 
2004). Cells were washed again and then either re-incubated in serum-free DMEM or 
stimulated for 24h with 1/100 bacterial supernatants in serum-free DMEM (Table 
4.2). Afterwards, cells were washed as previously. At this time point, serum starved 
untreated cells were either re-incubated with serum-free DMEM (control for both 
Bax, Bcl-2 and cyclin expression), or stimulated with DMEM containing10% FBS (as 
a positive control for cell cycle and DNA synthesis), or challenged with either 
2000ng/ml or 250ng/ml CsA. However, bacterial supernatant-pre stimulated cells 
were then either re-challenged with bacterial supernatants only or with a combination 
of bacterial supernatant plus 2000ng/ml or 250ng/ml CsA for further 24hr where the 
experiment was terminated and cells were then prepared for flow cytometry analysis. 
 
2.10.3. Controls:  
Three types of control were included in each experiment: 
1. Biologic controls: including stained-untreated cells. These controls allow 
determining the biological effect of CsA and bacterial supernatants comparing 
with these controls.  
2. Isotype matched negative controls: these controls have the same 
immunoglobulin type and conjugated with same fluorochrome as the primary 
antibodies under investigation. They are used to determine the background 
(autofluorescence, un-specific binding). 
3. Compensation controls: also known as fluorochromes minus one controls 
including the un-treated cells stained with all fluorochromes under 
investigation minus one. These controls are used to determine the spectral 
overlap of fluorochrome. 
 
2.10.4. Antibody panels design:  
Eight panels of antibodies were set up as shown in Table 2.4. Each panel contained 
1µg concentration of an appropriate antibody diluted in the permeabilization medium 
with a total volume of 100 µl. 
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Panel Cyclin B1 
Antibody 
1µg 
Cyclin D1 
Antibody 
1µg 
Bax 
Antibody 
1µg 
Bcl-2 
Antibody 
1µg 
Alexa flour 
647 isotype 
Antibody 
1µg 
Alexa flour 
488 isotype 
Antibody 
1µg 
Alexa flour 
488 isotype 
Antibody 
1µg 
1 √ √      
2 √       
3  √      
4     √ √  
5   √ √    
6   √     
7    √    
8     √  √ 
Table 2.4. Antibody panels used in for the FACS study 
 
2.10.5.  Protocol for Cell cycle , Edu and cyclin staining: 
Labelling cells with EdU: 
1. After washing twice with PBS, Cells were incubated for 1hr with 10µM Edu 
suspended in the culture medium at 37
o
C, 5% CO2. EdU-un labelled cells from 
the same population have been included as a negative staining control. 
2. The supernatant was then aspirated and cells were washed with FACS buffer 
(PBS    containing 5% FBS and 0.1% sodium azide). 
3. Cells were harvested with trypsin and suspension was centrifuged at 1500rpm 
for 5 minutes at 4
o
C. 
 
Cell fixation: 
1. Supernatant was removed and cells were resuspended at density 1 x 106 
cells/ml in FACS buffer. 
2. 100µl aliquot of each cell suspension was transferred to polystyrene round-
bottom 12 x 75cm Falcon tubes. 
3. 100µl Fixation Medium (Reagent A) (fix & perm Cell permeabilization kit, 
Invitrogen, UK) was added to the flow tube. Cells were incubated for 15 
minutes at room temperature in the dark. 
4. Cells were washed with 3ml FACS buffer, centrifuged at 1500 rpm at 4oC for 
5 minutes. Supernatant was then discarded and pellet was resuspended in 50µl 
FACS buffer. 
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Cell permeabilization and staining for flow cytometry: 
1. 100µl of the permeabilization medium (Reagent B) containing the appropriate 
fluorochrome- conjugated antibody cocktail was then added to the matched 
tube, mixed gently by vortexing and incubated for 30 minutes at room 
temperature in the dark. 
2. Each sample was then washed with 3ml of the FACS buffer and centrifuged at 
1500 rpm at 4
o
C for 5 minutes and the supernatant was discarded. 
3. Pellet cells were then dislodged and incubated with Click-it reaction cocktail 
(0.5ml/each tube) for 30 minutes at room temperature in the dark. 
4. Samples were washed once with 3ml FACS buffer and centrifuged for 5 
minutes at 4
o
C at 1500 rpm. Supernatant was discarded. 
5. Cells were resuspended in 0.5ml FACS buffer. 
6. 5µl Ribonuclease A (component L) was added to each tube and then mixed 
gently. 
7. 2µl of the cell cycle 488-red dye 7-aminoactinomycin D (7-AAD) was added 
to each tube and mixed well. 
8. Samples were incubated for 15 minutes at room temperature. 
9. Cell cycle, Edu-labelled cells (Phase S) and expression of cyclin D and cyclin 
B were then analyzed by flow cytometry. 
 
2.10.6.  Protocol for Bax and Bcl-2 staining: 
1. Cells were harvested with trypsin and suspension was centrifuged at 1500rpm 
for 5 minutes at 4
o
C. 
2. Cells were fixed and washed as described above. 
3. 100µl of the permeabilization medium (Reagent B) containing the appropriate 
fluorochrome- conjugated antibody cocktail was then added to the matched 
tube, mixed gently by vortexing and incubated for 30 minutes at room 
temperature in the dark. 
4. Each sample was then washed with 3ml of the FACS buffer and centrifuged at 
1500 rpm at 4
o
C for 5 minutes and the supernatant was discarded. 
5. Samples were resuspended in 500µl FACS buffer and expression of Bax and 
Bcl-2 was then measured immediately by flow cytometry machine. 
 
62 
 
2.10.7. Flow cytometric analysis: 
Flow cytometry is a technology of quantitative single particles analysis that allows 
simultaneous analysis of multiple biologic markers of single cells. It is based on the 
essential principle that single cells labelled with fluorescent dyes and suspended in a 
fluid stream can be individually analysed as they pass through a light laser beam 
directed onto a very small zone known as the “interrogated region”. At this point, 
each suspended cell scatters the light in different ways (forward scatter -FSC- and 
side scatter -SSC) and the fluorescent dye bound to the cells is excited and emits light 
at a higher wavelength than the light source. The light signals are collected by 
detectors and analysed to provide information about the chemical and physical 
structure of each single cell. FSC depends on the cell size and SSC correlates with cell 
granularity (Brown & Wittwer, 2000). 
 
In this study, a BD FACS Canto II equipped with three lasers, an argon ion Laser 
emitting 20mW at 488-nm, Red HeNe (15mW, 633-nm) and a violet laser (59mW, 
405-nm) (BD   Bioscience) was used. Data analysis was performed using the BD 
FACS Diva    software version 6.1.2 (BD Bioscience). 
 
Six parameters (FSC, SSC, PerCp-Cy5.5, Pacific blue, FITC, and APC) were 
analyzed from a cell sample stained with the Edu pacific blue, 7-AAD, Alexa fluor 
488- conjugated cyclin D antibody and Alexa fluor 647-conjugated cyclin B antibody, 
while four parameters (FSC, SSC, FITC, and APC) were analysed from a cell sample 
stained with Alexa fluor 488-conjugated Bax antibody and Alexa fluor 647- 
conjugated Bcl-2 antibody. 
 
Forward scatter (FSC) and side scatter (SSC) were collected using a 488nm band pass 
filter. FITC (Alexa flour 488) green fluorescence was excited with the 488nm blue 
argon laser and collected in the 530/30nm channel, APC (Alexa flour 647) red 
fluorescence was excited with the 633-nm red Diode laser and collected in the 
660/20nm channel, Pacific Blue was excited with the 405nm violet laser and collected 
in the 450/50 channel, PerCep-Cy5.5 (7-AAD) red fluorescence was excited with the 
488 nm blue argon laser and collected in the 670LP channel. 
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For analysis, isotype matched negative controls for all of the antibodies studied were 
run first to measure the non-specific binding (autofluorescence) and subsequently to 
determine the position of the positive and negative populations. Compensation for 
spectral overlap was set using single fluorochrome-labelled samples plus 
fluorochromes-minus one controls. The forward scatter (FSC) –versus- side scatter 
(SSC) dot plot was used to exclude cell debris and doublets. 10.000 to 30.000 cells/ 
sample within each gate were collected using the “medium” setting for sample flow 
rate. The gated population were then plotted to investigate the fluorescence signals of 
interest and shown as one parameter histogram displaying the intensity of the 
fluorescent signal reported on the X-axis against the number of events on the Y-axis 
or/and two-parameter displays (dot plots) showing two parameters with either linear 
or logarithmic axes that extend over a four to five decade ranges representing cells 
with fluorescence values. The vertical or/and the horizontal markers were set on each 
histogram using the isotype matched negative controls for the antibodies of interest. 
Data were reported as a percentage of positive cells from both the total population and 
the singlet gated one.   
 
2.11. Statistical Analysis: 
Data were analysed by using One-way ANOVA test along with Student’s independent 
t-test.  Statistical significance was considered when p<0.05. Findings were further 
confirmed using SPSS program by one-way ANOVA and Post hoc test. 
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Chapter Three 
Effect of CsA on cell viability and 
cytokine expression in monolayer cell 
cultures  
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 3.1. Introduction: 
This Chapter describes the effect of different doses of CsA on cell viability and 
cytokine expression in human gingival keratinocyte cell line, human oral keratinocyte 
cell line, and human gingival fibroblast cell line at different time intervals in an 
attempt to determine both the optimal doses of CsA and time intervals of challenging 
to be used in subsequent in vitro experiments.  
 
The cell lines were treated with 0,100, 500, 1000 and 2000ng/ml CsA for up to 144 h 
(6 days).  Cell viability was assessed by MTT assay after 4, 6, 8, 24 and 144h.  
Cytokine release was measured by ELISA at 4, 6, 8, 24, 48, 96 and 144h. 
 
3.2. Effect of CsA on cell viability: 
3.2.1 FIBS cells: 
Stimulation of FIBS with CsA caused two distinctive dose-dependent effects: 
100ng/ml CsA caused a slight but significant increase in cell viability at 12 and 24h 
(Fig 3.1 p < 0.05 compared to control). Conversely, CsA at doses ≥1000ng/ml caused 
a slight but significant reduction in the cell viability starting from 6h onwards with a 
maximal decrease being observed with 2000ng/ml CsA. 500ng/ml CsA had no 
significant effect on the cell viability.  
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Figure 3.1. Effect of CsA on viability of FIBS. 
FIBS were stimulated with increasing doses of CsA and cell viability was measured by MTT assay. 
Control cultures were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been 
omitted for clarity. 
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3.2.2 OKF6 cells: 
CsA had no effect on cell viability in the early hours of stimulation compared to 
control (Fig 3.2). However, after 8h of stimulation, CsA caused a slight but dose-
dependent increase in the cell viability with a maximal increase being observed at 24h 
with 2000ng/ml CsA (p < 0.05). Prolonged exposure to high doses (1000 and 
2000ng/ml) caused a significant reduction in cell viability (p < 0.05).  
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Figure 3.2. Effect of CsA on viability of OKF6. 
OKF6 were stimulated with increasing doses of CsA and cell viability was measured by MTT assay. 
Control cultures were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been 
omitted for clarity.  
 
 
 
3.2.3 TR146 cells: 
CsA had no effect on cell viability up to 24h (Fig 3.3). Prolonged exposure (144h) to 
higher doses (1000 and 2000ng/ml) however, caused a slight but significant reduction 
in viability (p < 0.05) compared to control. 
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Figure 3.3. Effect of CsA on viability of TR146. 
TR146 were stimulated with increasing doses of CsA and cell viability was measured by MTT assay. 
Control cultures were stimulated with Ethanol vehicle (1/1000 in DMEM). ); n = 9.  SEM has been 
omitted for clarity.  
 
3.2.4 HGF cells: 
CsA at doses ≤1000ng/ml caused a slight but significant increase in cell viability at 
24h (p < 0.05 versus control) but had no significant effect at the other intervals 
studied (Fig 3.4). 
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Figure. 3.4.  Effect of CsA on viability of HGF. 
HGF were stimulated with increasing doses of CsA and cell viability was measured by MTT assay. 
Control cultures were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been 
omitted for clarity.  
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3.3. Effect of CsA on IL-1α release: 
3.3.1 FIBS cells: 
100, 500 and 1000ng/ml had no significant effect on the release of IL-1 compared to 
control at all the time intervals studied (Fig 3.5).  2000ng/ml, however showed a 
significant increase (p < 0.05) between 8 and 24h (at 8h: 9.42 +/- 0.8 pg/ml vs control: 
7.53 +/- 0.7 pg/ml; at 24h: 15.67 +/- 3.2 pg/ml vs control: 7.1 +/- 1.2 pg/ml), with 
levels returning to control values at the later time points. 
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Figure. 3.5. Effect of CsA on IL-1 release by FIBS. 
FIBS were stimulated with increasing doses of CsA and IL-1 was measured by ELISA. Control 
cultures were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been omitted for 
clarity.  
 
3.3.2 OKF6 cells: 
100, 500 and 1000ng/ml had no significant effect on the release of IL-1 compared to 
control at all the time intervals studied (Fig 3.6).  2000ng/ml, however showed a 
significant increase (p < 0.05) between 24 and 48h (at 24h: 15.8 +/- 6.1 vs control: 7.5 
+/- 1.3 pg/ml; at 48h: 11.8 +/- 0.5 vs control: 7.3 +/- 0.7 pg/ml), with levels returning 
to control values at the later time point. 
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Figure 3.6. Effect of CsA on IL-1 release from OKF6. 
OKF6 were stimulated with increasing doses of CsA and IL-1 was measured by ELISA. Control 
cultures were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been omitted for 
clarity.  
 
3.3.3 TR146 cells: 
TR146 showed a dose dependent increase in IL-1 (Fig 3.7) with 2000ng/ml causing 
a maximum release after 24 hrs (13.5 +/- 1.2 vs control: 7.2 +/- 1 pg/ml).  This effect 
was not evident at later time points. 
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Figure. 3.7. Effect of CsA on IL-1 release from TR146. 
TR146 were stimulated with increasing doses of CsA and IL-1 was measured by ELISA. Control 
cultures were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been omitted for 
clarity.  
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3.3.4 HGF cells: 
CsA had no significant effect on the release of IL-1 from HGF cells (Fig 3.8). 
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Figure 3.8 Effect of CsA on IL-1 release from HGF. 
HGF were stimulated with increasing doses of CsA and IL-1 was measured by ELISA. Control 
cultures were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been omitted for 
clarity.  
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3.4. Effect of CsA on IL-6 release: 
3.4.1 FIBS cells: 
Control cultures and those treated with 100, 500 and 1000ng/ml CsA showed a similar 
pattern with IL-6 release increasing up to 24hr (Fig 3.9). There was no significant 
difference between CsA treated and control cultures at these time points.  2000ng/ml 
CsA, however caused a significant increase (p < 0.05) in IL-6 release at 12 and 24 hr 
(at 12h: 349 +/- 92 vs control: 198 +/- 111 pg/ml; at 24h: 355 +/- 69 vs control: 266 
+/- 61 pg/ml), returning to control values at the later time points 
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Figure 3.9 Effect of CsA on IL-6 release from FIBS. 
FIBS were stimulated with increasing doses of CsA and IL-6 was measured by ELISA. Control 
cultures were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been omitted for 
clarity.  
 
3.4.2 OKF6 cells: 
1000 and 2000ng/ml CsA caused a dose and time dependent increase in IL-6 release 
up to 24hr treatment (at 24h: 1000 ng/ml: 1023 +/- 246 and 2000ng/ml: 1355 +/- 271 
ng/ml vs control: 529 +/- 92 pg/ml; p < 0.05; Fig 3.10).  Levels of release returned to 
control values at the later time points.  100 and 500ng/ml had no significant effect on 
IL-6. 
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Figure 3.10 Effect of CsA on IL-6 release from OKF6. 
OKF6 were stimulated with increasing doses of CsA and IL-6 was measured by ELISA. Control 
cultures were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been omitted for 
clarity.  
 
 
3.4.3 TR146 cells: 
500. 1000 and 2000ng/ml CsA showed a maximum release of IL-6 after 12 h (424 +/- 
52, 462 +/- 73, and 565 +/- 130 pg/ml respectively vs control: 302 +/- 48 pg/ml; p < 
0.05; Fig 3.11) which returned to control levels by 24h (500 and 1000ng/ml) or 48h 
(2000ng/ml).  100ng/ml had no significant effect on IL-6 release.  
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Figure 3.11 Effect of CsA on IL-6 release from TR146. 
TR146 were stimulated with increasing doses of CsA and IL-6 was measured by ELISA. Control 
cultures were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been omitted for 
clarity.  
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3.4.4 HGF cells:  
CsA had no significant effect on IL-6 release in HGF at any point of the treatment 
time course (p < 0.05 Fig 3.12). 
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Figure 3.12 Effect of CsA on IL-6 release from HGF. 
HGF were stimulated with increasing doses of CsA and IL-6 was measured by ELISA. Control cultures 
were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been omitted for clarity.  
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3.5. Effect of CsA on IL-8 release: 
3.5.1 FIBS cells: 
500, 1000 and 2000ng/ml CsA showed slight but significant increases in IL-8 release 
up to 48h (at 24h: 1160 +/- 118, 1196 +/- 50, and 1202 +/- 98 pg/ml respectively vs 
control: 1016 +/- 120 pg/ml; p < 0.05; Fig 3.13). This increase was maintained up to 
144hr with 2000ng/ml CsA only (932 +/- 153 and 967 +/- 29 pg/ml at 96h and 144h 
respectively vs control: 445 +/- 122, and 69 +/- 27 pg/ml). 
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Figure 3.13 Effect of CsA on IL-8 release from FIBS. 
FIBS were stimulated with increasing doses of CsA and IL-8 was measured by ELISA. Control 
cultures were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been omitted for 
clarity.  
 
3.5.2 OKF6 cells: 
2000ng/ml CsA caused a slight but significant increase in IL-8 release up to 24h (625 
+/- 63, 740 +/- 28, 818 +/- 47, 882 +/- 91, and 1110 +/- 120 at 4, 6, 8, 12, and 24h 
respectively vs control: 463 +/- 40, 624 +/- 28, 691 +/- 104, 742 +/- 50, and 985 +/- 
138 pg/ml; p<0.05; Fig 3.14) but had no significant effect afterwards. Lower doses of 
CsA had a very little effect. 
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Figure 3.14 Effect of CsA on IL-8 release from OKF6. 
OKF6 were stimulated with increasing doses of CsA and IL-8 was measured by ELISA. Control 
cultures were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been omitted for 
clarity 
 
3.5.3 TR146 cells: 
 
TR146 showed a maximal IL-8 release after 12 exposure to 500, 1000 and 2000ng/ml 
CsA (88 +/- 31, 195 +/- 82, and 364 +/- 40 pg/ml respectively vs control: 42 +/- 25 
pg/ml; p < 0.05) returning to control levels by 24 – 48 h (Fig 3.15).  
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Figure 3.15 Effect of CsA on IL-8 release from TR146. 
TR146 were stimulated with increasing doses of CsA and IL-8 was measured by ELISA. Control 
cultures were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been omitted for 
clarity 
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3.5.4 HGF cells: 
CsA had no significant effect on the release of IL-8 from HGF cells (Fig 3.16) 
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Figure 3.16 Effect of CsA on IL-8 release from HGF. 
HGF were stimulated with increasing doses of CsA and IL-8 was measured by ELISA. Control cultures 
were stimulated with Ethanol vehicle (1/1000 in DMEM); n = 9.  SEM has been omitted for clarity 
 
3.6 Summary and Conclusions 
Viability 
All doses of CsA tested had little or no effect on the viability of FIBS, TR146 and 
HGF cells up to 144h exposure.  OKF6 cells, however only showed a significant 
reduction in viability after prolonged exposure (up to 144hr) to higher doses (1000 
and 2000ng/ml). 
 
Cytokine release 
Overall CsA had a variable effect on the release of IL-1α, IL-6 and IL-8 from the 
FIBS, OKF6, TR146 and HGF.  1000 and 2000ng/ml stimulated cytokine release 
from the keratinocytes after 12 – 24 h exposure whilst HGF cells were not affected by 
CsA.  Prolonged exposure did not demonstrate a significant change in cytokine 
release.  As a result 2000ng/ml CsA for 24h was chosen for the next phase of the 
study with 250ng/ml as the low concentration that reflects in vivo measurements 
(Fisher et al., 1988). 
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Chapter Four 
Effect of CsA and bacterial 
supernatants on cell viability and 
cytokine expression in monolayer cell 
cultures 
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4.1. Introduction: 
The results outlined in the previous chapter demonstrated that CsA had a limited 
effect on cell viability and that cytokine release was maximal after 24h exposure with 
the highest dose. However, in vivo any interaction between CsA and host cells will 
usually take place in the presence of dental plaque or plaque derived products. The 
aim of the next phase of the study, therefore was to examine the effect of the 
combination of CsA (2000ng/ml CsA for 24h) and four periodontopathic organisms 
(P.g, A.a, P.i, and F.n) on viability and cytokine release. In addition, the effect of 
250ng/ml CsA was also tested as this reflects in vivo measurements (Fisher et al., 
1988).  The cell viability and cytokine release were determined by MTT assay and 
ELISA respectively. The significant effect of each combined treatment of (CsA and 
bacterial supernatant) was determined by comparing to three controls:  control 
cultures, CsA alone, and the respective bacterial supernatant alone using one-way 
ANOVA together with Student’s independent t-test. 
 
4.2. Determination of the bacterial dose:  
Toxicity of bacterial supernatants was determined by evaluating the integrity of cell 
membrane of the studied cell lines after 24h of bacterial challenge through measuring 
the expression level of Lactate Dehydrogenase LDH in the culture medium using an 
in vitro Cytotoxicity Detection Kit
plus
 (LDH) (Roche, Mannheim, Germany).  The 
results were confirmed by measuring the effect of bacterial supernatants on the 
viability of cell lines by Alamar blue (Invitrogen.UK). 
 
Bacterial supernatants at 1:10 and 1:50 had a greater effect on LDH release and cell 
viability than 1:100 in FIBS (Fig 4.1 & 4.2). A similar result was obtained for the 
other cell lines (Appendix 1). Bacterial supernatant at 1:100 was therefore chosen for 
the subsequent experiments 
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Figure 4.1. LDH release from FIBS. Cell lines were challenged for 24h with ascending doses 
of bacterial supernatants. Extracellular release of LDH was then measured using a Cytotoxicity 
Detection Kit
plus
. Two controls were used in the study; high control which represents the totally lysed 
cells and low control which is medium containing un-treated cells. Results are expressed as percentage 
of total LDH. Bars represent Mean ± SEM of 12 samples. 
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Figure 4.2. FIBS viability. Cultures were stimulated for 24h with ascending concentrations of 
bacterial supernatant. Cell viability was measured by Alamar blue. Untreated cells were served as 
control. Results are expressed as the Mean ± SEM (n=9). Statistical significance was regarded when p< 
0.05 compared to control.  
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4.3. Treatment: 
Cells were seeded into 24 well plates and allowed to settle down for 24h. Cells were 
washed twice with PBS and then serum-starved for 24h.  
After washing with PBS, cells were pre-stimulated for 24h with bacterial supernatants 
(either 0 or 1:100 dilutions of P.g, A.a, F.n, and P.i in growth medium) at 37
o
C and 
5% CO2. Cells were washed with PBS and then stimulated for additional 24h with 
different concentrations of CsA (2000ng/ml, 250 ng/ml and 0ng/ml as a control). At 
the end of the experiment, culture supernatants were collected and frozen at -80
o
C 
until use for cytokine analysis and MTT assay was conducted to measure the cell 
viability. Controls included un-treated cultures, bacterial supernatant-treated cultures 
without CsA, and cultures treated with CsA only. 
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4.4. Effect of CsA and bacteria supernatants on cell viability:   
4.4.1. FIBS cells: 
250ng/ml CsA caused a slight increase in the FIBS cell viability compared to the 
control (250ng/ml CsA; 114 ± 12% vs control; 100 ± 4%. Fig 4.3; p<0.05).  
Conversely, 2000ng/ml CsA caused a slight decrease in the FIBS cell viability 
(2000ng/ml; 92 ± 7%; p<0.05)  
P. gingivalis 
P.g significantly decreased the viability of FIBS cells compared to the control (P.g; 86 
± 10%; p<0.05 vs control).  Addition of CsA significantly promoted this inhibitory 
effect on FIBS viability (P.g + 250ng/ml CsA; 72 ± 3, P.g + 2000ng/ml CsA; 71 ± 4%        
p<0.05 vs P.g)       
A. actinomycetemcomitans 
A.a significantly increased the viability of FIBS cells compared to the control (A.a; 
109 ± 9%; p<0.05 vs control). Addition of 250ng/ml CsA did not cause a significant 
modulation on FIBS viability. 2000ng/ml CsA, however abrogated the effect of A.a 
on cell viability with results returning to control levels (A.a + 2000ng/ml CsA; 93 ± 
10%; p<0.05 vs A.a). 
P. intermedia 
P.i significantly increased the viability of FIBS cells compared to that of control (P.i; 
147 ± 16%; p<0.05 vs control). Furthermore, addition of either 250ng/ml or 
2000ng/ml CsA significantly decreased the cell viability with results returning to 
levels found in cultures treated with 250ng/ml and 2000ng/ml CsA respectively (P.i + 
250ng/ml CsA; 118 ± 10, P.i + 2000ng/ml; 102 ± 16%; p<0.05 vs P.i).  
F. nucleatum 
F.n significantly increased the viability of FIBS cells compared to that of control (F.n; 
124 ± 11%; p<0.05 vs control). Addition of 250ng/ml CsA significantly promoted this 
stimulatory effect on FIBS cell viability (F.n + 250ng/ml CsA; 146 ± 22%; p<0.05 vs 
F.n).  Conversely, addition of 2000ng/ml CsA abrogated the effect of F.n on cell 
viability with results returning to control levels (F.n + 2000ng/ml CsA; 102 ± 13%; 
p<0.05 vs F.n) 
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Figure 4.3. Effect of (CsA + bacterial supernatant) combination on FIBS 
viability. Cultures were stimulated with CsA or/and bacterial supernatant. Cell viability was 
measured by MTT assay after 24h exposure. Untreated cells were served as a control. Results are 
expressed as the Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to 
control.  
 
4.4.2 OKF6 cells: 
CsA at either 250ng/ml or 2000ng/ml dose caused a significant increase in the cell 
viability compared to the control (250ng/ml; 121 ± 10, 2000ng/ml CsA; 132 ± 14 vs 
control; 100 ± 9%; Fig 4.4; p<0.05).  
P. gingivalis 
P.g significantly increased the viability of OKF6 cells compared to that of control 
(P.g; 144 ± 23%; p<0.05 vs control). Furthermore, addition of CsA had no significant 
effect on the cell viability (P.g + 250ng/ml CsA; 137 ± 24, P.g + 2000ng/ml CsA; 132 
± 21%; p>0.05 vs P.g). 
A. actinomycetemcomitans 
A.a significantly decreased the viability of OKF6 cells compared to that of control 
(A.a; 81 ± 11%; p<0.05 vs control). However, addition of 250ng/ml CsA significantly 
increased the cell viability with values returning to control level (A.a + 250ng/ml 
CsA; 105 ± 20%; p<0.05 vs A.a). Conversely, addition of 2000ng/ml CsA had no 
effect on OKF6 viability (A.a + 2000ng/ml CsA; 81 ± 13%; p>0.05 vs A.a).  
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P. intermedia 
P.i significantly increased the viability of OKF6 cells compared to that of controls 
(P.i; 158 ± 34%; p<0.05 vs control). However, addition of CsA had no significant 
effect on the cell viability (p>0.05 vs P.i). 
F. nucleatum 
F.n supernatant significantly increased the viability of OKF6 cells compared to that of 
control (F.n; 125 ± 34%; p<0.05 vs control). Furthermore, addition of CsA had no 
significant effect on the cell viability (p>0.05 vs F.n). 
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Figure 4.4. Effect of (CsA + bacterial supernatant) combination on OKF6 
viability. Cultures were stimulated with CsA or/and bacterial supernatant. Cell viability was 
measured by MTT assay after 24h exposure. Untreated cells were served as a control. Results are 
expressed as the Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to 
control. 
 
4.4.3 TR146 cells: 
CsA at either 250ng/ml or 2000ng/ml dose had no significant effect on TR146 
viability (107 ± 9 & 98 ± 11 respectively vs control; 100 ± 7%; Fig 4.5; p<0.05). 
P. gingivalis 
P.g significantly increased the viability of TR146 compared to the controls (P.g; 186 
± 21%; p<0.05 vs control and both 250ng/ml & 2000ng/ml CsA). Addition of 
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250ng/ml CsA did not cause a significant modulation on the cell viability. However, 
addition of 2000ng/ml CsA significantly decreased the cell viability (P.g + 2000ng/ml 
CsA; 131 ± 15%; p<0.05 vs P.g) with values still significantly higher than that of 
control and cultures treated with 2000ng/ml CsA (p<0.05 vs control and 2000ng/ml 
CsA). 
A. actinomycetemcomitans 
A.a significantly increased the viability of TR146 cells compared to the controls (A.a; 
125 ± 24%; p<0.05 vs control and both 250ng/ml & 2000ng/ml CsA). Furthermore, 
addition of 250ng/ml CsA significantly enhanced this stimulatory effect (A.a + 
250ng/ml CsA; 187 ± 30%; p<0.05 vs A.a). However, addition of 2000ng/ml CsA had 
no effect. 
P. intermedia 
P.i significantly increased the viability of TR146 cells compared to the controls (P.i; 
193 ± 27%; p<0.05 vs control and both 250ng/ml & 2000ng/ml CsA). Addition of 
250ng/ml CsA had no significant effect on the cell viability. However, addition of 
2000ng/ml CsA significantly reduced the cell viability (P.i + 2000ng/ml CsA; 156 ± 
17%; p<0.05 vs P.i) with values still significantly higher than that of control and 
cultures treated with 2000ng/ml CsA (p<0.05 vs control and 2000ng/ml CsA). 
F. nucleatum 
F.n significantly increased the viability of TR146 cells compared to the controls (F.n; 
136 ± 16%; p<0.05 vs control and both 250ng/ml & 2000ng/ml CsA). Addition of 
250ng/ml CsA significantly promoted this stimulatory effect on cell viability (F.n + 
250ng/ml CsA; 194 ± 27%; p<0.05 vs F.n). However, addition of 2000ng/ml CsA had 
no effect. 
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Figure 4.5. Effect of (CsA + bacterial supernatant) combination on TR146 
viability. Cultures were stimulated with CsA or/and bacterial supernatant. Cell viability was 
measured by MTT assay after 24h exposure. Untreated cells were served as a control. Results are 
expressed as the Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to 
control.  
 
 
4.4.4 HGF cells: 
250ng/ml CsA had no significant effect on cell viability (104 ± 12 vs control; 100 ± 
6%; p>0.05). However, 2000ng/ml CsA caused a significant increase in the HGF 
viability compared to the control (114 ± 15%; Fig 4.6; p<0.05 vs control).  
P. gingivalis 
P.g had no significant effect on HGF viability compared to the control (92 ± 12%; 
p>0.05 vs control). Addition of CsA at (250ng/ml or 2000ng/ml) had no significant 
effect on the cell viability (p>0.05 vs P.g).  
A. actinomycetemcomitans 
A.a significantly decreased the cell viability compared to the controls (86 ± 12%; 
p<0.05 vs control). Addition of 250ng/ml CsA did not cause a significant modulation 
on the cell viability (p>0.05 vs A.a). However, addition of 2000ng/ml CsA 
significantly increased the cell viability (A.a + 2000ng/ml; 104 ± 14%; p<0.05 vs A.a) 
with values returning to control levels (p>0.05 vs control & 2000ng/ml). 
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P. intermedia 
Stimulation of HGF with P.i supernatant either individually or in combination with 
CsA has no significant effect on HGF viability. 
F. nucleatum 
F.n supernatant significantly decreased the cell viability compared to controls (81 ± 
19%; p<0.05 vs controls). However, addition of CsA had no significant effect on cell 
viability (p>0.05 vs F.n). 
 
0
20
40
60
80
100
120
140
0
25
0
20
00 P
.g
P
.g
+2
50
P
.g
+2
00
0
A
.a
A
.a
+2
50
A
.a
+2
00
0 P
.i
P
.i+
25
0
P
.I+
20
00 F.
n
F.
n+
25
0
F.
n+
20
00
Treatment
 %
 o
f 
c
o
n
tr
o
l
Figure 4.6. Effect of (CsA + bacterial supernatant) combination on HGF 
viability. Cultures were stimulated with CsA or/and bacterial supernatant. Cell viability was 
measured by MTT assay after 24h exposure. Untreated cells were served as a control. Results are 
expressed as the Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to 
control. 
 
 
4.5. Effect of CsA and bacteria supernatants on IL-1α release:   
4.5.1  FIBS cells: 
250ng/ml CsA did not cause a significant modulation on IL-1α release compared to 
the control (250ng/ml CsA; 17 ± 5 vs control; 15 ± 4pg/ml; p>0.05). Furthermore, 
2000ng/ml CsA significantly increased IL-1α release (2000ng/ml CsA; 29 ± 7pg/ml; 
Fig 4.7; p<0.05 vs control). 
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P. gingivalis 
P.g had no significant effect on IL-1α release compared to that of the control (P.g; 18 
± 3pg/ml; p>0.05 vs control & 250ng/ml CsA). Addition of 250ng/ml CsA did not 
significantly modulate IL-1α release. However, addition of 2000ng/ml CsA 
significantly increased IL-1α release with values returning to that level being found in 
cultures treated with 2000ng/ml CsA (P.g + 2000ng/ml CsA; 28 ± 6pg/ml; p<0.05 vs 
P.g). 
A. actinomycetemcomitans 
A.a had no significant effect on IL-1α release compared to that of the control (A.a; 16 
± 3pg/ml; p>0.05 vs control & 250ng/ml CsA). Addition of 250ng/ml CsA did not 
significantly modulate the release of IL-1α. However, addition of 2000ng/ml CsA 
significantly increased IL-1α release with values still significantly lower than that of 
cultures treated with 2000ng/ml CsA (A.a + 2000ng/ml CsA; 21 ± 3pg/ml; p<0.05 vs 
A.a & 2000ng/ml CsA individually).  
P. intermedia 
P.i significantly decreased IL-1α release compared to that of controls (P.i; 10 ± 
1pg/ml; p<0.05 vs control and CsA 250ng/ml & 2000ng/ml). Addition of 250ng/ml 
CsA did not significantly modulate IL-1α release. However, addition of 2000ng/ml 
CsA significantly increased release of IL-1α with values still significantly lower than 
that of cultures treated with 2000ng/ml CsA(P.i + 2000ng/ml CsA; 19 ± 3pg/ml; 
p<0.05 vs P.i & 2000ng/ml CsA individually).  
 . 
F. nucleatum 
F.n caused a similar effect on IL-1α release to that found with P.i either individually 
or in combination with CsA.  
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Figure 4.7.  Effect of (CsA + bacterial supernatant) combination on release of IL-
1α in FIBS. Cultures were stimulated with CsA and/or bacterial supernatant. Untreated cells are 
served as a control. IL-1α was measured by Elisa assay after 24h exposure. Results are expressed as the 
Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to control.  
 
4.5.2 OKF6 cells: 
250ng/ml CsA did not cause a significant modulation on IL-1α release compared to 
the control (250ng/ml CsA; 5 ± 0.3 vs control 5 ± 0.3pg/ml; p>0.05). Furthermore, 
2000ng/ml CsA significantly increased IL-1α release compared to control (2000ng/ml 
CsA; 8 ± 0.4pg/ml; Fig 4.8; p<0.05 vs control). 
P. gingivalis 
P.g significantly decreased IL-1α release compared to that of controls (P.g; 3 ± 
0.2pg/ml; p<0.05 vs control and both 250ng/ml & 2000ng/ml CsA). Addition of 
250ng/ml CsA significantly increased IL-1α release with values returning to that level 
being found in control culture and cultures treated with 250ng/ml CsA (P.g + 
250ng/ml CsA; 4.6 ± 0.8pg/ml; p<0.05 vs P.g). However, addition of 2000ng/ml CsA 
had no significant effect.  
A. actinomycetemcomitans 
A.a significantly increased IL-1α release compared to that of controls (A.a; 22 ± 
3.5pg/ml; p<0.05 vs control and both 250ng/ml & 2000ng/ml CsA). Furthermore, 
addition of either 250ng/ml or 2000ng/ml CsA had no significant effect on IL-1α 
release (p>0.05 vs A.a).  
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P. intermedia and F. nucleatum 
P.i and F.n caused a significant decrease in IL-1α release compared to that of controls 
(2.5 ± 0.1 & 2.6 ± 0.2pg/ml respectively; p<0.05 vs control and both 250ng/ml & 
2000ng/ml CsA). However, addition of 250ng/ml or 2000ng/ml CsA had no 
significant effect on IL-1α release (p>0.05 vs the respective bacterial supernatant).  
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Figure 4.8.  Effect of (CsA + bacterial supernatant) combination on release of IL-
1α in OKF6. Cultures were stimulated with CsA and/or bacterial supernatant. Untreated cells are 
served as a control. IL-1α was measured by Elisa assay after 24h exposure. Results are expressed as the 
Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to control.  
 
4.5.3 TR146 cells: 
250ng/ml CsA did not cause a significant modulation on IL-1α release compared to 
the control (250ng/ml CsA; 9.6 ± 5.5 vs control; 6.6 ± 1.2pg/ml; p>0.05). However, 
2000ng/ml CsA significantly increased the release of IL-1α (2000ng/ml CsA; 14.1 ± 
4pg/ml; Fig 4.9; p<0.05 vs control). 
P. gingivalis 
P.g significantly increased IL-1α release compared to the control (P.g; 9.7 ± 3.3pg/ml; 
p<0.05 vs control). Addition of either 250ng/ml or 2000ng/ml CsA had no significant 
effect on IL-1α release.  
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A. actinomycetemcomitans 
A.a had no significant effect on IL-1α release compared to the control (A.a; 6.9 ± 
0.8pg/ml; p>0.05 vs control) Addition of 250ng/ml CsA had no significant effect. 
However, addition of 2000ng/ml CsA significantly increased the release of IL-1α with 
values still significantly lower than that of cultures treated with 2000ng/nl CsA only 
(A.a + 2000ng/ml CsA; 10.3 ± 2pg/ml; p<0.05 vs A.a & 2000ng/ml CsA 
individually).  
P. intermedia 
P.i significantly increased IL-1α release compared to the control (P.i; 10.3 ± 2.5pg/ml; 
p<0.05 vs control). Addition of 250ng/ml CsA did not significantly modulate the 
release of IL-1α. However, addition of 2000ng/ml CsA significantly increased IL-1α 
release with values returning to that level found in cultures treated with 2000ng/ml 
CsA (P.i + 2000ng/ml CsA; 16 ± 3.5pg/ml; p<0.05 vs P.i).  
F. nucleatum 
F.n did not cause a significant modulation on IL-1α release compared to the control 
(F.n; 7.4 ± 2.4pg/ml; p>0.05 vs control). Addition of 250ng/ml CsA had no 
significant effect. However, addition of 2000ng/ml CsA significantly increased the 
release of IL-1α with values returning to that level found in cultures treated with 
2000ng/ml CsA (F.n + 2000ng/ml CsA; 17.3 ± 2.6pg/ml; p<0.05 vs F.n).  
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Figure 4.9.  Effect of (CsA + bacterial supernatant) combination on release of IL-
1α in TR146. Cultures were stimulated with CsA and/or bacterial supernatant. Untreated cells are 
served as a control. IL-1α was measured by Elisa assay after 24h exposure. Results are expressed as the 
Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to control.  
 
4.5.4 HGF cells: 
CsA and bacterial supernatants had no significant effect on the release of IL-1α from 
HGF cells (Fig 4.10) 
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Figure 4.10.  Effect of (CsA + bacterial supernatant) combination on release of 
IL-1α in HGF. Cultures were stimulated with CsA and/or bacterial supernatant. Untreated cells are 
served as a control. IL-1α was measured by Elisa assay after 24h exposure. Results are expressed as the 
Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to control.  
 
92 
 
 
4.6. Effect of CsA and bacteria supernatants on IL-6 release:   
4.6.1  FIBS cells: 
250ng/ml CsA did not cause a significant modulation on release of IL-6 compared to 
the control (250ng/ml CsA; 314 ± 157 vs control; 264 ± 66pg/ml; p>0.05). However, 
2000ng/ml CsA significantly increased IL-6 release (2000ng/ml CsA; 392 ± 
116pg/ml; Fig 4.11; p<0.05 vs control). 
P. gingivalis 
P.g completely inhibited the release of IL-6 (10.6 ± 0.3pg/ml). However, addition of 
CsA at either 250ng/ml or 2000ng/ml had no significant effect (p>0.05 vs P.g). 
A. actinomycetemcomitans 
A.a significantly increased the release of IL-6 compared to the controls (A.a; 550 ± 
140pg/ml; p<0.05 vs control). Furthermore, addition of either 250ng/ml or 2000ng/ml 
CsA had no significant effect (p>0.05). 
P. intermedia 
P.i had no significant effect on the release of IL-6 compared to the controls (P.i; 434 ± 
205pg/ml; p>0.05 vs control and both 250ng/ml & 2000ng/ml CsA). Addition of 
250ng/ml did not significantly modulate the release of IL-6 (p>0.05 vs P.i). However, 
addition of 2000ng/ml CsA significantly increased the IL-6 release compared to that 
of controls (P.i + 2000ng/ml CsA; 856 ± 255pg/ml; p<0.05 vs P.i & 2000ng/ml CsA 
individually). 
F. nucleatum 
F.n significantly decreased the release of IL-6 compared to the controls (F.n; 83 ± 
70pg/ml; p<0.05 vs control and both 250ng/ml & 2000ng/ml CsA). Addition of 
250ng/ml CsA had no significant effect. However, addition of 2000ng/ml CsA 
significantly increased the release of IL-6 compared to the controls (F.n + 2000ng/ml 
CsA; 580 ± 177pg/ml; p<0.05 vs F.n & 2000ng/ml CsA individually). 
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Figure 4.11.  Effect of (CsA + bacterial supernatant) combination on release of 
IL-6 in FIBS. Cultures were stimulated with CsA and/or bacterial supernatant. Untreated cells are 
served as a control. IL-6 was measured by Elisa assay after 24h exposure. Results are expressed as the 
Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to control.  
 
4.6.2 OKF6 cells:  
250ng/ml CsA did not cause a significant modulation on release of IL-6 compared to 
the control (250ng/ml CsA; 758 ± 76 vs control; 723 ± 56pg/ml; p>0.05). However, 
2000ng/ml CsA significantly increased IL-6 release (2000ng/ml CsA; 1118 ± 
89pg/ml; Fig 4.12; p<0.05 vs control). 
P. gingivalis 
P.g completely inhibited the release of IL-6 (8.3 ± 1pg/ml). However, addition of CsA 
at either 250ng/ml or 2000ng/ml had no significant effect (p>0.05 vs P.g). 
A. actinomycetemcomitans 
A.a significantly increased the release of IL-6 compared to the controls (A.a; 1226 ± 
91pg/ml; p<0.05 vs control & 250ng/ml CsA). However, addition of either 250ng/ml 
or 2000ng/ml CsA had a limited effect on IL-6 release (p>0.05 vs A.a).  
P. intermedia 
P.i significantly increased the release of IL-6 compared to the control (P.i; 851 ± 
69pg/ml; p<0.05 vs control). Addition of 250ng/ml CsA did not cause a significant 
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modulation on the release of IL-6. However, addition of 2000ng/ml CsA significantly 
decreased IL-6 release compared to the controls (P.i + 2000ng/ml CsA; 562 ± 
118pg/ml; p<0.05 vs P.i & 2000ng/ml CsA individually). 
F. nucleatum 
F.n had no significant effect on the release of IL-6 compared to that of control. 
However, addition of either 250ng/ml or 2000ng/ml CsA did not significantly 
modulate the IL-6 release.  
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Figure 4.12.  Effect of (CsA + bacterial supernatant) combination on release of 
IL-6 in OKF6. Cultures were stimulated with CsA and/or bacterial supernatant. Untreated cells are 
served as a control. IL-6 was measured by Elisa assay after 24h exposure. Results are expressed as the 
Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to control.  
 
4.6.3 TR146 cells: 
250ng/ml CsA did not cause a significant modulation on IL-6 release compared to the 
control (250ng/ml CsA; 110 ± 26 vs control; 89 ± 27pg/ml; p>0.05). However, 
2000ng/ml CsA significantly increased IL-6 release (2000ng/ml CsA; 152 ± 40pg/ml; 
Fig 4.13; p<0.05 vs control). 
P. gingivalis 
P.g completely inhibited the release of IL-6 (10 ± 0.5pg/ml). However, addition of 
CsA at either 250ng/ml or 2000ng/ml had no significant effect (p<0.05 vs P.g). 
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A. actinomycetemcomitans 
A.a significantly increased the release of IL-6 compared to the controls (A.a; 711 ± 
44pg/ml; p<0.05 vs control and both 250ng/ml & 2000ng/ml CsA). Furthermore, 
addition of either 250ng/ml or 2000ng/ml CsA did not significantly modulate the 
release of IL-6 (p>0.05 vs A.a).   
P. intermedia and F. nucleatum 
P.i and F.n supernatants induced a similar effect to that found with A.a supernatant in 
both individual and CsA-combined exposure. 
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Figure 4.13.  Effect of (CsA + bacterial supernatant) combination on release of 
IL-6 in TR146. Cultures were stimulated with CsA and/or bacterial supernatant. Untreated cells are 
served as a control. IL-6 was measured by Elisa assay after 24h exposure. Results are expressed as the 
Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to control.  
 
4.6.4 HGF cells:  
250ng/ml CsA did not cause a significant modulation on release of IL-6 compared to 
the control (250ng/ml CsA; 73 ± 20 vs control; 75 ± 14pg/ml; p>0.05). However, 
2000ng/ml CsA significantly increased IL-6 release (2000ng/ml CsA; 203 ± 45pg/ml; 
Fig 4.14; p<0.05 vs control). 
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P. gingivalis 
P.g completely inhibited the release of IL-6 (9 ± 0.6pg/ml). However, addition of CsA 
at either 250ng/ml or 2000ng/ml had no significant effect (p>0.05 vs P.g). 
A. actinomycetemcomitans 
A.a significantly increased the release of IL-6 compared to the controls (A.a; 325 ± 
61pg/ml; p<0.05 vs control and both 250ng/ml & 2000ng/ml CsA). Addition of 
250ng/ml CsA did not significantly modulate the release of IL-6. However, addition 
of 2000ng/ml CsA significantly enhanced the stimulatory effect of A.a on IL-6 release 
(A.a + 2000ng/ml CsA; 522 ± 134pg/ml; p<0.05 vs A.a). 
P. intermedia 
P.i significantly increased the release of IL-6 compared to the control (P.i; 200 ± 
38pg/ml; p<0.05 vs control & 250ng/ml CsA individually). However, addition of 
either 250ng/ml or 2000ng/ml CsA significantly enhanced this stimulatory effect with 
a maximal level of release being found in cultures exposed to a combination of P.i 
supernatant plus 2000ng/ml CsA (P.i + 250ng/ml CsA; 313 ± 27 & P.i + 2000ng/ml 
CsA; 545 ± 71pg/ml; p<0.05 vs P.i). 
F. nucleatum 
F.n significantly increased the release of IL-6 compared to the control (F.n; 136 ± 
52pg/ml; p<0.05 vs control & 250ng/ml CsA individually). Addition of 250ng/ml 
CsA had no significant effect. However, addition of 2000ng/ml significantly enhanced 
the stimulatory effect of F.n on IL-6 release (F.n + 2000ng/ml CsA; 388 ± 113pg/ml; 
p<0.05 vs F.n). 
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Figure 4.14.  Effect of (CsA + bacterial supernatant) combination on release of 
IL-6 in HGF. Cultures were stimulated with CsA and/or bacterial supernatant. Untreated cells are 
served as a control. IL-6 was measured by Elisa assay after 24h exposure. Results are expressed as the 
Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to control.  
 
 
4.7. Effect of CsA and bacteria supernatants on IL-8 release:   
4.7.1 FIBS cells: 
250ng/ml or 2000ng/ml CsA had no significant effect on IL-8 release compared to the 
control (Fig 4.15; p>0.05).  
P. gingivalis 
P.g completely inhibited the release of IL-6 (2 ± 0.7pg/ml). Addition of 250ng/ml 
CsA had no significant effect (p>0.05). However, addition of 2000ng/ml CsA 
significantly increased the IL-8 release with values still significantly lower than that 
of control (P.g + 2000ng/ml CsA; 94 ± 49pg/ml; p<0.05 vs P.g but p>0.05 vs control) 
A. actinomycetemcomitans, P. intermedia and F. nucleatum 
A.a, P.i, and F.n supernatants had no significant effect on IL-8 release compared to 
controls. Furthermore, addition of CsA had no significant effect.  
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Figure 4.15.  Effect of (CsA + bacterial supernatant) combination on release of 
IL-8 in FIBS. Cultures were stimulated with CsA and/or bacterial supernatant. Untreated cells are 
served as a control. IL-8 was measured by Elisa assay after 24h exposure. Results are expressed as the 
Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to control.  
 
4.7.2 OKF6 cells:  
250ng/ml or 2000ng/ml CsA did not cause a significant modulation on release of IL-8 
compared to the control (785 ± 53 & 856 ± 36 respectively vs control 783 ± 51pg/ml; 
Fig 4.16; p>0.05).  
P. gingivalis 
P.g completely inhibited the release of IL-8 (3 ± 0.5pg/ml). However, addition of CsA 
at either 250ng/ml or 2000ng/ml dose had no significant effect (P.g + 250ng/ml;8 ± 5, 
P.g + 2000ng/ml;4 ± 0.8pg/ml; p>0.05 vs P.g). 
A. actinomycetemcomitans 
A.a significant decreased the release of IL-8 compared to that of controls (722 ± 
34pg/ml; p>0.05 vs control and both 250ng/ml and 2000ng/ml CsA). Addition of 
250ng/ml CsA did not cause a significant modulation on the release of IL-8. 
However, addition of 2000ng/ml CsA significantly increased IL-8 release with values 
returning to control level (A.a + 2000ng/ml CsA; 776 ± 44pg/ml). 
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P. intermedia and F. nucleatum 
P.i and F.n had no significant effect on the release of IL-8 compared to that of 
controls (p>0.05). Addition of CsA had no significant effect on the release of IL-8.  
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Figure 4.16.  Effect of (CsA + bacterial supernatant) combination on release of 
IL-8 in OKF6. Cultures were stimulated with CsA and/or bacterial supernatant. Untreated cells are 
served as a control. IL-8 was measured by Elisa assay after 24h exposure. Results are expressed as the 
Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to control.  
 
4.7.3 TR146 cells: 
250ng/ml CsA did not cause a significant modulation on release of IL-8 compared to 
the control (69 ± 12 vs control; 65 ± 15pg/ml; p>0.05). However, 2000ng/ml CsA 
significantly increased the release of IL-8 compared to the control (82 ± 8pg/ml; Fig 
4.17; p<0.05). 
P. gingivalis 
P.g completely inhibited the release of IL-8 (0.3 ± 0.1pg/ml). Addition of CsA at 
either 250ng/ml or 2000ng/ml did not alter this effect (p>0.05 vs P.g). 
A. actinomycetemcomitans 
A.a significantly increased the release of IL-8 compared to that of controls (104 ± 
6pg/ml; p<0.05 vs control and both 250ng/ml & 2000ng/ml CsA). Addition of 
250ng/ml CsA did not significantly modulate IL-8 release. However, addition of 
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2000ng/ml CsA significantly enhanced the stimulatory effect of A.a on IL-8 release 
(A.a + 2000ng/ml CsA; 118 ± 8pg/ml; p<0.05 vs A.a & 2000ng/ml CsA individually). 
P. intermedia and F. nucleatum 
P.i and F.n supernatants significantly increased the release of IL-8 compared to that of 
controls (P.i; 98 ± 10pg/ml, F.n; 105 ± 8pg/ml; p<0.05 vs control). Addition of CsA 
did not significantly modulate IL-8 release. 
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Figure 4.17 Effect of (CsA + bacterial supernatant) combination on release of IL-
8 in TR146. Cultures were stimulated with CsA and/or bacterial supernatant. Untreated cells are 
served as a control. IL-8 was measured by Elisa assay after 24h exposure. Results are expressed as the 
Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to control.  
 
4.7.4 HGF cells:  
250ng/ml CsA did not cause a significant modulation on release of IL-8 compared to 
the control (159 ± 45 vs control; 114 ± 31pg/ml; p>0.05). However, 2000ng/ml CsA 
caused a significant increase in IL-8 release compared to the control (450 ± 64pg/ml; 
Fig 4.18; p<0.05).  
P. gingivalis 
P.g completely inhibited the release of IL-8 (1 ± 0.5pg/ml). However, addition of CsA 
at either 250ng/ml or 2000ng/ml had no significant effect (p>0.05 vs P.g). 
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A. actinomycetemcomitans 
A.a significantly increased the release of IL-8 compared to that of control (512 ± 
52pg/ml; p<0.05 vs control & 250ng/ml). Addition of 250ng/ml CsA did not 
significantly modulate IL-8 release. However, addition of 2000ng/ml CsA 
significantly enhanced the stimulatory effect of A.a on IL-8 release (A.a + 2000ng/ml; 
657 ± 58pg/ml; p<0.05 vs A.a & 2000ng/ml CsA individually). 
P. intermedia 
P.i significantly increased the release of IL-8 compared to that of control (284 ± 
73pg/ml; p<0.05 vs control). Addition of 250ng/ml CsA had no significant effect. 
However, addition of 2000ng/ml CsA significantly enhanced the stimulatory effect of 
P.i on IL-8 release (P.i + 2000ng/ml; 605 ± 52pg/ml; p<0.05 vs P.i & 2000ng/ml CsA 
individually). 
F. nucleatum 
F.n induced a similar effect to that found with P.i supernatant in both individual and 
CsA-combined exposure. 
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Figure 4.18 Effect of (CsA + bacterial supernatant) combination on release of IL-
8 in HGF. Cultures were stimulated with CsA and/or bacterial supernatant. Untreated cells are 
served as a control. IL-8 was measured by Elisa assay after 24h exposure. Results are expressed as the 
Mean ± SEM (n=9). Results were considered significant when p< 0.05 compared to control.  
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4.8  Summary: 
Effect of CsA and bacterial supernatant combinations on cell viability: 
 
Bacterial supernatants caused different effects on cell viability. An increase in cell 
viability was found in TR146 (all bacterial supernatants), OKF6 (P.g, F.n, & P.i), and 
FIBS (A.a, P.i, & F.n). In contrast, P.g caused a significant reduction in FIBS cell 
viability. Likewise, a significant decrease in cell viability was found in OKF6 treated 
with A.a. None of the bacterial supernatants had a significant effect on viability of 
HGF cells. Co-incubation with CsA had no consistent effect on the viability of all cell 
lines studied.   
 
Effect of CsA and bacterial supernatant combinations on cytokine release: 
 
Bacterial supernatants caused cell type-dependent effects on IL-1α release. A 
significant increase in IL-1α release was found in TR146 (P.g & P.i) whereas a 
significant reduction in release of this cytokine was found in FIBS (F.n & P.i) and 
OKF6 (P.g, P.i, & F.n). A.a, however caused a significant increase in IL-1α release in 
OKF6. Combinations of 2000ng/ml CsA with bacterial supernatant only caused a 
significant increase in IL-1α in FIBS and TR146 but not OKF6 and HGF.  
 
P.g supernatant caused a complete inhibition in IL-6 release by all cell lines studied. 
A.a and P.i however caused a significantly increased release from all the cells. The 
combination of 2000ng/ml CsA plus supernatant of A.a, P.i, or F.n significantly 
promoted the release of IL-6 in all cell lines studied. Combinations of 250ng/ml plus 
bacterial supernatants had a little effect. 
 
P.g supernatant also caused a complete inhibition in IL-8 release in all cell lines 
studied. A.a, P.i, and F.n significantly increased IL-8 release in TR146 and HGF but 
had no effect on its release from FIBS and OKF6 cells. However, exposure to 
combinations of 2000ng/ml plus supernatant of A.a, P.i, or F.n significantly promoted 
the release of IL-8 in HGF. All combinations had no effect in all other cell lines. 
Furthermore, combinations of 250ng/ml plus bacterial supernatants had a little effect. 
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4.9  Conclusion: 
 
The exposure to a combination of bacterial supernatants along with CsA had a little 
effect on cell viability. Furthermore, the modulation in cytokine release, mostly 
presented by an increase, was more pronounced in cultures exposed to a combination 
of bacterial supernatant and 2000ng/ml CsA. There was no clear correlation between 
the variation in cell viability and the modulation in cytokine release.  
 
The MTT assay however is unable to determine whether the cells are able to replicate 
and does not differentiate between cycling cells or static cells. Therefore, more 
sophisticated assays were required to evaluate the cellular response to CsA and 
bacterial products and whether this response may involve a modulation in the cellular 
proliferative activity or cell apoptosis or both. Hence, a multi-parameter 
flowcytometric analysis was developed to analyse: cell cycle, proliferation rate (DNA 
synthesis), expression of proliferation-related proteins cyclin D1 and cyclin B1, in 
addition to analyse of expression of pro-apoptotic protein Bax and anti-apoptotic 
protein Bcl-2 after 24h exposure to a combination of bacterial supernatant and CsA 
(250ng/ml & 2000ng/ml). 
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Chapter Five 
Effect of CsA and bacterial 
supernatants on cell proliferation and 
apoptosis in monolayer cell cultures 
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5.1 Introduction: 
This chapter describes the results of the effect of a combination of CsA and bacterial 
supernatants on cell proliferation and apoptosis assessed using flow cytometry.   
 
5.2 Methods: 
The approach used to treat the cells is illustrated in Figure 5.1, whilst the 
methodology used for the flow cytometry was described in detail in Chapter 2.  A 
brief summary is, however, provided below: 
 
Cells were seeded and allowed to settle down 
Cells were serum starved 
24h
24h
Cells were re-incubated with serum-free DMEM Cells were stimulated with bacterial products
24h
Cells were re-stimulated 
With bacterial products
Cells were re-stimulated With
bacterial products plus either 
2000ng/ml or 250ng/ml CsA
Cells were re-incubated 
with serum-free DMEM 
(control for both Bax, Bcl-2
and cyclin expression) 
Cells were incubated with
DMEM containing 10% FBS
(positive control for cell cycle 
and Edu staining)
Cells were challenged with 
either 2000ng/ml or 250ng/ml CsA
24h
24h
Flow cytometry analysis
 
Figure 5.1.  Summary of treatment protocol 
 
Cell proliferation was assessed by a four-color flow cytometric analysis, which 
allowed the simultaneous detection of: 
 The proportion of cells in G0/G1, S, or G2/M phase by measuring total DNA 
content using 7-amino-actinomycin D (7-AAD) (Rabinovitch et al., 1986).  
The intensity of fluorescence is directly proportional to the amount of DNA 
within the cell.  Distribution into the different phases is thus achieved by 
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determining the current cellular DNA content; Go/G1 (2C DNA content), S 
(2C-4C), and G2/M (4C) (Jayat & Ratinaud, 1993). 
 Analysis of recently synthesized DNA (S-phase) using click-it Edu system that 
allows screening the incorporation of Edu (5-ethynyl-2´-deoxyuridine), a 
nucleoside analogue of thymidine that is incorporated into DNA during active 
DNA synthesis, using pacific blue fluorescent dye in a click reaction between 
the ethynyl group of the incorporated Edu in the double-stranded DNA and the 
small fluorescent azide-containing pacific blue fluorescent dye in presence of 
copper that catalyzes the click reaction (Buck et al., 2008). 
 Cyclin D1 and cyclin B1 expression using specific Alexa Fluor (488 and 647 
respectively) conjugated monoclonal antibodies. Cyclin D1 and B1 
expression was also analyzed against the cellular DNA levels to relate the 
expression of these proteins to the cell cycle distribution.  
 
Apoptosis was assessed by evaluating the ratio of Bcl-2 to Bax protein expression 
using two colour flow cytometry. Bcl-2 and Bax were stained with specific 
monoclonal antibodies conjugated with Alexa Fluor 488 and 647 respectively (see 
(Section 2.10 Chapter 2).   
 
An example of the FACS analysis results obtained for cell cycle distribution is 
illustrated in Fig 5.2 and 5.3 and Bax/Bcl2 expression in Fig 5.4.  From these the 
relative proportions of each parameter and the effect of CsA and bacterial supernatant 
was calculated.  A minimum of 10 – 30 x103 cells were counted and the proportion 
for each parameter calculated and expressed as a percentage of the total number of 
cells. 
 
For clarity the results for each parameter for each cell will be described individually.  
The plots from the FACS analysis are included in Appendix 1. 
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Figure 5.2  Isotype control for evaluating the total DNA content, proliferation 
rate and detection of the relative levels of cyclin B and cyclin D proteins 
expression in serum-starved untreated OKF6. (A) Dot plot (FSC-A versus SSC-A) on linear 
was used to discriminate the single cells and exclude the debris. (B) Isotype matched negative control for 
cyclin D1 antibody. (C) & (D) negative controls for Edu staining. (E) Single parameter histogram of isotype 
matched negative control for cyclin D1. (F) Single parameter histogram of isotype matched negative 
control for cyclin B1.  
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Figure 5.3.  Total DNA content, proliferation rate and detection of the relative 
levels of cyclin B and cyclin D proteins expression in serum-starved untreated 
OKF6.  
Cells were labelled with 10µM Edu for 1hour at 37C. Cells were then processed as described in the materials and 
methods using anti cyclin D –Alexa fluor 488, anti cyclin B – Alexa fluor 647 and 7-AAD as the cell cycle dye. 
Cells were analyzed using a BD FACS Canto II. For each histogram/dot plot, the horizontal and vertical markers 
were set using isotype-matched negative controls. (A) Dot plot (FSC-A versus SSC-A) on linear was used to 
discriminate the single cells and exclude the debris.(B) Dual parameter dot plot analysing the cyclin D positive 
cells against DNA content. (C) Dual parameter dot plot analysing the Edu positive cells against DNA content. (D) 
Dual parameter dot plot analysing the cyclin D positive cells against the Edu positive cells. (E) Single parameter 
histogram analysing the cyclin D1 positive cells versus cells count. (F) Single parameter histogram analysing the 
cyclin B1 positive cells versus cells count. (G) Single parameter histogram of DNA content displaying cell cycle 
distribution. 
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Figure 5.4.  Relative  levels of Bax and Bcl-2 expression in OKF6 cells after 
treatment with A.a supernatant for 24h. Isotype matched negative controls for both Bax and 
Bcl-2 antibodies studied were run firstly to measure the non-specific binding (autofluorescence) and 
subsequently to determine the position of the positive and negative populations as shown by the 
vertical markers (upper dot plots). Accordingly, Bax and Bcl-2 expression was measured in OKF6 cells 
treated with A.a supernatant (lower dot plots).    
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5.3. FIBS: 
5.3.1 Cell cycle distribution: 
58% of serum-starved untreated FIBS (Control -) were identified as being in G0/G1 
with 16.9%, and 23.3% in S and G2/M respectively (Fig 5.5).  Addition of serum to 
these cells (Control +) increased the proportion of cells in S (20.4%) and G2/M 
(36.1%) at the expense of G0/G1 (42.1%).  CsA (250 ng/ml or 2000ng/ml) had no 
effect on the proportion of cells in G0/G1, S and G2/M compared to the control (Fig 
A1, Appendix 2).  
P. gingivalis 
P.g alone had no effect on the cell cycle distribution.  2000ng/ml CsA, however 
caused a marked increase in cells in G2/M (34.3%) and a reduction in G0/G1 (44.4%) 
A. actinomycetemcomitans 
A.a alone or in combination with CsA increased the proportion of cells in G2/M 
(65%) with a reduction in both S and G0/G1.   
P. intermedia 
P.i alone or in combination with CsA had no apparent effect on the cell cycle 
distribution. 
F. nucleatum  
F.n alone or in combination with CsA had no effect on the cell cycle distribution. 
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Figure. 5.5. Cell cycle distribution of FIBS cells after treatment with bacterial 
supernatants and CsA. FIBS cells were stimulated for 24h with CsA and bacterial supernatant 
and cell cycle distribution assessed by FACS analysis using 7-AAD incorporation.  Results are 
expressed as a proportion of the total number of cells. 
X axis represents treatment and Y axis represents % cell cycle distribution 
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5.3.2 Proliferation rate:  
The addition of serum to serum free cells caused a 2-fold increase in the proliferation 
rate (39.9% & 20.8% respectively; Fig 5.6).  CsA had no effect on the proliferation 
rate (Fig A2, Appendix 2).  
P. gingivalis 
P.g alone or in combination with CsA had no effect on the proliferation rate. 
A. actinomycetemcomitans 
A.a alone had no effect on the proliferation rate.  A.a with 2000ng/ml CsA however 
increased the proliferation rate of FIBS cells. 
P. intermedia 
P.i alone had no effect on the proliferation rate.  P.i with 2000ng/ml CsA however 
increased the proliferation rate of FIBS cells. 
F. nucleatum 
F.n alone or in combination with CsA had no effect on the proliferation rate. 
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Figure 5.6. Effect of CsA and bacterial supernatants on proliferation rate of 
FIBS cells. FIBS cells were stimulated for 24h with CsA and bacterial supernatant and proliferation 
rate assessed by FACS analysis using Edu incorporation.  Results are expressed as a proportion of the 
total number of cells. 
X axis represents treatment and Y axis represents % of cells incorporating Edu 
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5.3.3 Cyclin D1 expression: 
The addition of serum or CsA (250ng/ml and 2000ng/ml) increased Cyclin D1 
expression compared to serum free controls (85%, 45.5%; 53% and 35% respectively; 
Fig 5.7) & (Fig A3, Appendix 2).  
P. gingivalis 
P.g alone increased Cyclin D1 expression (80%).  This was not affected by the 
addition of CsA. 
A. actinomycetemcomitans 
A.a alone increased Cyclin D1 expression (78%).  This was not affected by the 
addition of CsA. 
P. intermedia 
P.i alone had no effect on Cyclin D1 expression. 2000ng/ml CsA however increased 
the proportion of Cyclin D1 positive cells (45%). 
F. nucleatum 
F.n alone reduced Cyclin D1 expression (15%) compared to serum free controls 
(35%). CsA increased Cyclin D1 expression with 2000ng/ml returning to control 
levels (40%). 
 
It was revealed from the bivariate dot plot analyzing the cyclin D1 expression versus 
DNA content that the expression of cyclin D1 in FIBS cells was not exclusive to G1 
phase but instead, it was continuous throughout all the cell cycle phases with a 
maximal level being noticed in cells entering G2/M. This pattern of expression, 
however, was not affected by any of the treatments applied (Fig 5.8). 
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Figure 5.7. Cyclin D1 expression by FIBS exposed to a combination of CsA and 
bacterial supernatants for 24h. FIBS cells were stimulated for 24h with CsA and bacterial 
supernatant and Cyclin D1 assessed by FACS analysis.  Results are expressed as a proportion of the 
total number of cells. 
X axis represents treatment and Y axis represents % of cyclin D1 positive cells 
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Figure 5.8. Bivariate distributions showing the expression of cyclin D1 in relation 
to the cell cycle position in FIBS cells after 24h exposure to a combination of CsA 
plus bacterial supernatants. FIBS cells were stimulated for 24h with CsA and bacterial 
supernatant and fashion of Cyclin D1 expression was assessed by FACS analysis.  Dual parameter dot 
plots analysing the cyclin D1 positive cells against DNA content were shown. These dot plots show 
that cyclin D1 was expressed throughout the cell cycle phases. A)- Isotype control was used to 
determine the positive and negative populations. B)- serum-starved control. C)- serum-rechallenged 
control. D)- FIBS cells treated with 2000ng/ml CsA. E)- FIBS cells exposed to P.i supernatant. F)- 
FIBS cells exposed to a combination of P.i supernatant plus 2000ng/ml CsA.  
 
5.3.4 Cyclin B1 expression: 
Cyclin B1 was not detected in any of FIBS cultures 
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5.3.5  Bax expression:  
Bax expression was not present in control or CsA treated cells (Fig A10, Appendix 2).  
P. gingivalis 
P.g alone or in combination with CsA had no effect on Bax expression 
A. actinomycetemcomitans 
A.a increased Bax expression to 4.5%.  This effect was not markedly affected by CsA 
(Fig 5.9) 
P. intermedia 
P.i alone or in combination with CsA had no effect on Bax expression 
F. nucleatum 
F.n alone or in combination with CsA had no effect on Bax expression 
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Figure 5.9.  Bax expression by FIBS exposed to a combination of CsA and A.a 
supernatants for 24h. FIBS cells were stimulated for 24h with CsA and bacterial supernatant and 
Bax expression assessed by FACS analysis.  Results are expressed as a proportion of the total number 
of cells. Bax was not present in control and other supernatants treated cultures.  
X axis represents treatment and Y axis represents % cells expressing Bax 
 
5.3.6   Bcl-2 expression:  
Bcl-2 was not detected in any of FIBS cultures. 
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5.4 OKF6:  
5.4.1 Cell cycle distribution: 
76% of serum starved OKF6 cells were arrested in G0/G1 with 11.2% (S phase), 
13.4% (G2/M phase), whilst serum stimulated cells showed a higher proportion in S 
(34.9%) and G2/M (21.8%) and a lower proportion in G0/G1 (44.3%; Fig 5.10 & 
Appendix 2).  The addition of CsA (250 and 200ng/ml) to the serum free cells did not 
affect the cell cycle distribution compared to controls. 
P. gingivalis 
P.g supernatant caused a slight increase in the number of cells in G0/G1 (84.5%) with 
a parallel decrease in the percentage of S and G2/M fractions. CsA did not affect this 
distribution. 
A. actinomycetemcomitans 
A.a products either individually or in combination with CsA markedly increased the 
percentage of G2/M fraction (64%). This 5 fold higher than that in the serum-starved 
untreated OKF6 at the expense of G0/G1 fraction (16%). 
F. nucleatum and P. intermedia 
F.n and P.i supernatants (alone or in combination with CsA) had no effect on the 
proportion of cells in G0/G1, S or G2/M. 
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Figure 5.10. Cell cycle distribution of OKF6 cells after treatment with bacterial 
supernatants and CsA.  OKF6 cells were stimulated for 24h with CsA and bacterial supernatant 
and cell cycle distribution assessed by FACS analysis using 7-AAD incorporation.  Results are 
expressed as a proportion of the total number of cells. 
X axis represents treatment and Y axis represents % cell cycle distribution 
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5.4.2 Proliferation rate: 
Serum starved cells had a lower level of proliferation (11.4%) compared to those re-
challenged with serum (79.9%; Fig 5.11 & Appendix 2).  2000ng/ml CsA increased 
the proliferation rate to (28.5%), whilst stimulation with 250ng/ml had no effect.  
P. gingivalis 
P.g supernatant either alone or in combination with 250 ng/ml CsA had no apparent 
effect on the proliferation rate of OKF6 cells compared to the serum-starved untreated 
OKF6. Co-stimulated with 2000ng/ml CsA, however decreased the proliferation rate 
(P.g + 2000ng/ml CsA; 2.7% vs. P.g; 7.9%).  
A. actinomycetemcomitans 
A.a products caused a 7 fold increase in the proliferation rate compared to that of 
serum-starved untreated cells (81.8% vs. 11.4%).  The addition of CsA to cultures 
pre-exposed to A.a products decreased the proliferation rate; this was most 
pronounced with 250ng/ml with the proportion falling to control levels. 
P. intermedia 
Pi alone or in combination with CsA caused a dose dependent increase in the 
proliferation rate (39.2%; 59.5 & 89.1% for P.i, 250 and 2000ng/ml CsA 
respectively).  
F. nucleatum 
F.n caused a slight increase in the proliferation rate (22%) compared to control 
(11.4%).  250ng/ml CsA had no effect on the F.n induced change in proliferation, 
whilst 2000ng/ml CsA reduced the rate to control levels. 
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Figure 5.11  Effect of CsA and bacterial supernatants on proliferation rate of 
OKF6 cells. OKF6 cells were stimulated for 24h with CsA and bacterial supernatant and 
proliferation rate assessed by FACS analysis using Edu incorporation.  Results are expressed as a 
proportion of the total number of cells. 
X axis represents treatment and Y axis represents % of cells incorporating Edu 
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5.4.3 Cyclin D1 expression: 
The addition of serum caused a slight increase in Cyclin D1 expression (34.7%) 
compared to the serum free controls (27.5%), whilst 2000ng/ml CsA caused a marked 
reduction (13%; Fig 5.12 & Appendix 2). 
P. gingivalis 
P.g had a limited effect on cyclin D1 expression (Fig 5.12).  The addition of 
2000ng/ml CsA caused a slight increase in Cyclin D1 expression (40%) compared to 
P.g alone (24%) 
A. actinomycetemcomitans 
The maximal levels of cyclin D1 expression were observed in cultures exposed to A.a 
products either alone (55.4%) or in combination with CsA (250ng/ml – 79.9%; 
2000ng/ml CsA; 66.8%). 
F. nucleatum 
F.n had a limited effect on cyclin D1 expression (Fig 5.12).  The addition of 
2000ng/ml CsA caused a slight increase in Cyclin D1 expression (36%) compared to 
F.n. alone (21%). 
P. intermedia 
P.i, alone or in combination with CsA had no effect on cyclin D1 expression, 
compared to the untreated starved OKF6. 
 
It was revealed from the bivariate dot plot analyzing the cyclin D1 expression versus 
DNA content that the expression of cyclin D1 in OKF6 cells was not exclusive to G1 
phase but instead, it was continuous throughout all the cell cycle phases. This pattern 
of expression, however, was not apparently affected by any of the treatments applied 
(Fig 5.13). 
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Figure 5.12. Cyclin D1 expression by OKF6 exposed to a combination of CsA and 
bacterial supernatants for 24h. OKF6 cells were stimulated for 24h with CsA and bacterial 
supernatants and cyclin D1 assessed by FACS analysis.  Results are expressed as a proportion of the 
total number of cells. 
X axis represents treatment and Y axis represents % of cyclin D1 positive cells 
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 Figure 5.13. Bivariate distributions showing the expression of cyclin D1 in 
relation to the cell cycle position in OKF6 cells after 24h exposure to a 
combination of CsA plus bacterial supernatants . OKF6 cells were stimulated for 24h 
with CsA and bacterial supernatant and fashion of Cyclin D1 expression was assessed by FACS 
analysis.  Dual parameter dot plots analysing the cyclin D1 positive cells against DNA content were 
shown. These dot plots show that cyclin D1 was expressed throughout the cell cycle phases. A)- 
Isotype control was used to determine the positive and negative populations. B)- serum-starved control. 
C)- serum-rechallenged control. D)- OKF6 cells treated with 2000ng/ml CsA. E)- FIBS cells exposed 
to P.g supernatant. F)- OKF6 cells exposed to a combination of P.g supernatant plus 2000ng/ml CsA.  
 
5.4.4 Cyclin B1 expression: 
Cyclin B1 expression was not present in any of the cells studied.  
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5.4.5  Bax expression: 
Low levels of Bax expression was present in control or CsA treated cells (1.6% - 
1.8% Fig 5.14) & (Fig A11, Appendix 2).  
P. gingivalis 
P.g caused a slight increase in Bax expression (5%).  CsA caused a slight reduction in 
this effect (2-3%). 
A. actinomycetemcomitans 
A.a increased Bax expression (28%).  250ng/ml CsA increased this further to 30% 
whilst 2000ng/ml CsA reduced the effect (17%). 
P. intermedia 
P.i alone or in combination with CsA had little or no effect on Bax expression 
F. nucleatum 
F.n alone or in combination with CsA had little or no effect on Bax expression 
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Figure 5.14. Bax expression by OKF6 exposed to a combination of CsA and 
bacterial supernatants for 24h. OKF6 cells were stimulated for 24h with CsA and bacterial 
supernatant and Bax assessed by FACS analysis.  Results are expressed as a proportion of the total 
number of cells. 
X axis represents treatment and Y axis represents % cells expressing Bax 
 
5.4.6  Bcl-2 expression:  
Bcl-2 protein was not detected in OKF6 cells (Fig A12, Appendix 2).  
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5.5. TR146: 
5.5.1 Cell cycle distribution: 
76.2% of serum starved TR146 were in G0/G1 phase, whilst the addition of serum 
reduced this proportion to 57.3% and increased S and G2/M (23.3 and 20.2% 
respectively; Fig 5.15). CsA had a differential effect on the cell cycle:  2000ng/ml 
CsA caused a marked increase in G0/G1 (82.7%) with a parallel decrease in S and 
G2/M (11.1% and 6.1% respectively). 250ng/ml CsA increased the proportion in S 
phase fraction at the expense of G0/G1 (28.2% and 62.3% respectively) & (Fig A4, 
Appendix 2).  
P. gingivalis 
P.g alone reduced the proportion of cells in G0/G1 and an increase in S and G2/M 
compared to serum free controls.  The addition of CsA did not alter this effect. 
A. actinomycetemcomitans 
A.a alone or in combination with CsA increased the proportion of cells in G2/M (40 – 
50%) and S (with a reduction in G0/G1).    
P. intermedia 
P.i had no apparent effect on the cell cycle distribution, although the addition of 
2000ng/ml CsA caused a slight increase in G0/G1 fraction (85%)  
F. nucleatum  
F.n alone reduced G0/G1 and increased S and G2/M.  250ng/ml CsA had no effect on 
this pattern, whilst 2000ng/ml CsA abrogated the effect. 
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Figure 5.15. Cell cycle distribution of TR146 cells after treatment with bacterial 
supernatants and CsA.  TR146 cells were stimulated for 24h with CsA and bacterial supernatant 
and cell cycle distribution assessed by FACS analysis using 7-AAD incorporation.  Results are 
expressed as a proportion of the total number of cells. 
X axis represents treatment and Y axis represents % cell cycle distribution 
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5.5.2 Proliferation rate: 
The addition of serum to serum free cells increased the proliferation rate of TR146 
cells (75% & 39.6% respectively; Fig 5.16).  2000g/ml CsA caused a marked 
reduction (4.5%) whilst 250ng/ml had a similar effect to the addition of serum (Fig 
A5, Appendix 2).  
P. gingivalis 
P.g alone or in combination with 250ng/ml CsA had no effect on the proliferation 
rate. 2000ng/ml however reduced the rate. 
A. actinomycetemcomitans 
A.a and 250ng/ml CsA increased the proliferation rate, whilst 2000ng/ml CsA 
however reduced the rate of proliferation. 
P. intermedia 
P.i alone or in combination with 250ng/ml CsA had no effect on the proliferation rate. 
2000ng/ml however reduced the rate. 
F. nucleatum 
F.n alone or in combination with 250ng/ml CsA had no effect on the proliferation 
rate. 2000ng/ml however reduced the rate. 
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Figure 5.16. Effect of CsA and bacterial supernatants on proliferation rate of 
TR146 cells. TR146 cells were stimulated for 24h with CsA and bacterial supernatant and 
proliferation rate assessed by FACS analysis using Edu incorporation.  Results are expressed as a 
proportion of the total number of cells. 
X axis represents treatment and Y axis represents % of cells incorporating Edu 
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5.5.3 Cyclin D1 expression: 
The addition of serum increased Cyclin D1 expression (58%) compared to serum free 
controls (49% respectively, Fig 5.17).  CsA had no effect on Cyclin D (Fig A6, 
Appendix 2).  
P. gingivalis 
P.g reduced Cyclin D expression (35%).  This was not affected by the addition of 
CsA. 
A. actinomycetemcomitans 
A.a increased Cyclin D1 expression (60%).  This was not affected by the addition of 
CsA. 
P. intermedia 
P.i alone or in combination with CsA had no effect on Cyclin D1 expression. 
F. nucleatum 
F.n alone or in combination with CsA had no effect on Cyclin D1 expression. 
 
It was revealed from the bivariate dot plot analyzing the cyclin D1 expression versus 
DNA content that the expression of cyclin D1 in TR146 cells was expressed mainly in 
G0/G1 and cells entering S phase. This pattern of expression, however, was not 
affected by any of the treatments applied (Fig 5.18).  
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Figure 5.17. Cyclin D1 expression by TR146 exposed to a combination of CsA 
and bacterial supernatants for 24h. TR146 cells were stimulated for 24h with CsA and 
bacterial supernatant and cyclin D1 assessed by FACS analysis.  Results are expressed as a proportion 
of the total number of cells. 
X axis represents treatment and Y axis represents % of cyclin D1 positive cells 
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Figure 5.18. Bivariate distributions showing the expression of cyclin D1 in 
relation to the cell cycle position in TR146 cells after 24h exposure to a 
combination of CsA plus bacterial supernatants. TR146 cells were stimulated for 24h 
with CsA and bacterial supernatant and fashion of Cyclin D1 expression was assessed by FACS 
analysis.  Dual parameter dot plots analysing the cyclin D1 positive cells against DNA content were 
shown. These dot plots show that cyclin D1 was expressed throughout the cell cycle phases. A)- 
Isotype control was used to determine the positive and negative populations. B)- serum-starved control. 
C)- serum-rechallenged control. D)- TR146 cells treated with 2000ng/ml CsA. E)- FIBS cells exposed 
to P.i supernatant. F)- TR146 cells exposed to a combination of P.i supernatant plus 2000ng/ml CsA.  
 
5.5.4 Cyclin B1 expression: 
Cyclin B1 was not detected in any of TR146 cultures 
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5.5.5  Bax expression:  
Bax expression was not present in control or CsA treated cells (Fig A13, Appendix 2).  
P. gingivalis 
P.g alone or in combination with CsA had no effect on Bax expression 
A. actinomycetemcomitans 
A.a increased Bax expression to 3.9%, whilst 2000ng/ml CsA increased this further to 
7.5% (Fig 5.19). 
P. intermedia 
P.i alone or in combination with CsA had no effect on Bax expression 
F. nucleatum 
F.n alone or in combination with CsA had no effect on Bax expression 
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Figure 5.19. Bax expression by TR146 exposed to a combination of CsA and A.a 
supernatants for 24h. TR146 cells were stimulated for 24h with CsA and bacterial supernatant 
and Bax assessed by FACS analysis.  Results are expressed as a proportion of the total number of cells. 
Bax was not present in control and other supernatants treated cultures.  
 
5.5.6  Bcl-2 expression:  
Bcl-2 was not detected in any of TR146 cultures. 
 
135 
 
5.6 HGF: 
5.6.1 Cell cycle distribution:  
The addition of serum or 2000ng/ml CsA had little effect on the proportion of cells in 
G0/G1; S and G2/M (Fig 5.20) & (Fig A7, Appendix 2).  
P. gingivalis 
P.g alone reduced the proportion of cells in G0/G1 and an increase in S compared to 
serum free controls.  The addition of CsA did not alter this effect. 
A. actinomycetemcomitans 
A.a alone reduced the proportion of cells in G0/G1 and an increase in S compared to 
serum free controls.  The addition of CsA did not alter this effect. 
P. intermedia 
P.i alone reduced the proportion of cells in G0/G1 and an increase in S compared to 
serum free controls.  The addition of CsA did not alter this effect. 
F. nucleatum  
F.n alone reduced the proportion of cells in G0/G1 and an increase in S compared to 
serum free controls.  The addition of CsA did not alter this effect. 
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Figure 5.20. Cell cycle distribution of HGF cells after treatment with bacterial 
supernatants and CsA.  HGF cells were stimulated for 24h with CsA and bacterial supernatant 
and cell cycle distribution assessed by FACS analysis using 7-AAD incorporation.  Results are 
expressed as a proportion of the total number of cells. 
X axis represents treatment and Y axis represents % cell cycle distribution 
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5.6.2 Proliferation rate: 
The addition of serum or 2000ng/ml to serum free cells increased the proliferation 
rate of HGF cells (66%, 34% & 20.4% respectively; Fig 5.21) & (Fig A8, Appendix 
2).  
P. gingivalis 
P.g increased the proliferation rate to 42.1%, whilst 2000ng/ml CsA reduced this rate 
to 34.8% 
A. actinomycetemcomitans 
A.a increased the proliferation rate to 46%, whilst 2000ng/ml CsA increased this 
further to 58.6% 
P. intermedia 
P.i increased the proliferation rate to 38%, whilst 2000ng/ml CsA increased this 
further to 65% 
F. nucleatum 
F.n increased the proliferation rate to 52%, whilst 2000ng/ml CsA reduced this effect 
to 36% 
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Figure 5.21. Effect of CsA and bacterial supernatants on proliferation rate of 
HGF cells. HGF cells were stimulated for 24h with CsA and bacterial supernatant and proliferation 
rate assessed by FACS analysis using Edu incorporation.  Results are expressed as a proportion of the 
total number of cells. 
X axis represents treatment and Y axis represents % of cells incorporating Edu 
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5.6.3 Cyclin D1 expression: 
The addition of serum and CsA increased Cyclin D1 expression (63.7% & 56% 
respectively) compared to serum free controls (43.5%, Fig 5.22) & (Fig A9, Appendix 
2).  
P. gingivalis 
P.g increased Cyclin D expression (65.1%).  This was not affected by the addition of 
CsA. 
A. actinomycetemcomitans 
A.a increased Cyclin D expression (62.7%).  This was not affected by the addition of 
CsA. 
P. intermedia 
P.i increased Cyclin D expression (65.8%).  This was not affected by the addition of 
CsA. 
F. nucleatum 
F.n increased Cyclin D expression (64.2%).  This was not affected by the addition of 
CsA. 
 
It is evident from the bivariate dot plot analyzing the cyclin D1 expression versus 
DNA content that the expression of cyclin D1 was mainly found in cells in G1 and 
early S phases in most HGF cultures (Fig 5.23).   
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Figure 5.22. Cyclin D1 expression by HGF exposed to a combination of CsA and 
bacterial supernatants for 24h. HGF cells were stimulated for 24h with CsA and bacterial 
supernatant and Cyclin D1 assessed by FACS analysis.  Results are expressed as a proportion of the 
total number of cells. 
X axis represents treatment and Y axis represents % of cyclin D1 positive cells 
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Figure 5.23. Bivariate distributions showing the expression of cyclin D1 in 
relation to the cell cycle position in HGF cells after 24h exposure to a 
combination of CsA plus bacterial supernatants. HGF cells were stimulated for 24h with 
CsA and bacterial supernatant and fashion of Cyclin D1 expression was assessed by FACS analysis.  
Dual parameter dot plots analysing the cyclin D1 positive cells against DNA content were shown. 
These dot plots show that cyclin D1 was expressed throughout the cell cycle phases. A)- Isotype 
control was used to determine the positive and negative populations. B)- serum-starved control. C) 
HGF cells exposed to P.g supernatant. D)- HGF cells exposed to a combination of P.g supernatant plus 
2000ng/ml CsA.  
 
5.6.4  Cyclin B1 expression: 
Cyclin B1 was not detected in any of the HGF cultures 
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5.6.5  Bax expression: 
Bax expression was not present in control cells (Fig 5.24). CsA, however increased 
Bax expression to 5-6% (Fig A14, Appendix 2).  
P. gingivalis 
P.g increased Bax expression (6%) whilst the addition of CsA abrogated the effect. 
A. actinomycetemcomitans 
A.a caused a slight increased Bax expression (1%) which was augmented with 
250ng/ml CsA (4%).  2000ng/ml CsA reduced Bax expression to below detectable 
levels 
P. intermedia 
P.i increased Bax expression (9%) whilst the addition of CsA reduced the effect. 
F. nucleatum 
F.n treated cells had very low levels of Bax expression, which was increased to 5% by 
the addition of 250ng/ml CsA.  2000ng/ml CsA reduced Bax expression to below 
detectable levels 
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Figure 5.24. Bax expression by HGF exposed to a combination of CsA and 
bacterial supernatants for 24h. HGF cells were stimulated for 24h with CsA and bacterial 
supernatant and Bax assessed by FACS analysis.  Results are expressed as a proportion of the total 
number of cells. 
X axis represents treatment and Y axis represents % cells expressing Bax 
 
 
5.6.6  Bcl-2 expression:  
Bcl-2 was not detected in any of HGF cultures. 
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5.7 Summary: 
The addition of serum to FIBS, OKF6 and TR146 cells increased the proportion of 
cells in S and G2/M, whilst 250ng/ml and 2000ng/ml CsA had little effect on cell 
cycle distribution.  Of the bacterial supernatants examined, A.a consistently caused an 
apparent increase in G2/M fraction in the keratinocyte cell lines studied. This was 
accompanied by a decrease in G0/G1 and no change in S phase.  A.a also increased 
the proliferation of all the keratinocytes.  HGF cells demonstrated a different response 
with all bacterial supernatants increasing the proportion of S phase fraction without a 
change in G2/M. A similar increase was also found in TR146 cells exposed to any of 
the bacterial products. 
 
The combination of CsA with bacterial supernatants had a little effect on cell cycle 
distribution but caused a limited effect on proliferation rate.  P.i + 2000ng/ml CsA 
increased proliferation FIBS, OKF6 and HGF cells, all combinations of 2000ng/ml 
CsA and bacterial products inhibited the proliferation rate of TR146 cells. This late 
effect was associated with abrogating the cell cycle as shown with some 
combinations.  
 
Unfortunately, the expression level of cyclin D1 in our cell lines did not serve as a 
marker of the proliferative activity but, interestingly two cell type-dependent patterns 
of its expression were recognized; whilst its expression was recognized throughout 
the cell cycle phases in OKF6 and FIBS keratinocytes, an exclusive expression to G1 
phase was found in HGF and TR146. This variance in the pattern of cyclin D1 
expression, which normally peaks in end of G1 phase, has also been reported in other 
studies where it was related to the cell type and the transformation phenotype 
(Collecchi et al., 2000; Darzynkiewics et al., 1996). However, the biological 
explanation of the unscheduled expression of this cyclin is still unclear but it has been 
suggested to be a common event in transformed cell lines (Collecchi et al., 2000). In 
contrast to Cyclin D1, Cyclin B1 was not detected in all cultures studied.   
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The baseline level of Bax expression ranged from undetectable to very low amounts 
(0-6%). CsA alone induced very low levels of Bax expression in HGF cells (5-6%) 
but had no effect on all keratinocyte cells. Induction of Bax expression was frequently 
found in all keratinocyte cultures exposed to A.a supernatant. Combinations of A.a 
and 2000ng/ml CsA, however, caused a decrease in OKF6 cells and an increase in 
TR146. However, all bacterial supernatants induced Bax expression in HGF cells with 
a more pronounced effect with P.i. Addition of CsA caused a CsA dose and bacterial 
type-dependent effect on Bax expression in HGF; an increase was found when 
250ng/ml CsA was added to A.a or F.n but a decrease was found when CsA 
(2000ng/ml and 250ng/ml) was added to P.g or P.i.  Bcl-2 was not detected in any of 
cultures studied.  
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Chapter Six 
Materials and Methods (reconstructed 
epithelial models) 
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6.1 Introduction:  
In the first part of the study the effect of CsA and bacterial products on human 
keratinocytes and gingival fibroblasts was examined using a monolayer culture 
system.  Keratinocytes, in vivo, however, are present as part of a stratified epithelium 
and it is possible that this may affect the interaction with CsA and bacterial products. 
The aim, therefore of this next phase was to evaluate the effect of CsA and bacterial 
products on an in vitro reconstructed model of human gingival and oral epithelium.  
Tissue viability IL-1α, IL-6, and IL-8 release were assessed using MTT assay and 
ELISA. 
effects on proliferation and apoptosis were also evaluated by examining the 
expression of proliferation- related genes such as CCNB1 (Cyclin B1) and CCND1 
(Cyclin D1), , and the anti-apoptotic gene; B-cell CLL/lymphoma 2 (Bcl2), the gene 
encoding Bcl-2 protein, as well as pro-apoptotic genes such as Bcl2-associated X 
protein (Bax) and Fas ligand (Fas-L) that encode Bax and Fas-L proteins respectively.  
 
6.2. Mucosal models: 
Two types of reconstructed in vitro human epithelial models developed and supplied 
by SkinEthic Laboratories (Nice, France) were used in this study; 
 Reconstructed human oral epithelium (RHOE): This three-dimensional model 
of the human buccal epithelium has been developed using a transformed oral 
keratinocyte (TR146) cell line derived from a squamous cell carcinoma of the 
buccal mucosa (Rupniak et al, 1985). 
 Reconstructed human gingival epithelium (RHGE): This three-dimensional 
model is derived from normal human gingival keratinocytes. 
Epithelial cells were cultured on a 0.5cm
2
 inert polycarbonate filter raised to the air-
liquid interface in a serum free, chemically defined growth medium for 12 days 
(TR146) and 5 days (human gingival keratinocytes) to form a non-keratinized 
stratified epithelium with 10-12 cell layers (Buccal phenotype) or a keratinized 
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stratified epithelium (Gingival phenotype). (Rosdy & Clauss, 1990; Rosdy et al., 
1993). (Figs 6.1 - 6.3). 
SkinEthic laboratories also provided growth medium MCDB 153 containing 5µg/ml 
insulin, 1.5mM CaCl2, 25µg gentamycin and 0.4 µg hydrocortisone for use in the 
experiments. 
 
 
Figure. 6.1. Diagram of Reconstituted Mucosal Model (Courtesy of Dr A. T. 
Cruchley) 
 
 
Figure. 6.2. Light micrograph of uninfected control tissue of reconstituted human 
buccal mucosa stained with haematoxylin & eosin. Original magnification x 63. 
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Figure. 6.3. Light micrograph of uninfected control tissue of reconstituted human 
gingiva stained with haematoxylin & eosin. Original magnification x 63. 
 
6.3. Treatment: 
The mucosal cultures were shipped on agarose gel and, on arrival, were transferred 
into 24 well-plates pre-filled with 0.5 ml growth medium (GM).  50μl PBS (control) 
or bacterial supernatants (Table 6.1) was applied to the epithelial surface and the 
cultures were incubated overnight at 37
o
C in 5%CO2 in a humidified atmosphere. 
 
Bacteria Dilution (in PBS) 
P. gingivalis 1/10 
A. actinomycetemcomitans 1/10 
P. intermedia 1/10 
F. nucleatum 1/10 
Table 6.1.  Bacterial supernatants used in the study. 
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6.4. Experimental design: 
Cultures, pre-exposed to PBS or bacterial supernatants, were washed by gently 
pipetting 200μl PBS (3 times in 5 minutes) and transferred into 6 well-plates 
containing 2 ml GM supplemented with 0 (control) or 2000 ng/ml CsA (baseline). 
Fresh PBS or bacterial supernatant was then re-applied to the epithelial surface and 
the cultures were then incubated for up to 48hrs at 37
o
C and 5%CO2. Culture medium 
was collected at 6h, 24h, and 48h after the baseline point and stored at -80
o
C until 
used to assess cytokine and growth factor release. At each time point the culture 
medium was replaced and the epithelium was washed and re-challenged with PBS or 
CsA or/and bacterial supernatant. 
In addition to cytokine and growth factor release, epithelial viability was assessed 
using the MTT assay on triplicate samples of the epithelium at 48hrs. In addition, one 
culture was used for RNA extraction for qPCR, and one culture fixed in neutral 
buffered formalin for morphological and immunohistochemical investigation.  
Controls included cultures stimulated with 0ng/ml CsA and exposed to PBS only as a 
negative control, bacterial supernatant-exposed cultures without addition of CsA, and 
PBS-exposed cultures with addition of CsA. 
 
6.5. Epithelial viability: 
At the end of the treatment period, the cultures were transferred to a 24-well plate 
containing 500µl of MTT solution (0.5mg/ml 3-(4,5dimethythiazol-2-yl)-2,5-
diphenyltetrazolium bromide in PBS). The plate was wrapped in aluminium foil and 
incubated for 1 hour at 37ºC in 5% CO2 in a humidified atmosphere. After incubation, 
the cultures were transferred to a new 24-well plate containing 750µl isopropyl 
alcohol per well and 750µl of isopropyl alcohol applied to the epithelial surface.  The 
plate was carefully sealed with parafilm, to prevent evaporation, and then incubated at 
37ºC for 1 hour to extract the formazan. After 1 hour the membrane was punctured, 
expended cultures discarded and the isopropyl alcohol mixed in order to equilibrate 
the colour density.  
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The optical density (OD) was measured at 570nm using an Optima plate reader. 
Tissue viability was expressed as:  
Tissue viability = OD (570nm) Test/ OD (570nm) control x 100. 
 
6.6. Cytokine release:    
IL-1α, IL-6, and IL-8 release from RHGE and RHOE exposed to a combination of 
CsA along with bacterial products was determined by sandwich Elisa (Duo Set ; R & 
D systems, Abingdon, UK) according to the protocol outlined in chapter 2. 
 
6.7. RNA extraction: 
The epithelium was dissected from the insert using a clean, sterile scalpel and 
immediately immersed in 500 µl RNA Later solution (Qiagen, Hilden, Germany) and 
then stored at -80
o
C until use for RNA extraction.  
 
 Total RNA was extracted from mucosal samples using the Qiagen RNeasy mini kit 
(Qiagen, Hilden, Germany) according to manufacture’s instructions with simple 
modifications as follows: 
1. Defrost samples at room temperature. 
2. Remove RNA- Later with 1ml pipette; add 150µl RNeasy lysis buffer RLT 
(containing 1% β-mercaptoethanol) and vortex to ensure complete lysis.  
3. Transfer the lysate to QIAshredder spin column and homogenize by 
centrifugation for 2 minutes at maximum speed. 
4. Transfer the lysate to DNA genome - eliminator column and centrifuge for 30 
second at 7000 rpm. 
5. Add 150 µl of 70% ethanol to the lysate and mix well by pipetting up and 
down. 
6. Transfer the mixture into a RNeasy spin column and centrifuge for 15 seconds 
in 7000 rpm. Discard the flow-through.  
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7. Add 700µl RNeasy wash buffer (RW1) to the RNeasy spin column and 
centrifuge for 15 seconds in 7000rpm for washing purpose. Discard the flow-
through.  
8. Wash the RNeasy spin column with 500µl RPE buffer and centrifuge for 15 
seconds at 7000rpm for washing purpose. Discard the flow-through  
9. Wash the RNeasy spin column with further 500 µl RPE buffer and centrifuge 
for further 2 minutes at 7000 rpm to dry membrane. Discard the collection 
tube including the flow-throw. 
10. Place RNeasy spin column on a new 2ml collection tube and then centrifuge 
for one minute at max speed to eliminate residual ethanol. 
11. Transfer the RNeasy spin column to a new 1.5 ml collection tube and elute the 
RNA bound to the membrane with 30 µl RNase-free water with waiting time 
10 minutes and then centrifuge for 1 minute in 7000rpm to collect total RNA.   
12. Collect the eluate obtained in the last step and re pipette onto the membrane to 
re-elute any remaining RNA that might still be bound to the RNeasy spin 
column membrane with waiting time 10 minute and then centrifuge for further 
1 minute in 7000 rpm.  
Finally, discard the RNeasy spin column and measure the concentration of extracted 
RNA by NanoDrop (NanoDrop® ND-1000, Spectrophotometer Labtech 
International, UK) at wavelength of 260nm. Determine the purity of RNA by the 
260/280nm ratio which should be within range of 1.9 to 2.1. Store the extracted RNA 
at -80
o
C until use.  
 
 
6. 8. Reverse Transcription (RT): 
Since RNA can not be used as a template for PCR, the first step in an RT-PCR assay 
is the reverse transcription of the RNA into first strand cDNA. The reverse 
transcription system kit (Catalogue No: A3500, Promega Corporation, Madison, 
Wisconsin USA) was used for cDNA synthesis from total RNA extracted from 
mucosal cultures in two steps according to manufacture’s instructions.  
 
The primer composed of (0.5µl Oligo dT and 0.5µl random primer) was added to 13.5 
µl total volume of 2µg total RNA in nuclease-free water in 0.5 ml PCR tubes, 
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incubated at 70
o
C for 5 minutes, and subsequently chilled rapidly on ice and 
centrifuged briefly to collect the condensation.  
1. Reverse transcription was achieved by the addition of 12.25µl total volume of 
RT reaction master mix prepared at the final concentration of 5µl of MgCl2 
(25mM), 2.5µl of 10X buffer, 2.5µl of dNTP, 2.5µl of RNasin, and 0.5µl of 
AMVRT.  
2. The mixture was then vortexed for 3 seconds, centrifuged briefly to collect 
residual liquid from the walls of the tubes, and incubated in the PCR 
thermocycler (Thermal cycling system, HYBAID, Middlesex, UK) at 42
o
C for 
30 minutes, heated to 99
o
C for 3 minutes, and then cooled down to 4
o
C.  
3. At the end of the RT reaction, the yielded cDNA products were diluted in 50µl 
nuclease-free water (Promega Corporation, Madison, Wisconsin USA) to give 
a final total volume of 75 µl. cDNA and stored at -80
o
C until PCR 
amplification.  
 
6.9. Absolute Real time-quantitative PCR using SYBR Green I dye: 
6.9.1. Principle:  
Quantitative PCR is a method being used to simultaneously quantify and amplify a 
target DNA molecule. The SYBR Green system used in our study is based on a 
principle of binding of the SYBR-Green I dye to all double-stranded DNA in a PCR 
reaction that evokes fluorescence with intensity proportional to the concentration of 
DNA product. Hence, measurement of the fluorescence intensity generated at each 
cycle allows quantification of DNA concentrations (Arya et al., 2005). 
 
6.9.2. Primer design: 
The PCR primers were designed using the http//www.roche-applied   
science.com/sis/rtpcr/upl/adc.jsp software from gene sequences obtained from the 
National Centre for Biotechnology Information database (www.ncbi.nlm.nih.gov). 
Primers were selected to have approximately the same melting temperature (Tm) 
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ranging from 58 to 60
o
C and length of amplification product to be around 100bp. 
Primers were purchased from Sigma (Table 6.2). 
 
 
Table 6.2. Primer sequences used in the study 
Gene                             Sequence                                   Accession No                                         Size (bP)                    
 
Bax                    F: agcaaactggtgctcaagg                         NM_138764.3                                       93  
                          R: gctgaggcaggtgaatcg 
  
Bcl-2                  F: gcacctgcacacctggat                           NM_000633.2                                       96 
                          R: agccaggagaaatcaaacagag 
 
Cyclin B1          F: catggtgcactttcctcctt                            NM_031966.2                                      102 
                          R: aggtaatgttgtagagttggtgtcc 
 
Cyclin D1          F: tcacacgcttcctctccag                           NM_053056.2                                  120 
                          R: tggggtccatgttctgct 
 
 Fas-L                F: gttctggttgccttggtagg                          NM_000639.1                                  100 
                          R: tgtgcatctggctggtagac 
 
POLR2A           F: gcaaattcaccaagagagacg                      NM_000937                                          73 
                          R: cacgtcgacaggaacatcag 
 
YAP1                F: cccagatgaacgtcacagc                         NM_001130145                                     83 
                     R: gattctctggttcatggctga 
 
6.9.3. Control Reference Genes: 
All target gene expression levels were normalized using two reference genes, polymerase 
(RNA) II (DNA directed) polypeptide A (POLR2A) and Yes-associated protein 1 (YAP1) 
(Table 6.2), which were previously shown to be stable across various human normal oral 
mucosa, dysplastic and squamous cell carcinoma cells (Gemenetzidis et al.,, 2009). 
 
6.9.4. Construction of standard curve: 
In order to quantify the mRNA copy number, a standard curve was performed based 
on a serial dilution of the PCR product of each gene with a known starting 
concentration (Gemenetzidis et al.,, 2009). A standard curve for each gene studied 
was generated in two steps. First, a PCR reaction was run for each primer pair to 
amplify a large amount of PCR product from a pooled cDNA sample (containing 
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various human oral epithelial cell lines, a generous gift by Dr. Muy-Teck Teh, CDOS) 
using a SYBR Green 1 Master qPCR kit (Roche Diagnostics Ltd, Lewes, UK). The 
50µl final volume for each PCR reaction/per well consisted of; 20µl of fast start 
SYBR Green 1 master mix, 20µl dH2O, 5µl cDNA template, and 7µl of 5µM 
forward/reverse primer (0.7 µM final concentration of each primer). PCR 
amplification was performed using the LightCycler LC480 machine according to the 
following program:  
 An initial denaturation at 95oC for 5 minutes. 
 Followed by 40 cycles of 95oC for 10s, annealing at 60oC for 6s, and 
extension at 72
o
C for 6s.  
At the end of 40 cycles, a melting analysis was performed for each sample to check 
for a single peak to confirm the primer specificity for each gene. During the melting 
analysis, samples were heated from 65
o
C to 99
o
C at a steady rate of 0.10
o
C/s, and 
fluorescence measured continuously throughout this period.  
 
The PCR products were then purified using a DNA purification spin column 
(Qiagen).  
1. Each PCR product was placed onto a Qiagen spin column followed by 250µl 
PB (Binding Buffer, Lot No 11546581 Qiagen GmbH D-40724, Hilden, 
Germany) and then centrifuged at 15000 rpm for a maximum of 1 minute.  
2. The flow through was discarded and 0.7ml PE wash buffer (wash buffer, Lot 
No 124106145, Qiagen GmbH D-40724, Hilden, Germany) was then added 
and the columns were centrifuged at for a further up to 1 minute (maximum) 
followed by a dry spin for the same time.  
3. The bottom column was replaced with a new column and 40µl of H2O was 
added to the middle of the filter and DNA was eluted by centrifugation at for 1 
minute.  
4. The liquid from the bottom columns were collected and placed in pre-labelled 
tubes.  
5. The concentration of the purified PCR products for each gene was 
subsequently measured using the NanoDrop and the total number of copies in 
PCR product calculated using the Avogadro’s Constant where 1mole = 
6.02*10
23
 molecules. 
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A stock solution of 10
11
 copies/2µl for each PCR template was prepared and a 
dilution series of 10
9
, 10
7
, 10
6
, 10
5
, 10
4
, 10
3
 and 10
2
 DNA copies per 2µl was 
generated by diluting the stock in tRNA (25µg/ml; Sigma R8508) as a DNA carrier as 
follows: 
 To make 109 from 1011, add 2µl of 1011 into 198µl tRNA 
 To make 107 from 109, add 2µl of 109 into 198µl tRNA. …and so on. 
All standard dilutions were stored at -20
o
C until use. 
 
The standard curves for each PCR product was created by plotting the logarithm of 
the initial copy number of the standard template (X-axis) against the respective cycle 
number of crossing point (Cp), the point at which the fluorescence increases 
significantly above the background fluorescence (Y-axis). The PCR amplification 
efficiency for each gene was then calculated by an internal algorithm within the 
Roche LightCycler Software system. Subsequently, extrapolating the Cp values of 
unknown samples to this curve allows quantification of the initial copy numbers of 
the respective genes. Amplification efficiencies and melting temperatures for the 
target genes are shown in Table 6.3. 
 
Fig 6.4 displays the LightCycler qPCR amplification plot and the corresponding 
melting curve and standard curve for Bax gene quantification. The standard curve was 
linear (R
2
 = 0.99) within the range tested (from 10
2
 to 10
7
 copies/µl) by the triplicate 
reactions. 
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Melting curve for Bax gene apmlification
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Figure 6.4. LightCycler qPCR amplification reaction for quantification of Bax 
gene in a standard dilution series using SYBR Green I dye. The standard curve was 
generated from serial dilutions of PCR product ranging from 10
2
 to 10
7
 copies/µl. 
A- A representative plot of qPCR amplification for Bax gene performed using the LightCycler 480 
Machine. All samples were amplified for 45 cycles along with measuring the fluorescence emission at 
the end of each extension stage. The increase in fluorescence density was plotted versus the PCR cycle 
number. 
B- A representative standard curve for Bax gene was created by plotting the cycle number of crossing 
point (CP) generated from the amplification plot in A against the input cDNA copy number. Thus, by 
extrapolating the CP values of the unknown samples to this standard curve, the starting template 
concentration of the unknown samples can be measured. 
C- A representative melting curve analysis from the same amplification reaction. Samples were slowly 
melted along with continuous measurement of the fluorescence. The melting curve was created by 
plotting the negative derivative of fluorescence generated from each sample versus the temperature 
o
C. 
A single peak was detected at the temperature (88.5
o
C) confirming the specificity of primers. 
 
 
 
Table 6.3. Efficiencies and melting temperatures for qPCR amplifications from 
the house keeping and target genes. 
 
 
Gene                                     Efficiency                                             Tm (melting peak) 
  
 CCND1 ………………………….1.851……………………………………………… 89.13 ± 0.168 
 CCNB1…………………………..1.941……………………………………………… 80.65 ± 0.091 
 Bax   ……………………….........1.932………………………………………………  88.32 ± 0.07 
 Bcl-2 …………………………… 1.864……………………………………………….85.78 ± 0.17 
 Fas-L …………………………....1.782………………………………………………..84.22 ± 0.1 
YAP1…………………………….1.948………………………………………………..84.01±0.1 
POLR2A………………………   .1.970…………………………………………... …..82.12 ± 0.06 
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6.9.5. PCR procedure: 
Quantitative PCR was conducted using a LightCycler LC480 machine (Roche 
Diagnostics Ltd, Lewes, UK).  
1. Reactions were set up in 96-well optical plates (Roche Diagnostics) using the 
following final concentrations:  
4µl of Fast start DNA Master SYBR Green 1 mix (containing Taq DNA 
polymerase, dNTP, MgCl2, and SYBR Green I dye); 0.5 µl of each forward and 
reverse primer (5µM; 0.5 µM final concentration), 4.5 µl of dH2O and 
2 µl of cDNA template/DNA standard in a 10 ± 1µl total reaction 
mixture.  
2. Triplicate reactions were run for each sample along with reactions containing 
RNase-free water instead of DNA template (as negative control) in every 
qPCR run.  
3. The plates were tightly sealed with a Roche sealing film (Cat. NO 
04729692001) and spun for 30s at 3000 rpm.  
4. PCR reactions were then run in the LightCycler 480 machine according to the 
following cycling conditions: denaturation and “hot start”(95° C for 5 
minutes), 45 cycles of amplification and quantification consisted of (melting 
for 10s at 95°C, primer annealing at 60°C for 6s and extension/acquisition at 
72°C for 6s.  
5. A melting curve analysis was then performed to confirm the specificity of the 
PCR products according to the following program (melting at 95
o
C for 30s, 
cooling/annealing at 65
o
Cfor 30s, 65
o
C to 99°C gradual heating with a heating 
rate of 0.1° C/s along with continuously measuring the fluorescence and the 
program was then terminated with a cooling step to 40°C for 10s).  
6. Data were analyzed using LightCycler software and gene expression was then 
normalized to the reference genes (POLR2A and YAP1) and subsequently 
normalized to the biologic control (un-treated sample). 
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6.9.6. Agarose gel electrophoresis: 
In order to confirm the specificity of primers used, the corresponding amplified PCR 
products were confirmed to be single band at the predicted size using agarose gel 
electrophoresis.  
 
Briefly, 2% agarose (Melford Ltd. Ipswich. UK) was totally dissolved in 50ml 1x 
TAE by microwaving at max power for 3*30 second. The solution was then allowed 
to cool on the bench for 5 minutes, 1µl of ethidium bromide was afterwards added 
and dispersed into the solution by stirring, the gel was poured into the tank and 
bubbles were pushed away to the side, the comb was inserted and the gel was allowed 
to solidify for 40 minutes, the tank was then filled with 1x TAE. Afterwards, the 
samples were prepared by mixing 5µl of PCR product with 2µl of loading buffer 
(Invitrogen.Uk), 7µl of each sample and a DNA hyperladder V (Bioline. London. 
UK) was loaded into the appropriate wells, electrophoresis was run at 100V for about 
50 minutes. Finally, the DNA bands were visualized and photographed by using an 
ultraviolet transilluminator.  
 
6.10. Data Analysis: 
Data were analysed by using One-way ANOVA test along with Student’s independent 
t-test.  Statistical significance was considered when p<0.05. Findings were further 
confirmed using SPSS program by one-way ANOVA and Post hoc test. 
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Chapter Seven 
Effect of CsA and bacterial 
supernatants on reconstructed 
epithelial models 
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7.1  Introduction: 
 
This chapter shows the effect of 2000ng/ml CsA along with bacterial supernatants on  
an in vitro reconstructed model of human gingival and oral epithelium in terms of 
tissue viability, cytokine and chemokine release (IL-1α, IL-6, and IL-8), expression of 
proliferation-related genes (CCNB1 and CCND1), and apoptosis-related genes (Bax, 
Bcl-2, and Fas-L).  
 
 
7.2 Effect of CsA and bacterial supernatants on reconstructed human 
gingival epithelial cultures (RHGE): 
7.2.1  Tissue Viability: 
CsA alone had no significant effect on RHGE viability compared to the control (CsA; 
92.6 ± 10.8 vs. control; 100 ± 6%; p>0.05; Fig 7.1).   
P. gingivalis 
P.g caused a significant reduction in the tissue viability (68.4 ± 3.3%; p<0.05) 
compared to the control whilst the addition of CsA reduced this effect with viability 
returning to control levels (93 ± 7% p<0.05) 
A. actinomycetemcomitans 
A.a caused a significant reduction in the tissue viability (74.4 ± 5.6%; p<0.05) 
compared to the control whilst the addition of CsA reduced this effect with viability 
returning to control levels (90 ± 5.4%; p <0.05).  
P. intermedia 
P.i caused a significant reduction in the tissue viability (66.9 ± 4.8%; p<0.05) 
compared to the control whilst the addition of CsA caused a slight reduction in this 
effect (82.5 ± 5.8%, p<0.05)  
F. nucleatum 
F.n had no effect on tissue viability, although the subsequent addition of CsA caused a 
significant increase in tissue viability compared to controls (117.2 ± 1.8%, p<0.05 Fig 
7.1). 
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Figure 7.1. Effect of CsA and bacterial supernatants on RHGE viability. 
RHGE cultures were stimulated with 2000ng/ml CsA or/and bacterial supernatant. Cell viability was 
measured by MTT assay after 48h exposure. Control cultures were exposed to PBS. Results are 
expressed as the mean ± SEM (n=3). Statistical significance was regarded when p< 0.05 compared to 
control.  
 
 
7.2.2 IL-1α release: 
CsA alone had no significant effect on IL-1α release of compared to the control up to 
48h (Fig 7.2) 
P.g, A.a. P.i, and F.n alone or in combination with CsA had no significant effect on 
IL-1α release up to 48h (Fig 7.2). 
 
7.2.3  IL-6 release: 
CsA alone had no significant effect on IL-6 release compared to the control up to 48 h 
(Fig 7.3). 
P.g, A.a, P.i, and F.n alone or in combination with CsA had no significant effect on 
IL-6 release up to 48h (Fig 7.3).   
 
7.2.4  IL-8 release  
RHGE alone or in combination with CsA released low levels of IL-8 up to 48h 
(control; 3 ± 0.7pg/ml & 2 ± 0.3 pg/ml respectively; Fig 7.4) 
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P. gingivalis 
P.g had no effect on IL-8 release although the addition of CsA caused a significant 
reduction in IL-8 release (P.g + CsA; 2.4 ± 0.2 & 1.2 ± 0.2pg/ml at 24h & 48h 
respectively; p<0.05 vs. control).  
A. actinomycetemcomitans 
A.a caused a significant increase in the IL-8 release after 24 and 48h (A.a; 12 ± 2.9 & 
5.4 ± 1.1pg/ml respectively; p<0.05 vs. control & CsA). CsA significantly reduced 
this effect with values returning to controls levels (3.3 ± 0.6 & 1.7 ± 0.2pg/ml at 24h 
& 48h respectively; p<0.05) 
P. intermedia 
P.i caused a significant increase in the IL-8 release after 24 and 48h (14.4 ± 2.3pg/ml 
& 5.1 ± 0.4 pg/ml respectively)  CsA significantly reduced this effect with values 
returning to control levels 3.1 ± 0.73  & 1.9 ± 0.6 pg/ml at 24h & 48h respectively; 
p<0.05). 
F. nucleatum 
F.n alone or in combination with CsA had no significant effect on IL-8 release. 
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Figure 7.2.  Effect of CsA/CsA+ bacterial supernatant combinations on release of 
IL-1α in RHGE. RHGE cultures were stimulated with 2000ng/ml CsA and/or bacterial 
supernatant. Control cultures were exposed to PBS. IL-1α was measured by Elisa assay after 6h, 24h, 
and 48h exposure. Results are expressed as the mean ± SEM (n=5). Statistical significance was 
regarded when p< 0.05 compared to control. X axis represents treatment time (hours). Y represents 
concentration of cytokine (pg/ml). 
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Figure 7.3.  Effect of CsA/CsA+bacterial supernatant combinations on release of 
IL-6 in RHGE. RHGE cultures were stimulated with 2000ng/ml CsA and/or bacterial supernatant. 
Control cultures were exposed to PBS. IL-6 was measured by Elisa assay after 6h, 24h, and 48h 
exposure. Results are expressed as the mean ± SEM (n=5). Statistical significance was regarded when 
p< 0.05 compared to control. X axis represents treatment time (hours). Y represents concentration of 
cytokine (pg/ml). 
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Figure 7.4. Effect of CsA/CsA+bacterial supernatant combinations on release of 
IL-8 in RHGE. RHGE cultures were stimulated with 2000ng/ml CsA and/or bacterial supernatant. 
Control cultures were exposed to PBS. IL-8 was measured by Elisa assay after 6h, 24h, and 48h 
exposure. Results are expressed as the mean ± SEM (n=5). Statistical significance was regarded when 
p< 0.05 compared to control. X axis represents treatment time (hours). Y represents concentration of 
cytokine (pg/ml). 
 
 
7.3  Effect of CsA and bacterial supernatants on reconstructed human 
Buccal epithelial cultures (RHOE): 
7.3.1 Tissue viability: 
CsA alone had no significant effect on the viability of RHOE compared to the control 
(CsA; 119 ± 10 vs. control; 100 ± 15%; Fig 7.5).  
P.g, P.i, & F.n significantly increased the cell viability compared to the control (126 ± 
2.4%; 128 ± 14%; & 133 ± 2.8% respectively; p<0.05 vs. control), whilst addition of 
CsA had no further effect on viability. 
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A.a supernatant either individually or in combination with CsA had no significant 
effect on viability of the RHOE. 
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Figure 7.5.  Effect of CsA and bacterial supernatants on RHOE viability. 
RHOE cultures were stimulated with 2000ng/ml CsA or/and bacterial supernatant. Cell viability was 
measured by MTT assay after 48h exposure. Control cultures were exposed to PBS. Results are 
expressed as the mean ± SEM (n=3). Statistical significance was regarded when p< 0.05 compared to 
control.  
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7.3.2 IL-1α release: 
CsA alone had no significant effect on IL-1α release of compared to the control up to 
48h (Fig 7.6) 
P.g, A.a. P.i, and F.n alone or in combination with CsA had little or no significant 
effect on IL-1α release up to 48h (Fig 7.6). 
 
7.3.3 IL-6 release: 
CsA alone had no significant effect on IL-6 release compared to the control up to 48 h 
(Fig 7.7). 
P.g, A.a, P.i, and F.n alone or in combination with CsA had no significant effect on 
IL-6 release up to 48h (Fig 7.7).   
 
7.3.4 IL-8 release: 
CsA caused a slight but significant reduction in IL-8 release compared to the control 
(100 ± 12pg/ml 144 ± 18pg/ml at 48h; respectively; p<0.05 Fig 7.8). 
P.g, A.a, P.i and Fn significantly increased IL-8 release at all time points studied (e.g.  
400 ± 43, 436 ± 61, 392 ± 49 & 400± 30 pg/ml at 48h respectively; p<0.05 Fig 7.8). 
CsA had little or no effect at 6 h and 24h.  However after 48h, CsA significantly 
reduced P.g, A.a and P.i induced release of IL-8 (217 ± 30, 272 ± 32, &; 275 ± 
57pg/ml; respectively p<0.05), although these levels were still significantly greater 
than controls (p <0.05). 
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Figure 7.6. Effect of CsA/CsA+bacterial supernatant combinations on release of 
IL-1α in RHOE. RHOE cultures were stimulated with 2000ng/ml CsA and/or bacterial 
supernatant. Control cultures were exposed to PBS. IL-1α was measured by Elisa assay after 6h, 24h, 
and 48h exposure. Results are expressed as the mean ± SEM (n=5). Statistical significance was 
regarded when p< 0.05 compared to control. X axis represents treatment time (hours). Y represents 
concentration of cytokine (pg/ml). 
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Figure 7.7.  Effect of CsA/CsA+bacterial supernatant combinations on release of 
IL-6 in RHOE. RHOE cultures were stimulated with 2000ng/ml CsA and/or bacterial supernatant. 
Control cultures were exposed to PBS. IL-6 was measured by Elisa assay after 6h, 24h, and 48h 
exposure. Results are expressed as the mean ± SEM (n=5). Statistical significance was regarded when 
p< 0.05 compared to control. X axis represents treatment time (hours). Y represents concentration of 
cytokine (pg/ml). 
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Figure 7.8.  Effect of CsA/CsA+bacterial supernatant combinations on release of 
IL-8 in RHOE. RHOE cultures were stimulated with 2000ng/ml CsA and/or bacterial supernatant. 
Control cultures were exposed to PBS. IL-8 was measured by Elisa assay after 6h, 24h, and 48h 
exposure. Results are expressed as the mean ± SEM (n=5). Statistical significance was regarded when 
p< 0.05 compared to control. X axis represents treatment time (hours). Y represents concentration of 
cytokine (pg/ml). 
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7.4. Gene expression (qPCR): 
7.4.1. Confirmation of primer specificity: 
Melting curve analyses revealed that each qPCR amplification generated a single peak 
at a point corresponding to the product specific melting temperature (Fig 7.9). No 
primer-dimers were however detected during the 45 amplification cycles in all qPCR 
reactions. These findings were in agreement with agarose gel electrophoresis that 
showed a single band for each product corresponding to the predicted length. These 
results confirmed the absence of non-specific PCR products and thus, the specificity 
of the primer sets used in this study.  
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Figure 7.9. Confirmation of PCR product specificity. Panel A: melting curve analyses of 
two house keeping gene and five target gene amplification reactions displays a single melting peak for 
each PCR product at distinct melting temperature 
o
C. Water used as control is appearing flat and no 
primer-dimers were detected during the 45 amplification cycles in all qPCR reactions. 
Panel B: the specificity of the same PCR reactions was confirmed by agarose gel electrophoresis that 
showed single amplification products with the predicted length. 
Specificity of the amplification products from the house keeping genes were already confirmed by our 
staff in the department.  
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7.4.2. Effect of CsA and bacterial supernatants on gene expression from RHGE: 
 
7.4.2.1 CCNB1 expression: 
 
CsA significantly reduced the expression of CCNB1 compared to control (p<0.05; Fig 
7.10; Table 7.1). Stimulation with bacterial supernatants alone either significantly 
decreased (P.g, A.a, and F.n) or had no effect (P.i) on CCNB1 levels. The addition of 
CsA to RHGE pre-exposed to any of the bacterial supernatants, however, caused a 
significant increase in CCNB1 levels (p<0.05). This effect was most pronounced with 
P.i, A.a, and F.n (p<0.05; Fig 7.10; Table 7.1).  
 
Culture type Doses applied CCNB1 mRNA 
(Mean ± SEM)  
Sample      
(N) 
 
 
 
 
RHGE 
Control (PBS) 1 ± 0.047 3 
2000ng/ml CsA 0.70 ± 0.032 3 
P.g 0.70 ± 0.057 3 
P.g+CsA 1.10 ± 0.103 3 
A.a 0.66 ± 0.02 3 
A.a + CsA 1.54 ± 0.039 3 
P.i 1.04 ± 0.056 3 
P.i + CsA 1.41 ± 0.033 3 
F.n 0.69 ± 0.051 3 
F.n + CsA 1.28 ± 0.037 3 
 
Table 7.1. Expression of CCNB1 in RHGE cultures stimulated with PBS, or CsA, 
or bacterial supernatants, or combination of CsA and bacterial supernatant. 
Results were normalized to the control (PBS) and expressed as a fold mean ± SEM. 
 
0
0.5
1
1.5
2
P
BS C
sA P
.g
P
.g
+C
sA A
.a
A
.a
+C
sA P
.i
P
.i+
C
sA F.
n
F.
n+
C
sA
Treatment
R
e
la
ti
v
e
 n
o
rm
a
li
z
e
d
 C
C
N
B
1
 
m
R
N
A
 e
x
p
re
s
s
io
n
Figure 7.10. Expression of CCNB1 in RHGE exposed to either PBS, or CsA, or 
bacterial supernatant only, or a combination of CsA and bacterial supernatant. 
Results were normalized to both house keeping genes and afterwards to the biologic control PBS. Each 
bar represents a mean ± SEM of n=3. The significant effect was considered when p<0.05. 
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7.4.2.2 CCND1 expression: 
 
CsA had no effect on CCND1 compared to the control (Fig 7.11; Table 7.2). All the 
bacterial supernatants however, significantly increased CCND1 expression (p<0.05; 
Fig 7.11 and Table 7.2). CsA, significantly promoted this stimulatory effect on 
CCND1 mRNA expression.  
 
Culture type Doses applied CCND1mRNA 
(Mean ± SEM)  
Sample      
(N) 
 
 
 
 
RHGE 
Control (PBS) 1± 0.106                           3 
2000ng/ml CsA 1.046 ± 0.079                   3 
P.g 2.03 ± 0.09                      3 
P.g+CsA 2.99 ± 0.108 3 
A.a 2.12 ± 0.22                    3 
A.a + CsA 3.41 ± 0.22 3 
P.i 1.45 ± 0.09                  3 
P.i + CsA 2.77 ± 0.17 3 
F.n 1.73 ± 0.15                 3 
F.n + CsA 2.91 ± 0.32 3 
 
Table 7.2 Expression of CCND1 in RHGE cultures stimulated with PBS, or CsA, 
or bacterial supernatants, or combination of CsA and bacterial supernatant. 
Results were normalized to the control (PBS) and expressed as a fold mean ± SEM. 
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Figure 7.11. Expression of CCND1 in RHGE exposed to either PBS, or CsA, or 
bacterial supernatant only, or a combination of CsA and bacterial supernatants. 
Results were normalized to both house keeping genes and afterwards to the biologic control PBS. Each 
bar represents a mean ± SEM of n=3. The significant effect was considered when p<0.05. 
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7.4.2.3. Fas-L expression: 
 
CsA and bacteria supernatants had no effect on the expression of Fas-L mRNA in 
RHGE (Fig 7.12; Table 7.3). 
 
Culture type Doses applied Fas-L mRNA 
(Mean ± SEM)  
Sample      
(N) 
 
 
 
 
RHGE 
Control (PBS) 1 ± 0.90 3 
2000ng/ml CsA 1.09 ± 0.58 3 
P.g 8.89 ± 9.09 3 
P.g+CsA 3.54 ± 1.06 3 
A.a 3.14 ± 1.97 3 
A.a + CsA 9.56 ± 9.55 3 
P.i 2.29 ± 0.54 3 
P.i + CsA 1.77± 0.68 3 
F.n 0.74 ± 0.49 3 
F.n + CsA 2.84 ± 0.99 3 
 
Table 7.3 Expression of Fas-L in RHGE cultures stimulated with PBS, or CsA, 
or bacterial supernatants, or combination of CsA and bacterial supernatant. 
Results were normalized to the control (PBS) and expressed as a fold mean ± SEM. 
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Figure 7.12. Expression of Fas-L in RHGE exposed to either PBS, or CsA, or 
bacterial supernatant only, or a combination of CsA and bacterial supernatant. 
Results were normalized to both house keeping genes and afterwards to the biologic control PBS. Each 
bar represents a mean ± SEM of n=3. The significant effect was considered when p<0.05. 
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7.4.2.4. Bcl-2/Bax mRNA ratio expression: 
 
CsA and bacteria supernatants had no effect on the expression of Bcl-2/Bax mRNA in 
RHGE (Fig 7.13; Table 7.4). 
 
Culture type Doses applied Bcl2/Bax mRNA 
(Mean ± SEM) 
Sample      
(N) 
 
 
 
 
RHGE 
Control (PBS) 1 ± 0.5 3 
2000ng/ml CsA 1 ± 0.8 3 
P.g 1.6 ± 0.7 3 
P.g+CsA 1 ± 0.6 3 
A.a 1.3 ± 1.1 3 
A.a + CsA 1.1 ± 0.7 3 
P.i 0.7 ± 0.4 3 
P.i + CsA 1.3 ± 0.6 3 
F.n 1.1 ± 0.7 3 
F.n + CsA 0.8 ± 0.5 3 
 
Table 7.4. Expression of Bcl2/Bax mRNA ratio in RHGE cultures stimulated 
with PBS, or CsA, or bacterial supernatants, or combination of CsA and 
bacterial supernatant. Results were normalized to the control (PBS) and expressed as a fold 
mean ± SEM. 
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Figure7.13. Bcl-2/Bax mRNA ratio expression in RHGE exposed to either PBS, 
or CsA, or bacterial supernatant only, or a combination of CsA and bacterial 
supernatant. Results were normalized to both house keeping genes and afterwards to the biologic 
control PBS. Each bar represents a mean ± SEM of n=3. The significant effect was considered when 
p<0.05. 
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7.4.3. Effect of CsA and bacterial supernatants on gene expression from RHOE: 
 
7.4.3.1. CCNB1 expression: 
 
CsA alone had no significant effect on CCNB1 expression (Fig 7.14; Table7.5). 
P.g, A.a and P.i alone had no significant effect on CCNB1 expression compared to 
both control and cultures treated with CsA (p>0.05; Fig 7.14; Table7.5) whilst CsA 
significantly reduced CCNB1 expression compared to that of cultures exposed to the 
respective bacterial supernatant, cultures treated with CsA, and control culture 
(p<0.05; Fig 7.14; Table7.5).  
 
F.n alone however, significantly increased CCNB1 expression whilst the addition of 
CsA caused a significant decrease in CCNB1 mRNA levels (p<0.05; Fig 7.14; 
Table7.5).  
 
Culture type Doses applied CCNB1 mRNA 
(Mean ± SEM)  
Sample      
(N) 
 
 
 
 
RHOE 
Control (PBS) 1 ± 0.10                                3
2000ng/ml CsA 0.79 ± 0.051                  3 
P.g 0.99 ± 0.22                    3 
P.g+CsA 0.50 ± 0.017    3 
A.a 1.026 ± 0.22                      3 
A.a + CsA 0.36 ±0.019     3 
P.i 0.89 ± 0.098               3 
P.i + CsA 0.48 ± 0.012   3 
F.n 1.44 ± 0.16                       3 
F.n + CsA 0.94 ± 0.07    3 
 
Table 7.5 Expression of CCNB1 in RHOE cultures stimulated with PBS, or CsA, 
or bacterial supernatants, or combination of CsA and bacterial supernatant. 
Results were normalized to the control (PBS) and expressed as a fold mean ± SEM. 
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Figure 7.14. Expression of CCNB1 in RHOE exposed to either PBS, or CsA, or 
bacterial supernatant only, or a combination of CsA and bacterial supernatant. 
Results were normalized to both house keeping genes and afterwards to the biologic control PBS. Each 
bar represents a mean ± SEM of n=3. The significant effect was considered when p<0.05. 
 
 
7.4.3.2 CCND1 expression: 
 
CsA alone, Pg, Pi and F.n had no effect on CCND1 expression compared to the 
control (p<0.05; Fig 7.15; Table 7.6).  A.a however caused a significant increase in 
CCND1 gene expression compared to both control and cultures treated with CsA 
(p>0.05; Fig 7.15; Table 7.6).  
 
Culture type Doses applied CCND1mRNA 
(Mean ± SEM)  
Sample      
(N) 
 
 
 
 
RHOE 
Control (PBS) 1± 0.15                                3 
2000ng/ml CsA 0.84 ± 0.081                   3 
P.g 1.38 ± 0.02                    3 
P.g+CsA 1.28 ± 0.040 3 
A.a 1.511 ± 0.108                    3 
A.a + CsA 1.65 ± 0.123 3 
P.i 1.33 ± 0.097               3 
P.i + CsA 1.11 ± 0.029   3 
F.n 0.94 ± 0.06                      3 
F.n + CsA 1.15 ± 0.10 3 
 
Table 7.6 Expression of CCND1 in RHOE cultures stimulated with PBS, or CsA, 
or bacterial supernatants, or combination of CsA and bacterial supernatant. 
Results were normalized to the control (PBS) and expressed as a fold mean ± SEM. 
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Figure7.15. Expression of CCND1 in RHOE exposed to either PBS, or CsA, or 
bacterial supernatant only, or a combination of CsA and bacterial supernatant. 
Results were normalized to both house keeping genes and afterwards to the biologic control PBS. Each 
bar represents a mean ± SEM of n=3. The significant effect was considered when p<0.05. 
 
 
7.4.3.3. Fas-L mRNA expression: 
 
CsA and bacteria supernatants had no effect on the expression of Fas-L mRNA in 
RHOE (Fig 7.16; Table 7.7). 
 
Culture type Doses applied Fas-L mRNA 
(Mean ± SEM)  
Sample      
(N) 
 
 
 
 
RHOE 
Control (PBS) 1± 0.64                                3 
2000ng/ml CsA 0.93 ± 0.819                    3 
P.g 4.05 ± 4.08                    3 
P.g+CsA 2.80 ± 1.277 3 
A.a 1.25 ± 0.34                        3 
A.a + CsA 3.22 ± 3.76 3 
P.i 1.23 ± 1.16                  3 
P.i + CsA 0.617± 0.51 3 
F.n 2.26 ± 2.74                      3 
F.n + CsA 2.16 ± 2.65 3 
Table 7.7. Expression of Fas-L mRNA in RHOE cultures stimulated with PBS, 
or CsA, or bacterial supernatants, or combination of CsA and bacterial 
supernatant. Results were normalized to the control (PBS) and expressed as a fold mean ± SEM. 
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Figure7.16. Expression of Fas-L mRNA in RHOE exposed to either PBS, or CsA, 
or bacterial supernatant only, or a combination of CsA and bacterial 
supernatant. Results were normalized to both house keeping genes and afterwards to the biologic 
control PBS. Each bar represents a mean ± SEM of n=3. The significant effect was considered when   
p<0.05. 
 
 
7.4.3.4. Bcl-2/Bax mRNA ratio expression: 
 
CsA and bacteria supernatants had no effect on the expression of Bcl-2/Bax mRNA in 
RHGE (Fig 7.17; Table 7.8). 
 
Culture type Doses applied Bcl2/Bax mRNA 
(Mean ± SEM) 
Sample      
(N) 
 
 
 
 
RHOE 
Control (PBS) 1 ± 0.2 3 
2000ng/ml CsA 1.1 ± 0.2 3 
P.g 1.2 ± 0.1 3 
P.g+CsA 0.9 ± 0.2 3 
A.a 2.1 ± 1.2 3 
A.a + CsA 1.6 ± 0.6 3 
P.i 1.1 ± 0.1 3 
P.i + CsA 1.5 ± 1.1 3 
F.n 1.2 ± 0.6 3 
F.n + CsA 1.5 ± 0.7 3 
 
Table. 7.8 Expression of Bcl2/Bax mRNA ratio in RHOE cultures stimulated 
with PBS, or CsA, or bacterial supernatants, or combination of CsA and 
bacterial supernatant. Results were normalized to the control (PBS) and expressed as a fold 
mean ± SEM. 
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Figure7.17. Bcl-2/Bax mRNA ratio expression in RHOE exposed to either PBS, 
or CsA, or bacterial supernatant only, or a combination of CsA and bacterial 
supernatant. Results were normalized to both house keeping genes and afterwards to the biologic 
control PBS. Each bar represents a mean ± SEM of n=3. The significant effect was considered when 
p<0.05. 
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7.5 Summary:  
CsA alone had no effect on RHGE viability, whilst P.g, A.a, and P.i supernatants 
caused a significant reduction. In contrast a combination of CsA plus any of the 
bacterial supernatants increased the viability with the most pronounced effect being 
found with CsA/F.n where the level of viability was significantly higher than control.   
None of the treatments applied had a significant effect on the release of IL-1α and IL-
6 from RHGE. CsA, P.g, F.n individually had no effect on IL-8 release whereas A.a 
and P.i caused a a significant increase after 24h. However, addition of CsA reduced 
the level with values returning to the control level.  
 
CsA alone, P.g, A.a, and F.n caused a significant reduction in CCNB1 expression in 
RHGE. Interestingly, exposure to combinations of CsA and any of bacterial 
supernatant reversed that effect to a stimulatory effect. All bacterial supernatants 
significantly up-regulated the expression of CCND1 but no effect was found with 
CsA alone. Furthermore, exposure to combinations of CsA and any of bacterial 
supernatants significantly promoted this stimulatory effect on CCND1 expression. 
 
In contrast to RHGE, P.g, P.i, and F.n caused a significant increase in viability of 
RHOE but no effect was found with CsA alone and A.a. Furthermore, all 
combinations had no significant effect on the viability of RHOE. Similarly to RHGE, 
all treatments had no effect on the release of IL-1α and IL-6. However, CsA alone 
reduced the release of IL-8 whilst all bacterial supernatants caused a significant 
increase in release of this cytokine at all time intervals.  
 
CsA alone, P.g, A.a, and P.i had no significant effect on CCNB1 expression but 
surprisingly, all combination of CsA and bacterial supernatants significantly down-
regulated its expression. However, expression of CCND1 was not significantly 
modulated under influence all of the treatments applied.  
 
Expression of apoptosis-related genes has not been modulated under influence any of 
the treatments applied in both RHGE and RHOE cultures. 
 
185 
 
Collectively, CsA alone had a little effect on both RHGE and RHOE. However, these 
types of epithelium reacted differently when exposed to combinations of CsA and 
bacterial supernatants. All combinations stimulated the proliferative activity of RHGE 
by reversing the inhibitory effect of CsA and bacterial supernatants alone on CCNB1 
expression and promoting the stimulatory effect of bacterial supernatants on CCND1 
expression, In contrast these combinations of CsA and bacterial supernatants inhibited 
the proliferative activity of RHOE by down-regulating the expression of CCNB1, but 
had no effect on CCND1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
186 
 
 
 
 
 
 
 
 
 
Chapter Eight 
 Discussion 
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The mechanism underlying CsA-induced gingival hyperplasia is unclear (Cotrim et 
al., 2003; Yoshida et al., 2005; Birraux et al., 2006) and therefore, the main objective 
of our study was to evaluate the direct effect of CsA and to investigate whether the 
exposure to a combination of CsA and bacterial products might modulate the response 
of gingival and oral cells in vitro. This was evaluated using monolayer cultures of 
three keratinocyte cell lines (OKF6, FIBS and TR146) and HGF derived from human 
gingival fibroblasts and a stratified model oral and gingival epithelium (SkinEthic, 
Nice). 
 
8.1  Monolayer cultures: 
8.1.1 Cell viability: 
CsA alone exhibited a variable effect on the viability of the different cell lines.  FIBS, 
OKF6 and HGF showed an increase whilst there was no change in TR146. The 
concentrations chosen reflected physiological and local gingival tissue levels (Fisher 
et al., 1988; McGaw et al., 1987) and the peak effect was, in general present within 
24hrs. In contrast to previous studies (Barber et al., 1992), prolonged exposure had no 
effect or reduced viability rather than leading to an increase.   
 
Pre-stimulation of cells with bacterial supernatants also showed a variable effect on 
cell viability. Keratinocyte viability was increased by F.n and P.i, whilst P.g caused an 
increase in OKF6 and TR146 but a decrease in FIBS and A.a caused a decrease in 
OKF6 and an increase in TR146.  HGF showed no change (P.g, P.i) or inhibition with 
A.a and F.n.   
 
The MTT assay, however, only provides limited information about the modulation in 
cell viability and is unable to determine whether the cells are able to replicate and 
hence does not differentiate between cycling cells or static cells. CsA has been 
reported to alter cell proliferation without change in cell viability (Willershausen-
zönnchen et al., 1992) and therefore more sophisticated assays were required to 
evaluate the cellular response to CsA and bacterial products and whether this response 
involved  modulation in the local inflammatory response. 
 
 
188 
 
8.1.2 Cell proliferation: 
To gain an insight into the proliferative activity a flow cytometric assay was 
developed to simultaneously determine changes in cell cycle distribution, rate of DNA 
synthesis as determined by Edu incorporation, and expression of Cyclins D1 and B1. 
CsA, using this approach had a variable effect on the cell cycle distribution, Edu 
incorporation and Cyclin D1 expression.  These results are in keeping with previous 
studies in which CsA caused an inhibition in proliferation of human endothelial and 
renal tubular epithelial cells but not human skin fibroblasts (Esposito et al., 2000) and 
inhibited melanocyte proliferation in a dose-dependent manner with no apparent 
effect on cell viability (Lee & Kang, 2003). CsA has also been reported to inhibit 
DNA synthesis and proliferation of normal and transformed keratinocyte cell lines 
(Furue et al., 1988). Furthermore, Karashima et al (1996) showed that CsA inhibited 
human epidermal keratinocytes proliferation by arresting cells at the G0/G1 phases of 
cell cycle. Blocking of cell cycle in G1 phase has been suggested to be a potential 
mechanism of CsA-induced proliferation inhibition of cultured human epidermal 
keratinocytes (Khandke et al., 1991). Kato et al (1987) found that CsA within the 
therapeutic levels did not inhibit the proliferation of animal epidermal cells. 
Collectively, these findings indicates that the sensitivity of cells to CsA is varied 
which could explain the different responses of various types of keratinocytes to CsA.   
 
Previous attempts to evaluate the direct effects of CsA on proliferation of HGF 
resulted in conflicting data ranging from an increase (Cotrim et al., 2003), decrease 
(Pistorius et al., 2003) or no effect (James et al., 1995). These discrepancies may stem 
from differences in the methodologies and experimental conditions dose, duration 
(Kataoka et al., 2000). Furthermore, the variability in the response to CsA among 
HGF strains has previously been reported (Tipton et al., 1991). These findings were 
supported by other reports revealing that HGFs derived from nifedipine-responder 
patients showed higher proliferative rate, illustrated by enhanced BrdU incorporation 
and upregulated mRNA expression of Cyclin B1 and D1 as well as more promoted 
cell cycle progression than those derived from nifedipine-non responder individuals 
(Takeuchi, 2004; Takeuchi et al., 2007). Thus, the heterogeneity among the HGF 
populations may also account for the different responses to CsA between HGF 
derived from patients with CsA-induced gingival hyperplasia and those derived from 
healthy or CsA-non responder individuals (Sukkar et al., 2007). 
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Recent attention has been drawn to the gingival keratinocytes as a potential part of the 
pathogenesis of CsA-associated gingival hyperplasia but findings are still 
inconclusive (Cetinkaya et al., 2006). Yoshida et al (2005) assessed proliferation of 
cultured rat gingival cells after incubation for 3days using MTS assay showing that 
CsA at concentration of 200-800ng/ml induced hyper proliferation of gingival cells by 
23-25% compared to control. However, in this study they used a mixture of 
keratinocyte and mesenchymal cells. In contrast, Birraux et al (2006) demonstrated 
that low concentration of CsA had no effect on the proliferation of an immortalized 
normal human oral keratinocyte cell line (HOK-16B), primary oral keratinocytes, and 
epitheloid cervical carcinoma cell line (Hela) cultured for up to 96h. They did report, 
however, that higher concentration 10
3
ng/ml of CsA exhibited an inhibitory effect on 
proliferation of all cell types. Furthermore (Lauer et al., 2006) showed both the 
inhibitory and stimulatory effect of CsA on human gingival keratinocyte proliferation; 
CsA significantly reduced their proliferation rate from day 3 to day 6 and then 
stimulated their proliferation from day 6 to day 9 with maximal increase being 
observed on day 9 at concentration 10
3
ng/ml. It is possible that these different 
findings may be related to different methodologies used in each study.   
 
The exposure to combinations of bacterial supernatants with CsA also caused a 
variable cell type-dependent effect. The proliferation rate (Edu incorporation) was 
increased in FIBS, OKF6, and HGF cultures exposed to P.i and 2000ng/ml CsA. 
These results were supported by an earlier study conducted by Bartold (1989) who 
found that CsA up-regulated DNA synthesis and enhanced proliferation rate of HGF 
after treatment with CsA with the most noticeable stimulation being reported in 
presence of 10%FBS. This capacity was also retained even in absence of FBS or in 
the presence of lipopolysaccharide that would normally inhibit proliferation of 
fibroblasts (Bartold, 1989). 
 
2000ng/ml CsA / F.n, in contrast, caused a reduction in proliferation rate of HGF with 
a corresponding decrease in G2/M fraction.  Barber et al (1992) demonstrated that 
addition of CsA to HGFs pre-exposed to a lipopolysaccharide derived from 
Fusobacterium nucleatum or Escherichia coli changed the inhibitory effect of these 
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bacterial products on DNA synthesis to a stimulatory effect instead. However, this 
discrepancy between our findings and their results may simply be interpreted by the 
different bacterial products used as we used the whole bacterial products while they 
used only LPS. Collectively, our findings along with the above mentioned data 
suggests that the bacterial products, in particular P.i, may be an essential co-factor in 
the pathogenesis of CsA- associated gingival hyperplasia and may explain, in part, 
why gingival hyperplasia mostly occurs in areas of intensive dental plaque 
accumulation (Barber et al., 1992; Bartold, 1989). 
 
 
8.1.3 Cell cycle: 
An apparent blockade of the cell cycle machinery at G2/M was observed in all 
keratinocyte cell cultures exposed to A.a products. However, such effect was not 
observed in HGF culture. Instead, an enhanced proliferation rate with corresponding 
increase in S and G2/M phase was found in HGF cultures exposed to a combination 
of 2000ng/ml CsA and A.a product. It is possible that this variation may reflect 
different cell surface receptors used by A.a in each cell type (Kent et al., 1998). 
However, White et al (1998) found that A.a products caused an inhibition in HGF 
proliferation by blockade of the cell cycle at G2/M phase and down regulating cyclin 
B1 expression.  
  
In the present study, cell cycle analysis showed that the magnitude of serum starvation 
influence in arresting cell cycle was cell type dependent. While 80% of OKF6 cells 
were arrested in G1, a less effective arrest was seen in both FIBS (60%) and HGF 
(57%).  
 
This deficiency in arresting of all cell line types at G0/G1 following 24h of serum 
starvation was consistent with previous study that observed that 72h of serum 
starvation could not synchronize all the mammalian cell lines studied but an effective 
arrest was seen in human breast cancer cell lines (95%) (Gao & Dou, 2000). Thus 
these discrepancies in cell type-dependent sensitivity to serum-starvation and 
therefore in cell synchronization may reflect the differences in expression level of 
Cyclin D1 between cells. However, the cell cycle analysis did not provide a 
conclusive profile and it was not accurately corresponding to the findings of 
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proliferate rate. This discrepancy in the value of S phase determined by both DNA 
content and Edu incorporation may be interpreted by the in-accuracy of cell cycle 
staining often resulting in overlapping the phases together (Takeuchi et al., 2007) or 
because of the discrepancy in the incubation periods cells were pulsed by Edu for 1h 
while incubated with cell cycle dye for 30 minutes.  
 
Cyclin D1 expression is normally present during G1 Phase (Juan & Cardo, 2001).  
However in this study cyclin D1 was present in keratinocytes throughout all the cell 
cycle phases. Such aberrant expression of cyclin D1 was noticed in most cancer cell 
lines (Collecchi et al., 2000; Juan et al., 1996). Therefore, this type of expression 
could also be related to the method of transforming our keratinocyte cell lines.  
 
HGF, however, showed a typical pattern of cyclin D1 expression being found in G1 
phase. Furthermore, this difference in the pattern of cyclin D1 expression between 
keratinocyte and fibroblast cell lines could be related to the type of cells and the way 
of transformation to cell lines.  
 
An increase in the proliferation rate, illustrated by DNA synthesis, with an increase in 
the viability of HGFs after CsA treatment has also been reported recently (Chae et al., 
2006; Kim et al., 2008) 
 
Although Cyclin B1 expression has been reported in fibroblasts (Parkar et al., 2004) it 
was not expressed by any of the cells in our study. It is not clear why this occurred but 
it may reflect the instability of the proteins under the fixation conditions applied or 
low levels of expression in the studied cells.  
 
8.1.4 Pro-inflammatory cytokine release: 
It has been suggested that pathogenesis of CsA-induced gingival hyperplasia may 
involve alteration in the expression levels of various inflammatory cytokines in the 
gingival tissues (Ruhl et al., 2004) who found an increase in the saliva content of IL-
1α, IL-6, and IL-8 in patients with CsA-induced gingival hyperplasia. Williamson et 
al (1994) also demonstrated that CsA-hyperplastic gingiva had a significantly higher 
expression of the IL-6 gene compared to control gingiva. Theses studies and most of 
the previous in vitro reports (Myrillas et al., 1999; Morton & Bagtzoglou, 1999) have 
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focused on the potential role of alterations in cytokine release in the pathogenesis of 
altered functions of gingival fibroblasts in response to CsA. There are, however, no 
reports available on implication of these cytokines in the epithelial changes induced 
by CsA. 
 
2000ng/ml CsA consistently caused a significant increase in IL-1α and IL-6 from all 
keratinocyte cell lines with a maximal release being found in the period between 12h 
and 24h. These results were consistent with a previous study that reported an increase 
in IL-1
 
 from cultured human epidermal keratinocytes after CsA treatment 
(Marionnet et al., 1997) and by an in vivo study that showed that stimulation of hair 
growth by CsA in nude mice was associated with
 
up-regulated expression of IL-1  
(Gafter-Gvili et al., 2003). However, this increase in IL-1α release might be attributed 
to the irritating effect of the high dose of CsA that may cause a perturbation in the 
permeability of cell membrane and thus leaking the intracellular content of pre-
formed IL-1α. This suggestion therefore may explain the lack of effect of low doses 
of CsA on IL-1α release and the early release of IL-1α induced by high doses of CsA 
and its depletion afterwards. Moreover, the corresponding release of IL-6 from the 
same cultures might support the notion of amplifier effect of IL-1α on inflammatory 
response and thus, suggesting that this pattern of IL-6 release might be IL-1α 
receptor-dependent (Feliciani et al., 1996; Bonifati & Ameglio, 1999).  
 
2000ng/ml CsA also caused a significant increase in release of IL-6 and IL-8 from 
HGF cells but with no change in IL-1α. These results are consistent with previous 
studies revealing a significant increase in IL-6 expression from HGF cultures 
following treatment with CsA (Chae et al., 2006; Morton & Bagtzoglou, 1999). 
Myrillas et al (1999) also found that expression of IL-1β was undetectable in both 
normal and overgrown gingival fibroblast cultures exposed to CsA but in contrast to 
our findings; they reported a dose dependent manner inhibition in IL-6 release in both 
HGF strains with a maximal inhibition being reported at 2000ng/ml CsA. However, 
these discrepancies in findings may be attributed to heterogeneity of HGF strains 
(Bagtzoglou et al., 1998).  
 
Furthermore, Leonardi et al (2001) found that the exposure to CsA for 24h caused a 
significant increase in IL-6 and IL-8 release with a parallel decrease in IL-1β release 
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along with a reduction of cultured human conjunctival fibroblasts viability. In this 
study they related their findings to the toxic activity of the high doses used of CsA. 
However, our results showed no such correlation between cell viability and release of 
cytokines.  
 
The up-regulated release of IL-8 and IL-6 in an IL-1α-independent manner observed 
in our HGF cultures treated with CsA has also been reported in a recent study in 
which it was suggested that IL-6 and IL-8 release in HGFs may be mediated by Toll-
like cell surface receptors (TLRs) (Suzuki et al., 2009). This suggestion is in parallel 
with an earlier report showing that IL-6 and IL-8 release was not caused by the signal 
transduction induced via IL-1α but rather, occurred independently of IL-1α receptor 
IL-1R (Kent et al., 1998). Similarly, Cheng et al  (2008) found that exposure of 
human cervical carcinoma epithelial cells to Chlamydia trachomatis caused over 
expression of IL-6 and IL-8 before IL-1α was released suggesting that IL-6 and IL-8 
release was independent of cell surface IL-1R receptor signalling pathway. 
   
An increase in IL-6 release was also found in primary cultures of HGFs derived from 
healthy individual after stimulation with CsA and the magnitude of this release varied 
among HGF cultures according to the donors (Morton & Bagtzoglou, 1999). 
However, in their study, CsA appeared to abrogate the stimulatory effect of bacteria 
on expression of IL-6 in HGFs. Interestingly, Maita et al  (2002) reported that release 
of IL-6 in CsA-treated HGFs derived from periodontitis sites was much higher than 
that in CsA-treated HGFs derived from healthy gingiva but however, CsA failed to 
induce IL-β and IL-8 release in any of HGF strains used.  
 
Bagtzoglou et al (1998) attributed the discrepancies in studies in terms of cytokine 
release to differences in the cytokine secretory phenotype among HGF populations 
suggesting that the increased expression of IL-6 and IL-8 by HGF in periodontitis 
sites may be interpreted by predominance of subpopulations with higher cytokine 
expression capacity. Considering that cytokines are key mediators of the gingival 
inflammatory response, the aforementioned suggestion which may be clinically 
relevant and explain the discrepancies in the susceptibility of individuals to dental 
plaque may also interpret the variable release of cytokines among HGF strains in 
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response to CsA. Thus, it may explain at least in part, the variable susceptibility 
among individuals to develop CsA-associated gingival changes.  
 
Our study showed that bacterial supernatants induced a consistent effect on cytokine 
release in all cell lines, A.a caused a significant increase in IL- 1α release whilst F.n 
and P.i reduced the release. A.a, P.i, and F.n caused a significant increase in IL-6 
release in most cell lines whilst, IL-8 was increased in HGF by all bacterial 
supernatants except P.g. Furthermore, bacterial supernatants had limited effect on IL-
8 release in keratinocytes. Interestingly, P.g caused a complete inhibition in IL-6 and 
IL-8 release in all cell lines studied.  
 
Combinations of CsA plus bacterial supernatants had no synergistic effect on IL-1α 
release. However, effect of the combinations on IL-6 release had bacterial and cell 
type-dependent manner; in FIBS cells, a synergistic effect was found with 
combinations of CsA plus P.i/F.n. Likewise, such synergistic effect on release of IL-6 
and IL-8 was found in HGF with combinations of CsA and all bacterial supernatants 
except P.g. However, no synergistic effect on IL-8 release was found in all 
keratinocytes. 
 
Although P.i, F.n and A.a have been shown to be strong stimulators of IL-8 in human 
gingival and oral epithelial cells (Han et al., 2000; Sfakianakis et al., 2001), no 
prominent effect was reported in our study in combination with CsA in all 
keratinocytes. Furthermore, the differences in the ability of bacteria to stimulate or 
inhibit cytokine release could be attributed to the unique receptors and signal 
transduction pathways used by each stimulant (Kent et al., 1998). Therefore, it is 
possible to speculate that the different receptors and signalling pathways used by CsA 
and bacterial products in each cell type may cause the different levels of cytokine 
expression among the cultures.  
 
However, the increase in IL-6 and IL-8 release induced by a synergistic effect of CsA 
plus bacterial supernatants found in HGF and FIBS (IL-6 only) may be a clinically 
relevant where this up-regulation in inflammatory cytokines release may enhance the 
recruitment and activation of inflammatory cells in addition to enhancing the 
interaction between these inflammatory mediators and gingival cells and ultimately 
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establishing the inflammatory process in the periodontal tissue that might lead to 
gingival enlargement. Therefore, this synergistic effect of CsA and bacterial 
supernatant combinations may provide further explanation of why the CsA-induced 
gingival hyperplasia is mainly associated with areas of heavy dental plaque 
accumulation 
 
8.1.5 Apoptosis 
Recently, it was reported that the increased number in HGF observed in CsA-induced 
gingival hyperplasia was the result of reduced apoptosis coupled with increased 
proliferative activity (Kantarci et al., 2007). Furthermore, Nishikawa et al., (1996) 
suggested that the excessive number of fibroblasts in drug-induced gingival 
hyperplasia may be caused by inhibition of apoptosis. Jung et al., (2008) reported that 
CsA increased the cell viability of HGF cultures in vitro and this increase was resulted 
from a reduced apoptosis, illustrated by reduced expression Bax/Bcl-2 ratio, rather 
than increased cell proliferation. 
   
Keratinocytes showed that the basal level of Bax expression was ranging from 
undetectable to a very low level. CsA had no effect on Bax expression in all 
keratinocytes cultures. Furthermore, a pronounced expression of Bax was found 
consistently in all keratinocyte cultures exposed to A.a products. However, adding 
CsA to cultures exposed to A.a caused a cell type-dependent effect; ranging from 
reduction in OKF6 to an increase in TR146.  The result in TR146 is supported by a 
recent study in which high doses of CsA increased the Bax expression in a human 
gingival squamous carcinoma cell line (Tu et al., 2009). 
 
CsA induced Bax expression in HGF. Such expression was also observed in all HGF 
exposed to all bacterial products with more prominent expression was being found in 
P.i, addition of 2000ng/ml caused an apparent reduction in Bax expression. However, 
this reversal effect exerted by CsA might explain partly why this pathogenesis mostly 
seen in areas with heavily dental plaque accumulation and indicate that CsA might 
acts in different pathways where it up-regulates Bax expression when applied 
individually but it downregulates this expression when applied in combination with 
bacterial products.   
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It was surprising that Bcl-2 expression was not present in any of the cells studied. 
However, the half-life of theBcl-2 gene and its protein are unstable and differ 
according to the cell type (Seto et al., 1988; Blagosklonny et al., 1996) cell systems 
(Gao & Dou, 2000) or in response to various stimuli.  In support of this, Buduneli et 
al (2003) reported that the P53 and Bcl-2 contents in gingival crevicular fluid (GCF) 
of patients with CsA-induced gingival hyperplasia were below the minimum 
detectable ranges Furthermore, Birraux et al (2006) also found that an anti-
proliferative effect of CsA on immortalized normal human oral keratinocyte cell lines 
(HOK-16B) and primary oral keratinocyte cultures but this effect was not associated 
with changes in the level of TNF-α- induced apoptosis, or Bcl-2 expression. The 
absence of Bcl-2 expression in our cultures therefore can be explained by instability 
of this protein under the fixation process followed, or that it is expressed in low levels 
in these cells, or that the half-life of Bcl-2 in these cells is very short thus its 
expression may be undetectable.  
 
Despite the limitations of our study including only one sample for each treatment 
group and being our study focused on two mediators of apoptosis, these findings will 
lay the foundation for future studies directed towards the importance of periodontal 
bacteria, in particular P.i, in pathogenesis of CsA-induced gingival hyperplasia.  
 
 
 
8.2. Multilayer cultures: 
Monolayer cultures lack the multilayered structure of normal mucosa and 
consequently the concentrations of an agent required to induce responses in these 
cultures are several orders of magnitude lower that those which cause such response 
in vivo (Coquette et al., 2003). Therefore, extrapolating the data obtained to the in 
vivo situation is limited. As a result, a limited study to was undertaken using a 
commercially available stratified model mucosa (SkinEthic), that has previously been 
used for screening the compatibility of new pharmaceutical products and dental 
materials and to examine the response of the epithelium to infection (de Brugerolle de 
Fraissinette et al., 1999; Vannet et al., 2007). 
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8.2.1 Cell Viability: 
The MTT assay was used as an initial approach to evaluate the response of RHGE and 
RHOE to CsA and bacterial products. CsA had no effect on tissue viability of both 
RHGE and RHOE, whilst the bacterial supernatants caused a tissue dependent- effect. 
RHGE viability was decreased after treatment with P.g, A.a and P.i whilst all bacterial 
supernatants increased RHOE viability. Furthermore, combinations of CsA plus any 
of the bacterial supernatants increased the viability of RHGE with the most 
pronounced effect being found with CsA/F.n where the level of viability was 
significantly higher than control. However, all combinations had no effect on RHOE 
viability. The scope of MTT assay as mentioned above is limited to the cell viability 
without providing an idea on the cellular pathways involved, Therefore more 
sophisticated studies were also required to evaluate the cellular response to CsA and 
bacterial products and whether this response may involve a modulation in the local 
inflammatory response. 
 
8.2.2 Cell proliferation: 
The multiparameter FACS analysis used to assess cell proliferation and turnover was 
not applicable to the stratified cultures and therefore a qPCR approach was used to 
investigate CCND1 and CCNB1 gene expression that encodes cyclin D1 and cyclin 
B1 respectively.    
 
CsA alone had no effect on CCND1 expression in RHGE, whilst a significant increase 
was seen cultures exposed to all of the bacterial supernatants. This increase in 
CCND1 expression was further enhanced by addition of CsA. Conversely, a 
significant reduction in CCNB1 expression was observed in RHGE cultures exposed 
to CsA alone or all bacterial supernatants.  Interestingly, exposure of RHGE cultures 
to combinations of CsA and any of bacterial products caused a reversal of the 
inhibitory effect with the most marked change being with A.a and P.i.  
 
Thus, our results indicate that the exposure to bacterial products caused a bimodal 
effect on cyclin expression in RHGE; while they stimulated CCND1 expression 
which, in turn, accelerates the entry of cell cycle machinery into S phase (Tashiro et 
al., 2007). They arrested the cell cycle at G2/M by down-regulating the CCNB1 
expression and consequently inhibition of the cellular mitosis. This later effect may 
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explain at least partly the decrease in RHGE viability determined by MTT assay after 
the exposure to bacterial products.  
 
RHOE cultures reacted differently to bacterial products where an up-regulated 
expression of CCNB1 and CCND1 was only observed in cultures exposed to F.n and 
A.a supernatants respectively. CsA had no significant effect on expression of these 
genes whilst the combination of CsA and all of the bacterial supernatants caused a 
significant reduction in CCNB1 expression but had no effect on CCND1.  
 
The reasons behind the differences in the response to CsA and bacterial products 
between the RHGE and RHOE in the present study is not fully understood but it 
might partly be related to the differences in the keratinisation level of each tissue or 
the different turnover rate between these cultures (Carranza, 1990). 
 
However, this bi-model and gingival region-dependent effect of bacterial products on 
the proliferative activity of epithelium (stimulatory on RHOR and inhibitory on 
RHGE) observed in our study may interpret the discrepancy in studies on the effect of 
gingival inflammation on the dividing activity of gingival keratinocytes; Celenligil et 
al (2000) showed that the proliferative activity of the inflamed oral gingival 
epithelium was significantly higher compared to that in healthy gingival. Conversely, 
Carro et al (1997) showed that the proliferation rate of keratinocyte cultures derived 
from clinically healthy to slightly inflamed human gingival tissue was much higher 
than that of cultures derived from severely inflamed gingiva.  
 
The increase in the proliferative activity of RHGE exposed to combinations of CsA 
and bacterial products is consistent with the clinical observation of CsA-induced 
gingival hyperplasia being confined to the keratinized gingiva (Friskopp & 
Klintmalm, 1986) and further supported by an animal study revealing that this 
condition was more prominent in the buccal gingiva (Spolidorio et al., 2001). These 
findings are also supported by earlier in vivo study in which CsA-induced gingival 
hyperplasia was associated with hyperproliferation mainly in the oral gingival 
epithelium. In this study Nurmenniemi et al (2001) attributed the lack of proliferative 
activity in the sulcular epithelium to direct contact with the dental plaque or 
inflammation (Carro et al., 1997) masking the proliferative effect of CsA.  
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Our study was also partly consistent with an animal study that found an increase in 
the proliferative activity mainly in the buccal and to a lesser extent in the sulcular 
epithelium of rats subjected to CsA treatment along with ligature-induced gingival 
inflammation suggesting that CsA-induced gingival hyperplasia might be mediated by 
an increase in the proliferative activity of epithelium cells and that dental plaque 
might aggravate the condition (Cetinkaya et al., 2006). 
 
In light of our findings, it appears that CsA does not exert a direct effect on the 
proliferative activity of keratinocytes but instead, the hyper-proliferative activity 
observed in CsA-induced gingival hyperplasia may be an indirect consequence of 
drug interactions with other intrinsic or extrinsic factors.g., modulation of the local 
inflammatory response and cytokine release. Consequently, the different pattern of 
response between RHGE and RHOE may reflect the complexity in the direct and 
indirect effect of CsA on proliferation of keratinocytes.  
 
8.2.3 Pro-inflammatory cytokines: 
Low levels of IL-1α and IL-6 were released from RHOE and RHGE cultures and CsA 
and bacterial supernatants alone or in combination did not modulate their release. IL-8 
release in RHOE cultures was much higher than that in RHGE cultures. A.a, Pi and 
F.n stimulated IL-8 release from RHGE whilst all 4 bacteria stimulated release from 
RHOE.  CsA alone caused a significant reduction in IL-8 release from RHOE but not 
RHGE whilst CsA in combination with all bacterial supernatants inhibited the release 
of IL-8 from both RHGE and RHOE.  The finding that IL-8 release was upregulated 
by the bacterial supernatants is in contrast to the results seen with the monolayer 
cultures.  The reason for this is unclear, but may reflect subtle interactions within 
stratified epithelium that would not be present in monolayer cultures.  The increase is 
however, perhaps not surprising as IL-8 is a potent neutrophil chemoattractant and 
significance of acute inflammation in gingivitis and periodontitis (Bickel, 1993; Tsai 
et al., 1995).  CsA inhibition of IL-8 release has been reported in psoriatic lesions 
(Prens et al., 1995) and so it was perhaps surprising that CsA alone had no effect in 
RHGE.  This may however, be related to the low levels released as inhibition was 
present after stimulation with bacterial supernatant. Acute inflammation leads to 
changes in the tissue (Tsai et al., 1995) and whether the abrogation of the stimulatory 
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effect of bacterial products on IL-8 release exerted by CsA may play a role in 
hyperplasia requires further investigation.  
 
The absence of an effect on IL-6 release was in contrast with the effect seen in the 
monolayer keratinocytes cultures.  An increased expression of IL-6, IL-8 and IL-1β 
has also been reported in engineered human oral mucosa exposed to P.g (Andrian et 
al., 2004).  This study, however, used a suspension of live bacteria. In addition, the 
type of mucosa used in their study was different from ours as they used a full- 
thickness mucosa that included the epithelial/connective tissue interaction.    
 
Furthermore, our study did not find a positive correlation between cell viability and 
release of any of the cytokines studied. These findings were further supported by an 
early in vitro study that found that the release of IL-1a and IL-8 in reconstructed 
human epidermis was not correlated with cell viability or cytotoxicity, but to the 
nature of agent applied. (Coquette et al., 1999). While IL-1a release served as a good 
parameter for irritancy, release of IL-8 was linked to sensitizing potency (Coquette et 
al., 2003). These findings reflect the complexity of molecular pathways underlying 
the cytokines expression and imply interactions with various cellular targets (Coquette 
et al., 1999).  
 
The differences in the findings between monolayer cultures and stratified cultures 
may be attributed to the different culture system as the multilayered nature of the 
mucosa along with numerous tight junctions may limit the agent diffusion through the 
tissue layers. An additional protection may also be provided by the superficial layers 
when the epithelium is keratinized. (Gaballah et al., 2007; Gaballah et al., 2008). 
Therefore, the lack of this structure renders the monolayer cultures more susceptible 
to the drugs where doses triggering responses are usually several folds of magnitude 
lower than those which provoke biological reactions in vivo (Coquette et al., 2003). 
Thus, upon direct exposure to non-physiological concentrations of agents, cell 
damage seems to occur more rapidly in monolayer cultures compared to their 
counterpart in multilayered cultures (Tomakidi et al., 2000). Therefore, results 
obtained from monolayer culture tests are normally difficult to be interpreted or 
extrapolated to the in vivo situation (Welss et al., 2004).  
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8.2.5 Apoptosis: 
There was no significant alteration in either Bax/Bcl-2 gene ratio or Fas-L gene in any 
of the treatment groups. However, due to the limitations of our study that included a 
limited number of samples for each treatment group in addition to the limited key 
apoptotic mediators involved in our study, more investigations are required in this 
regard to obtain conclusive findings whether the dysregulated apoptosis may be 
involved in pathogenesis of the gingival changes associated with CsA.  
 
However, Buduneli et al (2007) minimized the importance of dental plaque in 
pathogenesis of CsA-induced gingival hyperplasia suggesting that that the 
dysregulation of tissue homeostasis observed in CsA-induced gingival hyperplasia 
could be attributed to the independent effect of CsA rather than to the influence of 
chronic gingival inflammation. In this study they found that that CsA-hyperplastic 
gingiva had significantly less numbers of apoptotic cells compared to the inflamed 
gingival. However, one limitation when compare our results with theirs is that our 
study was in vitro versus their in vivo study that involves a complex of 
microorganisms.  
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8.3 Conclusion and Future work 
The results of the monolayer cultures suggest that CsA, at a clinically relevant dose, 
appears to modulate cytokine release and proliferative activity by gingival cells. There 
was also clear evidence that combinations of CsA and P.i or A.a caused marked 
changes in the proliferative activity of the cells.  Although these findings suggest that 
they may have an important role in CsA-associated gingival changes, further studies 
are necessary to confirm the results. These results were supported by the stimulatory 
effect of CsA and bacterial supernatants on proliferation of the model RHGE.  
Interestingly the changes seen in cytokine release by monolayers were not evident in 
the stratified cultures.  This may reflect the fact that the models used in this study 
exclusively consist of keratinocytes and lack Langerhans cells, which play a 
fundamental role in initiating the cutaneous immune response and cytokine expression 
(Srivastava et al., 1994; Cumberbatch et al., 1996), in addition to absence of the 
leukocytes diminishing the complexity of the observable cytokine milieu (Vannet et 
al., 2007). Furthermore, the absence of mesenchyme-keratinocyte interaction may 
mask the complexity of the cellular interactions observable in vivo.  Further studies 
involving co-cultures of fibroblast and the model mucosa are therefore needed to 
establish the significance of these changes.  
 
Taken together these results, outlined in this thesis suggest that CsA may affect the 
gingival fibroblast and keratinocytes both directly and indirectly via modulation of the 
cytokine release and the host response to bacterial products indicating a potential role 
of bacterial products in pathogenesis of gingival hyperplasia.  
 
 
 
 
 
 
 
` 
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Appendix 1  
Determination of bacterial supernatant toxicity 
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Figure A1. LDH release from OKF6. Cell lines were challenged for 24h with ascending 
doses of bacterial supernatants. Extracellular release of LDH was then measured using a Cytotoxicity 
Detection Kit
plus
. Two controls were used in the study; high control which represents the totally lysed 
cells and low control which is medium containing un-treated cells. Results are expressed as percentage 
of total LDH. Bars represent Mean ± SEM of 12 samples. 
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Figure A2. FIBS viability. Cultures were stimulated for 24h with ascending concentrations of 
bacterial supernatant. Cell viability was measured by Alamar blue. Untreated cells were served as 
control. Results are expressed as the Mean ± SEM (n=9). Statistical significance was regarded when p< 
0.05 compared to control. 
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Figure A3. LDH release from TR146. Cell lines were challenged for 24h with ascending 
doses of bacterial supernatants. Extracellular release of LDH was then measured using a Cytotoxicity 
Detection Kit
plus
. Two controls were used in the study; high control which represents the totally lysed 
cells and low control which is medium containing un-treated cells. Results are expressed as percentage 
of total LDH. Bars represent Mean ± SEM of 12 samples. 
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Figure A4. FIBS viability. Cultures were stimulated for 24h with ascending concentrations of 
bacterial supernatant. Cell viability was measured by Alamar blue. Untreated cells were served as 
control. Results are expressed as the Mean ± SEM (n=9). Statistical significance was regarded when p< 
0.05 compared to control. 
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Figure A5. LDH release from HGF. Cell lines were challenged for 24h with ascending doses 
of bacterial supernatants. Extracellular release of LDH was then measured using a Cytotoxicity 
Detection Kit
plus
. Two controls were used in the study; high control which represents the totally lysed 
cells and low control which is medium containing un-treated cells. Results are expressed as percentage 
of total LDH. Bars represent Mean ± SEM of 12 samples. 
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Appendix 2 
FACS plots 
 
 
List of abbreviations: 
 
CsA……………………..Cyclosporin-A (250 & 2000ng/ml) 
P.g ……………………...P. gingivalis 
A.a………………….…..A. actinomycetemcomitans 
P.i……………………… P. intermedia 
F.n………………………F. nucleatum 
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Fig A1. Single parameter histograms of DNA content displaying the cell cycle distribution of 
FIBS after 24h of exposure to a combination of CsA and bacterial supernatant. A; serum starved 
B; serum rechallenged C; 2000ng/ml CsA. D; P.g. E; P.g plus 2000ng/ml CsA F; A.a. G; A.a plus 
2000ng/ml CsA. H; P.i. I: P.i plus 2000ng/ml CsA, J: F.n. K: F.n plus 2000ng/ml CsA. 
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Fig A2. Dual parameter dot plots analysing the Edu positive cells against DNA content in FIBS 
after 24h of exposure to a combination of CsA and bacterial supernatants. Results were expressed 
as a % of positive cells incorporating Edu. 
A. Serum-starved. B; Serum-rechallenged. C; 2000ng/ml CsA. D; A.a. E; A.a plus 2000ng/ml CsA. F; 
F.n. G; F.n  plus 2000ng/ml CsA.  
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Fig A3. Flow cytometric analysis of cyclin D1 expression in FIBS cells after 24h exposure to a 
combination of CsA and bacterial supernatants. 
Expression of cyclin D1 was analysed using single parameter histograms in: A. Serum-starved. B; 
Serum-rechallenged. C; 2000ng/ml CsA. D; P.i. E; P.i plus 2000ng/ml CsA. F; F.n. G; F.n plus 
2000ng/ml CsA. Results were expressed as a % of positive cells expressing cyclin D1. 
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Fig A4. Single parameter histograms of DNA content displaying the cell cycle distribution of 
TR146 after 24h exposure to a combination of CsA and bacterial supernatants. A; serum starved. 
B; serum rechallenged. C; 250ng/ml CsA. D; 2000ng/ml CsA. E; A.a. F; A.a plus 250ng/ml. G; A.a 
plus 2000ng/ml. H; P.i. I; P.i plus 2000ng/ml CsA. J: F.n. K: F.n plus 2000ng/ml CsA. 
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Fig A5. Dual parameter dot plots analysing the Edu positive cells against DNA content in TR146 
after 24h of exposure to a combination of CsA and bacterial supernatants. Results were expressed 
as a % of positive cells incorporating Edu. 
A; serum starved. B; serum rechallenged. C; 250ng/ml CsA. D; 2000ng/ml CsA. E; P.g. F; P.g plus 
2000ng/ml. G; A.a. H; A.a plus 2000ng/ml CsA. I; P.i. J: P.i plus 2000ng/ml CsA. K: F.n. L; F.n plus 
2000ng/ml CsA. 
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Fig A6. Flow cytometric analysis of cyclin D1 expression in TR146 cells after 24h exposure to a 
combination of CsA and bacterial supernatants. 
Expression of cyclin D1 was analysed using single parameter histograms in: A. Negative isotype 
control showing a strong background by 35% that was afterwards deducted from values of all studied 
samples. B; Serum-starved. C; Serum-rechallenged. D; 250ng/ml CsA. E; 2000ng/ml CsA. F; P.g. G; 
P.g plus 250ng/ml CsA. Results were expressed as a % of positive cells expressing cyclin D1. 
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Fig A7. Single parameter histograms of DNA content displaying the cell cycle distribution of 
HGF after 24h exposure to a combination of CsA and bacterial supernatants. A; serum starved. B; 
serum rechallenged. C; 2000ng/ml CsA. D; F.n. E; F.n plus 2000ng/ml.  
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Fig A8. Dual parameter dot plots analysing the Edu positive cells against DNA content in HGF 
after 24h exposure to a combination of CsA and bacterial supernatants. Results were expressed as 
a % of positive cells incorporating Edu. A. Serum-starved. B; Serum-rechallenged. C; 2000ng/ml CsA. 
D; P.g. E; P.g plus 2000ng/ml CsA. F; A.a. G; A.a plus 2000ng/ml CsA. H; P.i. I; P.i plus 2000ng/ml 
CsA J; F.n.  K; F.n  plus 2000ng/ml CsA. 
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Fig A9. Flow cytometric analysis of cyclin D1 expression in HGF after 24h exposure to a 
combination of CsA and bacterial supernatants. 
Expression of cyclin D1 was analysed using single parameter histograms in: A; Serum-starved. B; 
Serum-rechallenged. C; 2000ng/ml CsA. Results were expressed as a % of positive cells expressing 
cyclin D1. Results were expressed as a % of positive cells expressing cyclin D1. 
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Fig A10. Flow cytometric analysis of Bax expression in FIBS cells after 24h exposure to a 
combination of CsA and bacterial supernatants. 
Expression of Bax was analysed using single parameter histograms in: A; Negative isotype control. B; 
untreated FIBS (control). C; 250ng/ml CsA. D; 2000ng/ml CsA. E; P.g. F; P.g plus 2000ng/ml CsA. 
G; A.a. H; A.a plus 250ng/ml CsA. I; A.a plus 2000ng/ml CsA. Results were expressed as a % of 
positive cells expressing Bax. 
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Fig A11. Flow cytometric analysis of Bax expression in OKF6 cells after 24h exposure to a 
combination of CsA and bacterial supernatants. 
Expression of Bax was analysed using single parameter histograms in: A; Negative isotype control. B; 
untreated OKF6 (control). C; 250ng/ml CsA. D; 2000ng/ml CsA. E; P.g. F; P.g plus 250ng/ml CsA. 
G; A.a. H; A.a plus 250ng/ml CsA. I; A.a plus 2000ng/ml CsA. Results were expressed as a % of 
positive cells expressing Bax. 
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Fig A12. Flow cytometric analysis of Bcl-2 expression in OKF6 cells after 24h exposure to a 
combination of CsA and bacterial supernatants. 
Expression of Bcl-2 was analysed using single parameter histograms in: A; Negative isotype control. 
B; untreated OKF6 (control). C; 250ng/ml CsA. D; 2000ng/ml CsA. E; P.g. F; P.g plus 250ng/ml CsA. 
Results were expressed as a % of positive cells expressing Bcl-2. 
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Fig A13. Flow cytometric analysis of Bax expression in TR146 cells after 24h exposure to a 
combination of CsA and bacterial supernatants.  
Expression of Bax was analysed using single parameter histograms in: A; Negative isotype control. B; 
untreated TR146 (control). C; 250ng/ml CsA. D; 2000ng/ml CsA. E; A.a. F; A.a plus 250ng/ml CsA. 
G; A.a plus 2000ng/ml CsA.  Results were expressed as a % of positive cells expressing Bax. 
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Fig A14. Flow cytometric analysis of Bax expression in HGF cells after 24h exposure to a 
combination of CsA and bacterial supernatants. 
Expression of Bax was analysed using single parameter histograms in: A; Negative isotype control. B; 
untreated HGF (control). C; 250ng/ml CsA. D; 2000ng/ml CsA. E; P.g. F; P.g plus 2000ng/ml CsA. 
G; A.a. H; A.a plus 250ng/ml CsA. I; A.a plus 2000ng/ml CsA J; P.i. K; P.i plus 250ng/ml CsA. L; 
P.i plus 2000ng/ml CsA. M; F.n. N; F.n plus 250ng/ml CsA. O; F.n plus 2000ng/ml CsA. Results were 
expressed as a % of positive cells expressing Bax. 
 
 
